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A B S T R A C T
Background
A number of treatments can help smokers make a successful quit attempt, but many initially successful quitters relapse over time. Several
interventions have been proposed to help prevent relapse.
Objectives
To assess whether specific interventions for relapse prevention reduce the proportion of recent quitters who return to smoking.
Search methods
We searched the Cochrane Tobacco Addiction Group trials register, clinicaltrials.gov, and the ICTRP in May 2019 for studies mentioning
relapse prevention or maintenance in their title, abstracts, or keywords.
Selection criteria
Randomised or quasi-randomised controlled trials of relapse prevention interventions with a minimum follow-up of six months. We
included smokers who quit on their own, were undergoing enforced abstinence, or were participating in treatment programmes. We
included studies that compared relapse prevention interventions with a no intervention control, or that compared a cessation programme
with additional relapse prevention components with a cessation programme alone.
Data collection and analysis
We used standard methodological procedures expected by Cochrane.
Main results
We included 81 studies (69,094 participants), five of which are new to this update. We judged 22 studies to be at high risk of bias, 53 to be at
unclear risk of bias, and six studies to be at low risk of bias. FiBy studies included abstainers, and 30 studies helped people to quit and then
tested treatments to prevent relapse. Twenty-eight studies focused on special populations who were abstinent because of pregnancy (19
studies), hospital admission (six studies), or military service (three studies). Most studies used behavioural interventions that tried to teach
people skills to cope with the urge to smoke, or followed up with additional support. Some studies tested extended pharmacotherapy.
We focused on results from those studies that randomised abstainers, as these are the best test of relapse prevention interventions. Of
the 12 analyses we conducted in abstainers, three pharmacotherapy analyses showed benefits of the intervention: extended varenicline in
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assisted abstainers (2 studies, n = 1297, risk ratio (RR) 1.23, 95% confidence interval (CI) 1.08 to 1.41, I2 = 82%; moderate-certainty evidence),
rimonabant in assisted abstainers (1 study, RR 1.29, 95% CI 1.08 to 1.55), and nicotine replacement therapy (NRT) in unaided abstainers (2
studies, n = 2261, RR 1.24, 95% Cl 1.04 to 1.47, I2 = 56%). The remainder of analyses of pharmacotherapies in abstainers had wide confidence
intervals consistent with both no eHect and a statistically significant eHect in favour of the intervention. These included NRT in hospital
inpatients (2 studies, n = 1078, RR 1.23, 95% CI 0.94 to 1.60, I2 = 0%), NRT in assisted abstainers (2 studies, n = 553, RR 1.04, 95% CI 0.77 to
1.40, I2 = 0%; low-certainty evidence), extended bupropion in assisted abstainers (6 studies, n = 1697, RR 1.15, 95% CI 0.98 to 1.35, I2 = 0%;
moderate-certainty evidence), and bupropion plus NRT (2 studies, n = 243, RR 1.18, 95% CI 0.75 to 1.87, I2 = 66%; low-certainty evidence).
Analyses of behavioural interventions in abstainers did not detect an eHect. These included studies in abstinent pregnant and postpartum
women at the end of pregnancy (8 studies, n = 1523, RR 1.05, 95% CI 0.99 to 1.11, I2 = 0%) and at postpartum follow-up (15 studies, n = 4606,
RR 1.02, 95% CI 0.94 to 1.09, I2 = 3%), studies in hospital inpatients (5 studies, n = 1385, RR 1.10, 95% CI 0.82 to 1.47, I2 = 58%), and studies
in assisted abstainers (11 studies, n = 5523, RR 0.98, 95% CI 0.87 to 1.11, I2 = 52%; moderate-certainty evidence) and unaided abstainers (5
studies, n = 3561, RR 1.06, 95% CI 0.96 to 1.16, I2 = 1%) from the general population.
Authors' conclusions
Behavioural interventions that teach people to recognise situations that are high risk for relapse along with strategies to cope with them
provided no worthwhile benefit in preventing relapse in assisted abstainers, although unexplained statistical heterogeneity means we are
only moderately certain of this. In people who have successfully quit smoking using pharmacotherapy, there were mixed results regarding
extending pharmacotherapy for longer than is standard. Extended treatment with varenicline helped to prevent relapse; evidence for
the eHect estimate was of moderate certainty, limited by unexplained statistical heterogeneity. Moderate-certainty evidence, limited by
imprecision, did not detect a benefit from extended treatment with bupropion, though confidence intervals mean we could not rule out a
clinically important benefit at this stage. Low-certainty evidence, limited by imprecision, did not show a benefit of extended treatment with
nicotine replacement therapy in preventing relapse in assisted abstainers. More research is needed in this area, especially as the evidence
for extended nicotine replacement therapy in unassisted abstainers did suggest a benefit.
P L A I N   L A N G U A G E   S U M M A R Y
Do any treatments help people who have successfully quit smoking to avoid starting smoking again?
Background
Some people start smoking again shortly aBer quitting and are said to have 'relapsed'. Treatments used to help people avoid relapse usually
focus on teaching the skills to cope with temptations to smoke, but can also involve extending the length of the treatment that helped
them to quit, or giving additional treatment, like follow-up calls, leaflets, or stop-smoking medicine. We set out to see if these types of
approaches can be helpful, either for people who quit on their own or with the help of treatment, or for those who quit because they were
pregnant or in hospital.
Study characteristics
We updated our searches of research databases in May 2019. We found 81 studies that tested various ways of trying to help people who
had recently quit smoking not to relapse. Five of them were new for this update. FiBy studies included people who had already quit, and
30 studies helped people to quit and then tested treatments to prevent relapse. Twenty-eight studies focused on people who needed to
stop smoking for a limited period of time because they were pregnant (19 studies), in hospital (six studies), or because of military service
(three studies). Most of the studies used behavioural support treatments that tried to teach people skills to cope with the urge to smoke, or
followed up with additional leaflets or calls, internet or mobile phone resources, or additional counselling. Some studies tested extending
the use of medicines for helping people to quit smoking, in the hope of preventing relapse.
Key results
The evidence we found does not support the use of behavioural treatments to help prevent relapse aBer quitting smoking. This result was
the same in all of the diHerent groups of people studied. The most promising treatments involved extending treatment with stop-smoking
medicine, in particular, varenicline. Extending treatment with bupropion did not appear to help and there was not enough evidence on
extending treatment with nicotine replacement therapy.
Certainty of the evidence
For behavioural treatments, the certainty of the evidence was moderate. This is because of the diversity of results among studies.
The certainty of evidence for treatments with quit-smoking medicines varied. There was moderate-certainty evidence for varenicline,
moderate-certainty evidence for bupropion, and low-certainty evidence for nicotine replacement therapy (NRT), and for NRT and
bupropion together. Certainty in the evidence was limited by small study sizes.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Behavioural interventions for assisted abstainers
Behavioural interventions for relapse prevention for people who have quit smoking using a cessation intervention
Patient or population: people who have quit smoking using a cessation intervention
Intervention: behavioural interventions for relapse prevention
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes











Study population (average)Smoking cessa-
tion
Follow-up: 9 to 15
months









*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence:
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1The majority of included studies judged to be at unclear or high risk of bias in two or more domains. However, as this would likely bias the results towards favouring the
intervention, and the results did not favour the intervention, we did not downgrade the evidence on the grounds that we could still be confident that there was not a positive eHect.
2Downgraded one level for inconsistency: unexplained statistical heterogeneity (I2 = 52%)
 
 
Summary of findings 2.   Pharmacotherapy for assisted abstainers
Pharmacotherapy for relapse prevention for people who have quit smoking using a cessation intervention
Patient or population: people who have quit smoking using a cessation intervention






































































































































Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes











Study population (average)NRT versus placebo Smoking
cessation









Study population (average)Bupropion versus placebo
Smoking cessation









Study population (average)Combination NRT & bupropi-
on versus placebo Smoking
cessation
Follow-up: 12 to 15 months









Study population (average)Varenicline versus placebo
Smoking cessation
Follow-up: 12 months









*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence:
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1 Downgraded two levels for imprecision: total number of events < 100
2 Downgraded one level for imprecision: confidence intervals incorporated possibility of no eHect and clinically significant eHect
3 Downgraded one level for imprecision: high level of statistical heterogeneity (I2 = 82%). While both studies found statistically significant benefits in favour of the intervention,
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B A C K G R O U N D
Description of the condition
A number of interventions can help people who smoke to
quit. These include pharmacological treatments, such as nicotine
replacement, some antidepressants (e.g. bupropion) and nicotine
receptor partial agonists (e.g. varenicline); and behavioural
approaches, whether delivered individually or in groups (Hughes
2014; Lancaster 2017; Stead 2017; Hartmann-Boyce 2018). These
interventions increase long-term quit rates compared with control
interventions, but there is a steady attrition in overall success rates
due to a proportion of initially successful participants returning to
smoking over time (relapsing).
Description of the intervention
Relapse prevention interventions can include behavioural support
or extended use of smoking cessation medications, or both. There
is no clear definition of a relapse prevention intervention as distinct
from an extended cessation treatment because, in principle,
resumption of smoking at any time aBer the quit date can count
as relapse. In general, relapse prevention is considered to apply
to interventions that explicitly seek to reduce relapse rates aBer
an acute treatment phase is successfully completed, or at some
time aBer the quit date. The duration of the acute treatment phase
varies, leading to variability in the point at which measurement of
a relapse prevention eHect begins.
Studies of interventions for relapse prevention may randomly
assign people who have already quit, or they may randomly
assign smokers before their quit attempt and provide a general
smoking cessation intervention to all participants, in addition to an
extra component provided for those randomly assigned to relapse
prevention. The former design has a number of methodological
strengths, which are discussed later in this review. We have
included both types of study in the review.
How the intervention might work
There are several strategies for helping to prevent relapse. These
typically aim to prevent initial lapses, prevent any lapses form
leading to full relapse, or both. The most widely studied has
been the skills approach, whereby participants learn to identify
high-risk situations for relapse and are provided with cognitive
and behavioural strategies to cope with these situations (Marlatt
1985; Marlatt 2008). Quitters can also be encouraged to ‘embrace
a smoke-free lifestyle’ (Segan 2008). Alternative behavioural
interventions (oBen implemented in combination with the skills
approach) include imaginary cue exposure, writing tasks, aversive
smoking, role-play, social support, and exercise. Recently, attempts
have been made to provide common-sense relapse prevention
advice (e.g. reminders about the reasons for and importance
of remaining abstinent, avoiding triggers to smoking, advice
on coping with urges to smoke, and mood management) via
mobile applications and social media (Cheung 2015; Hicks 2017),
where it can be supplemented by peer support. Alternatively,
relapse prevention might be assisted by extending the duration
of therapeutic contact used to aid initial cessation (Segan 2011).
Finally, the use of pharmacotherapy, either by extending duration
of initial cessation treatment, or by administering to those already
abstinent, may help to prevent relapse by alleviating cravings
(Schnoll 2015).
Why it is important to do this review
To sustain the positive health eHects of quitting smoking, it is
important to prevent relapse. A number of interventions have been
hypothesised as potential relapse prevention tools and these need
to be investigated so that healthcare providers, healthcare systems,
and people who smoke can make informed decisions about the
best ways to help ensure short-term quitting can be sustained in the
longer term.
O B J E C T I V E S
To assess whether specific interventions for relapse prevention
reduce the proportion of recent quitters who return to smoking.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials with a minimum
follow-up of six months from quit date.
Types of participants
We considered three types of participants: people who had quit
smoking on their own; people who were undergoing enforced
abstinence (e.g. hospitalised, military training), whether or not
they intended to quit permanently; and smokers participating in
treatment programmes to assist initial cessation.
Types of interventions
We included interventions identified by study investigators as
intended to prevent relapse, compared with no intervention or
a shorter intervention or an intervention not oriented towards
relapse prevention. We considered behavioural interventions
delivered in any format, including group meetings, face-to-face
sessions, written or other materials, proactive or reactive telephone
support, and pharmacological interventions.
Types of outcome measures
The preferred outcome was prolonged or multiple point prevalence
abstinence at follow-up of at least six months since randomisation.
We also included studies that reported only point prevalence
abstinence (number of participants not smoking at the point
when assessment was made but not necessarily continuously since
treatment) at six months or longer. For studies that reported more
than one definition of abstinence, we considered whether the
choice of outcome would aHect any pooled eHect estimate. We
excluded studies with less than six months follow-up.
Search methods for identification of studies
We searched the Cochrane Tobacco Addiction Group register
of trials, which includes the results of comprehensive searches
of electronic bibliographic databases and conference abstracts,
and the clinical trials registries clinicaltrials.gov and the ICTRP.
We checked for relevance all reports of studies with 'relapse
prevention' or 'maintenance' or 'relapse near prevent*' in title,
abstract or keywords. See Appendix 1 for the full strategy. At the
time of the search in May 2019, the Register included the results
of searches of the Cochrane Central Register of Controlled trials
(CENTRAL), issue 1, 2018; MEDLINE (via OVID) to update 20190409;
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Embase (via OVID) to week 201915; PsycINFO (via OVID) to update
20190401. See the Tobacco Addiction Group website for full search
strategies and list of other resources searched.
Data collection and analysis
Selection of studies
In this update, two review authors (from JLB, EN and EC)
identified potentially eligible studies for inclusion. We included
studies that randomly assigned people already abstaining from
smoking. In studies that randomly assigned smokers before
quitting, almost all behavioural interventions included relapse
prevention components. Therefore, in studies that randomly
assigned smokers, we included only studies that explicitly
identified in their titles or abstracts a focus on relapse prevention
or maintenance. Unless abstainers were randomly assigned, we
did not include studies of exercise, aversive smoking, or incentives
because the interventions used are similar, whether described as
relapse prevention or not, and are covered in separate Cochrane
Reviews (Hajek 2001a; Ussher 2012; Notley 2019). We excluded
most interventions for hospitalised participants because studies
generally did not describe whether participants were already
abstinent or not, and interventions typically contained a mixture of
cessation and relapse prevention components. Studies of this type
are also covered by a separate review (Rigotti 2012).
Data extraction and management
For this update, two review authors (from JLB, EN and EC)
performed data extraction in duplicate on all new eligible
studies. We reported the following study characteristics in the
'Characteristics of included studies' table:
• Country and setting in which study was undertaken, including
population targeted for recruitment;
• Methods of randomisation, allocation concealment, and
blinding;
• Demographics of participants, including age, sex, baseline
cigarette consumption, and period of prior quitting, if relevant;
• Intervention components, including numbers and types of
contacts and periods of contact
• Control condition(s);
• Outcome, including length of follow-up, definition(s) of
cessation used in review, and any other measures used;
• Validation of self-reported smoking status, including method
used, and cut-oH point for biochemical validation.
Assessment of risk of bias in included studies
We assessed all included studies for risk of bias using the
Cochrane 'Risk of Bias' tool. We assessed each study's risk of
bias on five domains: random sequence generation; allocation
concealment; blinding of participants and personnel; blinding
of outcome assessment; and incomplete outcome data. We
noted other risks of bias, where relevant. Studies that provided
insuHicient information on which to make judgements were coded
as 'unclear' in the relevant domains. Studies were considered to
be at high risk of attrition bias (incomplete outcome data) when
lack of information meant that we were unable to include post-
randomisation dropouts in our denominators, or when less than
50% of participants were followed up at six months or longer, or
when there was a diHerence in follow-up rate of 20% or more.
Had studies of pharmacotherapies not used placebo, we would
have considered these to be at high risk of performance bias
(blinding of participants/personnel), but in the case of behavioural
interventions where blinding of participants was not possible,
we judged other study characteristics such as similar amounts of
contact between conditions, or participants not knowing about
other conditions, which may indicate that performance bias is
less likely. We judged studies to be at high risk of detection bias
(blinding of outcomes assessors) when no biochemical validation
was used and the intervention arm received more face-to-face
contact than the control arm, as we considered diHerential
misreport a possibility in these cases.
Measures of treatment e=ect
The primary outcome was the number of quitters at the
longest follow-up. We used biochemically validated cessation in
preference to self-report, where available. When given a choice, we
included continuous abstinence in preference to point prevalence
abstinence. Randomly assigned participants who withdrew, were
lost to follow-up, or failed to provide samples for validation were
usually classified as relapsers or continuing smokers. We noted any
exceptions to this in the study details.
Dealing with missing data
In the protocol for this review, we planned to approach authors
to ask for additional data about end of treatment quit rates and
long-term quit rates in early quitters. In view of the heterogeneity
of interventions, timing of assessments, and ways of defining
abstinence, we decided that additional data, even if suitable and
available, would not strengthen the review.
Assessment of heterogeneity
To investigate heterogeneity, we used the I2 statistic, given by the
formula [(Q - df)/Q] × 100%, where Q is the Chi2 statistic anddf is its
degrees of freedom (Higgins 2003). This describes the percentage
of variability in eHect estimates that is due to heterogeneity rather
than to sampling error (chance). A value greater than 50% may be
considered to indicate substantial heterogeneity.
Data synthesis
We used risk ratios to summarise individual study outcomes and
to determine estimates of pooled eHect. In line with new Cochrane
Tobacco Addiction Group policy, for comparisons of behavioural
interventions, we estimated a pooled weighted average of risk
ratios with 95% confidence intervals, using a Mantel-Haenszel
random-eHects model to account for the expected variability in
the interventions delivered; for comparisons of pharmacological
interventions, we used a fixed-eHect model. Had a study reported
an odds ratio corrected for clustering or baseline imbalance, and
where we were unable to derive a risk ratio, we planned to pool
odds ratios for studies in the same subgroup of a comparison using
the inverse variance method to check whether there was an eHect
on the results.
Subgroup analysis and investigation of heterogeneity
We planned not to pool results from studies that randomly
assigned abstainers with results from those that randomly assigned
smokers, but we made two exceptions to this: see discussion
of Killen 2006 and Wetter 2011 in Description of studies. Our
predefined subgroups were based on the type and intensity of
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intervention. We separated studies in which contact time was
matched from those in which relapse prevention included a longer
duration of contact.
Other prespecified subgroups included studies of spontaneous
quitters, such as pregnant women, and of smokers seeking smoking
cessation treatment. We added further subgroup analyses to
distinguish between longer (longer than four weeks) and shorter
intervention and control durations. We also considered subgroup
analyses for 'skills' and social support studies. This replaced our
planned subgroup division based on the format of the intervention
(group versus individual) as this was more relevant within the
available sample of studies.
At the request of NICE (the National Institute for Health and Care
Excellence; the guideline development organisation for England
and Wales), for analyses of studies randomising abstainers, we
conducted subgroup analyses grouping studies by the duration
of prior abstinence of participants. We grouped studies based on
whether participants had been abstinent for four or more weeks,
less than four weeks, or if prior abstinence varied or was not
adequately specified.
Summary of findings table
We created 'Summary of findings' tables for our primary outcomes
in assisted abstainers, following standard Cochrane methods, and
used the five GRADE considerations (study limitations, consistency
of eHect, imprecision, indirectness, and publication bias) to assess
the certainty of evidence for each outcome.
R E S U L T S
Description of studies
We identified 81 studies for inclusion (69,094 participants), five of
which were new for this update. Details of the flow of studies are
recorded in a PRISMA diagram in Figure 1. One paper reported
two studies, each of which had multiple arms relevant to diHerent
comparisons (Buchkremer 1991 1; Buchkremer 1991 2), and six
studies had subgroups or factorial designs that contributed to
diHerent sections or subgroups (Curry 1988; Killen 1990; Fortmann
1995; Schmitz 1999; Covey 2007; Croghan 2007). Most studies were
conducted in the United States. Details of each included study can
be found in the Characteristics of included studies table.
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Figure 1.   Study flow diagram for current update
 
We described and analysed separately those studies that randomly
assigned people who had already stopped smoking and those
that randomly assigned people who were still smoking. We made
two exceptions to this scheme: we considered Killen 2006 along
with other extended pharmacotherapy trials, and we considered
Wetter 2011 along with other studies testing behavioural adjuncts
to cessation programmes.
Details of 57 excluded studies are listed in the Characteristics
of excluded studies table. The main reasons for exclusion were
follow-up of less than six months or not meeting our criteria for a
study of relapse prevention. We excluded one previously included
study (Schnoll 2015), because we removed the analysis of extended
pharmacotherapy in smokers, as this is more extensively covered
in reviews of individual pharmacotherapies (Hughes 2014; Cahill
2016; Lindson 2019). We identified 18 ongoing studies, details of
which can be found in the Characteristics of ongoing studies table.
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Section 1. Studies randomly assigning abstainers
FiBy-one studies included people who had already stopped
smoking.
We considered separately studies involving unaided abstainers
who had stopped smoking where it was prohibited or discouraged
for a set amount of time, due to factors such as pregnancy, hospital
stay, or military training. Another group of studies concerned ex-
smokers recruited from the general population.
We divided studies into those assessing behavioural interventions
and those assessing pharmacotherapy. We further divided the
studies of general population abstainers into those that focused on
unaided abstainers, and those that focused on aided abstainers.
We classified behavioural interventions into intensive and less
intensive categories. Intensive interventions involved repeated
face-to-face contact, usually aimed at teaching clients to identify
tempting situations and to apply a range of coping skills and
cognitive strategies assumed to be of help in resisting relapse.
Less intensive interventions usually attempted to teach these
skills via written materials and could involve one brief face-to-
face session and telephone contacts. In the event that any studies
used telephone contacts of suHicient frequency and duration to be
considered an intensive intervention, we would have investigated
the sensitivity of our findings to alternative categorisation.
Interventions in special populations
Twenty-eight studies focused on special populations such as
pregnant and postpartum women, hospital inpatients and army
recruits. Most used minimal face-to-face contact and relied
primarily on written materials and/or phone calls. Studies
examining more intensive interventions had very small sample
sizes.
Eight studies among pregnant women (Severson 1997; McBride
1999; Hajek 2001; McBride 2004; Pbert 2004; Morasco 2006; Ruger
2008; Hannöver 2009) and one study in hospital inpatients (Schmitz
1999) included both current smokers and recent ex-smokers but
analysed the two subgroups separately and so were eligible
for inclusion here. Coleman-Cowger 2018 included current and
recently-quit pregnant smokers but did not report outcomes
separately for each group so we excluded this study from the meta-
analysis. Two studies randomised smokers and recent ex-smokers
during pregnancy and evaluated the eHects of post-pregnancy
interventions on women from both groups who did not smoke at
delivery (McBride 1999; McBride 2004).
Pregnant and postpartum ex-smokers
Nineteen studies randomised pregnant (ErshoH 1995; Secker-
Walker 1995; Lowe 1997; Secker-Walker 1998; McBride 1999; Hajek
2001; McBride 2004; Pbert 2004; Morasco 2006; Ruger 2008; Reitzel
2010; Brandon 2012; Levine 2016; Pollak 2016; Coleman-Cowger
2018) or postpartum (Severson 1997; Ratner 2000; Van't Hof 2000;
Hannöver 2009) ex-smokers to interventions designed to assist
them in remaining abstinent throughout their pregnancy and/or
aBer delivery.
Six studies evaluated relatively brief interventions, comprising
an initial face-to-face counselling session supported by written
materials given out at the session (Secker-Walker 1995; Lowe
1997; Secker-Walker 1998; Hajek 2001), repeated mailings over
a period of time (ErshoH 1995), or the addition of a video
(Severson 1997). In each case, there was provision for opportunistic
support of diHerent intensity at other routine visits. Van't Hof
2000 provided the initial relapse prevention counselling session
and reinforcements at later visits without written pamphlets. Two
studies included no face-to-face contact specific to the intervention
but provided a series of phone calls (McBride 2004) or calls and
letters, booklets, and newsletters (McBride 1999). Brandon 2012
provided no face-to-face contact, mailing a series of nine booklets
over the course of the pregnancy and postpartum period. Morasco
2006 used a 90-minute psychotherapy session and additional
phone calls. Hannöver 2009 and Ruger 2008 evaluated motivational
interviewing, and Levine 2016 provided an enhanced cognitive
behavioural intervention that began before delivery and continued
through to 24 weeks postpartum. Ratner 2000 assessed a more
intensive postpartum intervention that included a series of eight
supportive telephone calls in addition to the initial session and
written materials. Reitzel 2010 evaluated six telephone-based
counselling sessions that included two calls postpartum and
four calls up to sixteen weeks postpartum. This was a three-
armed study, and participants in the second intervention arm
were given two in-person counselling sessions, in addition to
telephone counselling. The two intervention arms did not diHer
in outcomes, hence we combined them in our analysis. Pollak
2016 oHered participants one in-person session during pregnancy
and a series of phone calls lasting until nine months postpartum.
The number of phone calls received depended on what their bio-
behavioural risk profile was judged to be. Coleman-Cowger 2018
evaluated 10 proactive phone calls given during pregnancy and
continuing through six months postpartum. We excluded three
studies from the meta-analysis. Pbert 2004 randomly assigned
clinics to implement a provider counselling and oHice systems
intervention. We were unable to extract data from this study in a
comparable format to pool with the other studies, so we reported it
separately. Unlike the other studies, Levine 2016 matched contact
between the two intervention groups, so the study was not
included in the meta-analysis. Coleman-Cowger 2018 did not report
separate outcomes for current and recently-quit smokers so could
not be included in the meta-analysis.
Hospital inpatients
Six studies randomised hospital inpatients who were abstinent
whilst admitted to interventions to help them stay abstinent post-
discharge. Two studies evaluated pharmacotherapy in conjunction
with behavioural support. Cummins 2016 randomised hospitalised
smokers undergoing enforced abstinence to receive either
telephone counselling, NRT, or both, compared with a usual care
control, and Brandstein 2012 gave participants eight weeks of NRT
and telephone counselling post-discharge. The remaining studies
tested solely behavioural interventions. Two studies randomised
hospital inpatients diagnosed with cardiovascular illness who
had not smoked from the time of hospital admission. Hajek
2002 evaluated a brief, routine, one-oH intervention supported by
written materials, and Schmitz 1999 compared six weekly sessions
of skills-oriented relapse prevention with didactic presentations.
Hasuo 2004 randomly assigned participants who had quit during or
shortly before hospitalisation to receive three telephone calls aBer
discharge; all participants received counselling in hospital. Campos
2018 gave inpatients either a 40-minute counselling session (with
relapse prevention component) or 10-minute counselling session
(purely educational about the dangers of smoking).
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Military recruits
Three studies provided interventions to smokers undergoing
enforced abstinence during armed forces training. Two randomly
assigned United States Air Force recruits: Klesges 1999 provided
a 50-minute session during training that covered the short-term
health consequences, costs and social impact of smoking, and
Klesges 2006 provided two one-hour sessions. Conway 2004
randomly assigned naval recruits; in addition to regular smokers,
the intervention targeted former, occasional, and experimental
smokers. Two interventions were tested: (1) written materials
mailed in six instalments aBer the conclusion of training, and (2)
access to a telephone help line.
Behavioural interventions in unselected populations
Sixteen studies explored behavioural interventions in general
populations of abstainers.
Behavioural interventions for unaided abstainers
Five studies randomly assigned participants recruited from local
communities.
• In Killen 1990, volunteers recruited by advertisements were
encouraged over the phone to set a quit date and were randomly
assigned if they managed to abstain for 48 hours.
• In Fortmann 1995, volunteers recruited with the help of random
digit dialling and incentives were randomly assigned following
a 24-hour abstinence.
• Brandon 2000 and Brandon 2004 recruited volunteers who
reported at least one week of abstinence (the average duration
of prior abstinence was 16 months in Brandon 2000 and 75 days
in Brandon 2004).
• In Borland 2004, callers to a quitline were recruited into a study
a day or two later, and we included only the subgroup of callers
who had already quit at this baseline.
All interventions were of relatively low intensity, involving self-help
materials or telephone contact.
• Killen 1990 examined eHects of an eight-week self-guided
relapse prevention programme based on 16 modules.
Participants received the basic module at the first session. ABer
this, another seven modules, either selected by participants or
assigned randomly, were dispensed via weekly mailings over
the next seven weeks. The factorial study also included nicotine
chewing gum conditions (covered later).
• Fortmann 1995 evaluated a two-phase self-help relapse
prevention programme that included 12 weekly progress
reports to be mailed by participants to the programme
oHice. The factorial study also included nicotine chewing gum
conditions (covered later).
• Brandon 2000 compared eHects of a single booklet with
eHects of a partially proactive telephone helpline, eight booklet
mailings, and a combination of helpline and mailings.
• Borland 2004 compared the provision of tailored advice letters
based on telephone assessments with the provision of standard
materials only.
• Brandon 2004 manipulated contact and content by comparing
eight booklet mailings over 12 months, the same booklets at a
single mailing, eight supportive letters over 12 months, and a
single booklet which we treated as the control in the analysis.
Behavioural interventions for assisted abstainers
Twelve studies randomly assigned abstaining smokers who had
taken part in a formal treatment programme. We judged five study
interventions to be of higher intensity (Powell 1981; Stevens 1989;
Razavi 1999; Smith 2001; Mayer 2010), and the rest to be of lower
intensity.
• Powell 1981 randomly assigned abstainers at the end of a five-
day programme to a four-week support group, a telephone
'buddy' system, or a no-treatment control.
• Stevens 1989 recruited smokers who had a quit date one
week earlier and were smoking no more than one cigarette in
the previous four days. Participants were randomly assigned
to three weekly skills-training group sessions, three weekly
discussion group sessions, or a no-treatment control.
• Razavi 1999 randomly assigned clients abstinent at the end of a
three-month treatment with nicotine patch and group support
to monthly group meetings focusing on relapse prevention
strategies, monthly group meetings run by former smokers
oHering general support, or to a no-treatment control.
• Smith 2001 randomly assigned participants eight days aBer
quit date, using stratification based on smoking status, so that
those who were abstinent during this week were analysed
separately. The two intensive interventions consisted of six
90-minute group sessions spaced over four weeks aBer the
randomisation session. They focused on developing cessation
skills and negative aHect (cognitive-behavioural treatment)
or on fostering intrinsic motivation and resolving participant
ambivalence (motivational interviewing). The control group did
not receive any intervention aBer the randomisation session.
• Mermelstein 2003 randomly assigned people at the end of a
seven-week group behavioural programme to receive tailored
counselling calls or non-specific calls from their counsellor. We
included only the subgroup of participants who were abstinent
at the end of the group meeting.
• Mayer 2010 studied participants in workplace cessation
programmes. At the end of the programme, abstinent
participants were randomly assigned to ten sessions of
workplace group counselling or ten sessions of proactive
telephone counselling over the course of nine months. This
study did not include a control group; therefore it was not
included in the meta-analysis. Results are reported narratively
later.
• McNaughton 2013 randomised participants who had quit
following a 12-week course of varenicline and interactive voice
response calls to receive additional biweekly calls from weeks
13 to 52, compared with no further calls.
• Blyth 2015 randomised participants who had successfully quit
for four weeks using the NHS Stop Smoking service to receive
a set of eight revised Forever Free booklets targeted at relapse
prevention, compared with a single 'Learning to Stay Stopped'
booklet.
• Cheung 2015 randomised participants who had successfully
quit for seven days using a combination of pharmacotherapy
and behavioural support to receive one of two social media
interventions lasting two months compared with usual care.
• McDaniel 2015 randomised Quit for Life or employer health-
plan enrollees who had quit for 24 hours or more to receive
either 10 or 20 interactive voice response (IVR) delivered relapse
risk assessments, which triggered a transfer to a Quit Coach
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for participants exceeding a risk threshold, compared with a
standard treatment control.
• Hayes 2018 provided participants who had quit for 24 hours
using a state quitline with a print-based self-administered
six-month parenting program designed to engage parents of
school-aged children in antismoking socialisation.
• Veldheer 2018 assigned participants who had quit following
six weekly group support sessions to receive either eight
self-directed relapse prevention materials or one information
booklet on cigarettes.
Pharmacological interventions
Pharmacological interventions for short-term unaided abstainers
Two studies of nicotine gum randomly assigned participants who
had briefly stopped unaided.
• Killen 1990 randomly assigned participants who stopped
unaided for 48 hours to nicotine gum on a fixed or ad lib dosing
schedule and included a no-gum control.
• Fortmann 1995 randomly assigned participants who stopped
smoking unaided for 24 hours to nicotine chewing gum and no
medication groups. Both of these factorial studies also included
behavioural interventions, as discussed above.
Pharmacological interventions for abstainers following cessation
pharmacotherapy
Eight studies enrolled people to use pharmacotherapy to aid
initial cessation before randomly assigning successful abstainers
to pharmacotherapy for maintenance. We also included in this
subgroup a ninth study, Killen 2006, in which participants
were randomly assigned before starting the quit attempt. The
classification of this study is discussed further in EHects of
interventions. Six studies evaluated the eHects of extended
treatment with bupropion. Three of them also included arms that
used nicotine replacement therapy (NRT). Two studies evaluated
the eHects of extended use of varenicline and one study evaluated
the eHects of extended use of rimonabant.
• Hays 2001 used bupropion to aid cessation, and participants
were randomly assigned if they had quit for at least one week at
the end of seven weeks of treatment. Bupropion or placebo was
used for the rest of the year, and participants were followed up
for a second year.
• Hurt 2003 used a nicotine patch to aid cessation, and abstainers
were eligible for randomisation at the end of eight weeks of
patch therapy. Bupropion or placebo was used for six months
aBer randomisation and participants were followed up for
another six months.
• Killen 2006 used combination therapy of nicotine patch,
bupropion, and individual relapse prevention counselling for
almost three months, then either bupropion or placebo (aBer
tapering of bupropion) for 14 weeks. Follow-up was at 12
months from quit date. Because participants were randomly
assigned at baseline, people who had failed to quit were still
eligible for the randomised phase and were included in the
denominator.
• STRATUS-WW 2006 randomly assigned participants to 5 mg or
20 mg rimonabant for 10 weeks. In the second phase, abstainers
in the 5 mg group were randomly assigned to a further 42 weeks
of 5 mg rimonabant or placebo, and abstainers in the 20 mg
group were randomly assigned to a further 42 weeks of 5 mg of
rimonabant, 20 mg of rimonabant or placebo. Participants were
followed up at the end of treatment (52 weeks from baseline).
• Tonstad 2006 used open-label varenicline for 12 weeks.
Abstainers were randomly assigned to varenicline or placebo for
a further 12 weeks, and then were followed up for six months for
assessment of abstinence 12 months from quit date.
• Covey 2007 used a bupropion and nicotine patch combination
to aid cessation and randomly assigned abstainers aBer
eight weeks. The double-blind placebo-controlled maintenance
phase tested bupropion and nicotine gum in a factorial design.
Therapy lasted 16 weeks, and participants were followed up for
another six months to assess abstinence 12 months from quit
date.
• Croghan 2007 randomly assigned participants to bupropion,
nicotine inhaler, or combination therapy for three months. In a
second phase, abstainers using a single therapy were randomly
assigned to continue the same therapy or receive a placebo
for a further nine months, with post-therapy follow-up for a
further three months. Abstainers using combination therapy
were randomly assigned factorially to bupropion or placebo pill
and nicotine inhaler or placebo inhaler.
• Hays 2009 used weekly counselling and nicotine patches to aid
cessation in a group of recovering alcoholics. At the end of eight
weeks of treatment, participants who had quit for at least the
last week of patch therapy were randomly assigned to either
bupropion or placebo for 44 weeks.
• Evins 2014 enrolled community mental health centre
outpatients diagnosed with schizophrenia or bipolar disease
who had successfully quit for two weeks with 12 weeks
of varenicline and cognitive behavioural therapy (CBT).
Participants received 40 weeks of maintenance varenicline and
a tapering schedule of relapse prevention-focused CBT.
Section 2. Studies randomly assigning smokers before their
quit date
All studies in this section assessed behavioural interventions.
We included two categories of behavioural studies: those that
compared time-matched interventions with and without the
relapse prevention elements, and those that looked at the eHect
of extended participant contact. For studies with more than two
arms, we included the most intensive versus the least intensive in
the main meta-analysis, and we discussed additional diHerences in
the results. We referred to the least intensive intervention as the
'control'.
To evaluate the impact of treatment intensity, we considered
separately interventions providing treatment for up to four weeks
and interventions providing participant contact for longer than four
weeks.
Intervention and control groups matched for contact time
In ten studies, intervention and control conditions were matched
for the amount of contact (some studies also compared a longer
intervention, in which case the relevant arms were compared in
the next category). Eight used a group format for behavioural
intervention (Hall 1984; Davis 1986; Curry 1988; Emmons 1988;
Buchkremer 1991 1; Buchkremer 1991 2; Becona 1997; Schroter
2006) and two used an individual counselling format (Niaura 1999;
Schmitz 1999). Three provided pharmacotherapy in all treatment
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conditions (Emmons 1988; Buchkremer 1991 1; Buchkremer 1991
2). In one study, a factorial design was used to test nicotine gum
against no gum (Niaura 1999).
The components used for relapse prevention were varied.
• Hall 1984 was a factorial study. The arms comparing two variants
of aversive smoking were combined in this analysis. In six of
the 14 sessions, the relapse prevention (RP) group received
relaxation and relapse prevention skills training and reviewed
the cost of smoking and the benefits of abstinence, while the
control group met for general discussion.
• Davis 1986 compared three six-session treatments (i.e. active
skills training, discussion of high-risk situations (not shown in
graphs), and a standard programme). Only 45 participants were
included in the study.
• In one arm of a factorial study, Curry 1988 compared two
programmes in a self-help format: one using a skills-oriented
relapse prevention training permissive to slips, and the other
stressing absolute abstinence. The other arm compared these
two approaches delivered in a format of eight weekly group
sessions, where the absolute abstinence approach also included
gradual reduction and a quit date two weeks later than in the
relapse prevention group. The two study arms were treated
separately.
• Emmons 1988 compared two programmes with diHerent
numbers of sessions across the same period of time,
both accompanied by nicotine gum. The relapse prevention
programme consisted of eight weekly sessions focused
on coping with high-risk situations, cognitive behavioural
strategies, and role-play. The 'Broad Spectrum' behavioural
programme consisted of 12 sessions that focused on strategies
for dealing with cravings and weight control, with quitting
preceded by nicotine fading over three weeks.
• Two studies by Buchkremer and colleagues explored a variety of
behavioural components, as well as diHerent dosing schedules,
for the nicotine patch. The programme consisted of nine weekly
sessions with a target quit date aBer six weeks of gradual
reduction. Relapse prevention components including role-play
were included in one intervention, and this was compared
with a control of the same length (Buchkremer 1991 1). In a
second study, an alternative relapse prevention approach was
used; the programme was modified to reach total abstinence
aBer four weeks, and behaviour therapy techniques such as
covert sensitisation and thought-stopping were added. As the
diHerences were relatively small, we combined the two relapse
prevention programmes (Buchkremer 1991 2).
• Becona 1997 compared eight-week behavioural treatment
programmes with and without a relapse prevention problem-
solving component.
• Niaura 1999 tested imaginary cue exposure as an addition to
individual cognitive behavioural treatment. All groups had five
post-quit sessions, and we have included them in the matched
contact control group, although the duration of both control
conditions was diHerent. In a factorial design, a nicotine gum
condition and a no-gum condition were compared.
• Schmitz 1999 used a sample of women with cardiac risk and
compared six sessions of skills-oriented relapse prevention with
six sessions of didactic presentations on cardiac risk and the
benefits of quitting.
• Schroter 2006 compared six sessions that included components
such as role-playing, coping responses to high-risk situations,
and self-awareness with a standard behavioural cessation
programme that focused on positive changes attained through
abstinence.
Intervention and control arms not matched for contact time or
duration
Almost all smoking cessation studies that compared more and
less intensive treatments included some intervention to prevent
relapse. We included only studies that specified relapse prevention
as an explicit focus of the intervention in the title or abstract.
We did not include studies that oHered treatment proactively to
special populations such as pregnant or hospitalised smokers
because all studies using these groups provided some relapse
prevention input within the active treatment arm, and they were
covered in separate meta-analyses. When studies had three or more
treatment conditions, the main analyses compared the most and
least intensive interventions.
Behavioural interventions
Varying intensity of face-to-face treatment
Seven studies compared longer and shorter programmes. The
relative intensity of the common cessation programme and of
the additional relapse prevention component was variable. We
subgrouped studies according to whether the control group
received more than four sessions.
• Killen 1984 provided nicotine gum and one-week intensive
behavioural treatment, which included relapse prevention
components plus seven further brief visits, and compared
groups with and without two additional group sessions and
optional drop-in visits. A group with no gum was also included
but was not used in our analysis.
• Brandon 1987 treated a sample of smokers in six sessions over
two weeks and compared a group receiving no further treatment
with a group receiving four additional relapse prevention
sessions. Another arm with a rapid puHing component was not
covered in this review.
• Hall 1987 combined nicotine or placebo gum with five or 14
sessions, and the more intensive treatment also contained a
larger relapse prevention component.
• Buchkremer 1991 1 tested the addition of three booster sessions
six months aBer the basic nine-session programme and a
programme with relapse prevention components. All groups
received nicotine patches.
• Shoptaw 2002 studied smokers treated for heroin dependence
and compared the nicotine patch combined with 12 weeks
of brief visits with the additions of a behavioural programme
that included relapse prevention and mood management, a
contingency management programme in which participants
were paid for abstinence, and a combination of the latter two.
In two studies, control groups were oHered four or fewer sessions.
• Hall 1985 combined nicotine gum with four educational sessions
over three weeks or a behavioural treatment that included
relapse prevention components provided in 14 sessions over
eight weeks (a behavioural treatment-only group was not
included here).
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• Lifrak 1997 combined nicotine patch treatment with three
supportive sessions with a nurse over nine weeks or with 16
relapse prevention sessions with a behavioural therapist over 16
weeks.
Extended contact using proactive phone calls
Three studies tested extended contact via proactive phone calls.
Lando 1996 provided group-based behavioural therapy for eight
weeks and compared a group receiving no further treatment
with a group receiving proactive calls 1, 8, and 11 months later.
Segan 2011 randomly assigned callers to the Victoria, Australia,
quitline to four to six additional calls explicitly designed to prevent
smoking relapse and compared this with a control group with
no additional calls. Blebil 2014 recruited people attending stop-
smoking clinics. Both groups received a series of calls following
smoking clinic visits over three months, with the intervention
group receiving additional phone calls. We excluded other studies
that tested the use of telephone counselling as an adjunct
(add-on) to nicotine replacement therapy because they did not
describe the intervention as relapse prevention, and most of
the behavioural support was provided during the period of
intended pharmacotherapy (i.e. not extending the overall duration
of treatment).
Additional print-based support
Unrod 2016 randomised quitline callers to receive eight Forever
Free relapse prevention booklets either all at once or over a 12-
month period, compared with usual care. In SheHer 2010, quitline
callers were randomly assigned to standard quitline service or
to standard quitline service plus eight printed self-help booklets
aimed at relapse prevention. This was a quasi-randomised trial
with significant baseline imbalances. Simmons 2018 randomised
participants to either receive intensive repeated mailings (10
booklets over 18 months), standard repeated mailings (eight
booklets over 12 months) or one traditional self-help booklet.
Both the intensive mailings and standard mailings used self-help
materials with a relapse prevention component, and we compared
each with the self-help control separately in the meta-analysis, with
the control group split between the two comparisons.
Additional intervention delivered by computer or mobile phone
Four studies tested additional support provided by computer
or mobile phone. Japuntich 2006 provided bupropion and
brief individual counselling to all participants. The intervention
consisted of internet access to the Comprehensive Health
Enhancement Support System for Smoking Cessation and Relapse
Prevention (CHESS SCRP) for 12 weeks. Wetter 2011 tested the
addition of computer-delivered treatment. All participants were
provided with six weeks of nicotine patch therapy, five group
counselling sessions, and ecological momentary assessment (EMA)
procedures for one month post-quit date. In addition to the EMA,
the intervention arm received computer-delivered treatment on
palmtop computers for one month post-quit date, consisting of
three modules. Hicks 2017 recruited adult smokers with post-
traumatic stress disorder (PTSD). All participants received a mobile
phone with a preinstalled contingency management app. The
intervention group also received a Stay Quit Coach app tailored
for the specific needs of patients with chronic PTSD and designed
to be integrated into ongoing psychotherapy. Durmaz 2019 sent
participants in the intervention group 60 WhatsApp messages
which provided informative support leading up to and following the
quit date, with a focus on preventing relapse. However, participants
in the control group received relapse prevention support as part of
the usual care common to both groups.
Formulation of coping strategies
Van Osch 2008 provided participants in a national Quit and Win
contest with computer-tailored cessation advice and telephone
counselling for one month post-quit date. The intervention and
control arms received the exact same programme, but in the
intervention arm, participants were asked to formulate three
coping plans when completing the baseline survey.
Combined behavioural and pharmacological interventions
Joseph 2011 tested extended treatment with counselling and NRT.
All participants were provided with NRT and five telephone calls
over four weeks. In the intervention arm, participants received
extended telephone counselling and NRT for a further 48 weeks.
The control arm received one additional call at eight weeks and no
additional NRT.
Risk of bias in included studies
Risk of bias assessments are summarised in Figure 2 and Figure 3.
Judgements were summarised by the domains below. We judged
22 studies to be at high risk of bias in one or more domains, 53 to be
at unclear risk of bias in one or more domains and not high in any
domain, and six studies to be at low risk of bias across all domains.
Details on 'Risk of bias' judgements for each study can be found in
Characteristics of included studies.
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Figure 3.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Sample size
Many studies were small and therefore had limited power to detect
realistic diHerences in quit rates, especially in the group that
randomly assigned smokers before the quit date.
Study design
Studies randomly assigning successful end-of-treatment quitters
provide the most straightforward test of relapse prevention
interventions designed for clinical practice (see Discussion). Eight
studies of pharmacological treatments used this approach, but
only six studies of behavioural treatments randomly assigned
participants who were abstinent aBer more than one week
of treatment (Razavi 1999; Mermelstein 2003; Mayer 2010;
McNaughton 2013; Blyth 2015; Cheung 2015).
Definition of smoking cessation
All studies were required by our inclusion criteria to report smoking
status a minimum of six months from the start of the intervention.
In the case of studies that randomly assigned smokers before
quitting, this could have been from the quit date. Some studies
timed follow-up from the end of treatment. FiBeen studies had six
months' follow-up (Emmons 1988; Schmitz 1999; Van't Hof 2000;
Japuntich 2006; Reitzel 2010; SheHer 2010; Brandstein 2012; Blebil
2014; Cheung 2015; Cummins 2016; Hicks 2017; Campos 2018;
Coleman-Cowger 2018; Veldheer 2018; Durmaz 2019), and all others
had a longer follow-up period from the start of intervention. Some
studies did not provide a definition of abstinence (Powell 1981;
Becona 1997; Klesges 1999; Hasuo 2004; Campos 2018), and most
others reported a point prevalence rather than a sustained measure
of abstinence.
Allocation
Thirty-three studies adequately reported their method of
randomisation and we judged them to be at low risk of bias. Forty-
six studies did not adequately report on randomisation and we
judged them at unclear risk. We judged three studies to be at
high risk of bias. Van Osch 2008 assigned participants based on
odd or even registration numbers. Hannöver 2009 based allocation
on alternation of study screening forms. SheHer 2010 assigned all
callers to a quitline within a six-week period to the intervention
group and callers during the six weeks preceding and following the
given six-week period to the control group.
As well as judging the randomisation of studies, we also evaluated
the concealment of that randomisation. We judged 19 studies to be
at low risk of bias. Seven studies did not conceal allocation and thus
were at high risk of selection bias. The remaining studies did not
adequately describe allocation concealment; we judged the risk of
bias for these studies as unclear.
In total, eight studies were at high risk for some kind of selection
bias, and 15 studies were at low risk for selection bias from both
sources. The remaining studies were at unclear risk of bias from
either randomisation or concealment.
Blinding (performance bias)
Most studies did not provide suHicient detail to allow evaluation
of risk of performance bias and hence were judged to be at
unclear risk in this domain. Twenty-seven studies provided details
of blinding procedures suHicient to rate them at low risk of
bias in this domain (or, in the case of behavioural interventions
where blinding of participants was not possible, where other
study characteristics such as similar amounts of contact between
conditions, or participants not knowing about other conditions,
meant that performance bias was judged to be unlikely). We judged
five studies to be at high risk of performance bias: two studies
testing NRT did not provide placebo to the control arms (Killen
1984; Hall 1985); in one study of a behavioural intervention, neither
participants nor providers were blinded, and control participants
were aware that the intervention arm was receiving additional
treatment (Reitzel 2010); in Segan 2011 blinding was broken; and
in Coleman-Cowger 2018 blinding was not possible and there was
a substantial diHerence in contact levels between the intervention
and control groups.
Validation of self-reported abstinence (detection bias)
Biochemical validation of most or all self-reports of abstinence
was reported for most studies. Sixteen studies did not attempt any
validation (Powell 1981; Severson 1997; Klesges 1999; Van't Hof
2000; Mermelstein 2003; Borland 2004; Conway 2004; Klesges 2006;
Schroter 2006; Van Osch 2008; Hannöver 2009; SheHer 2010; Joseph
2011; Segan 2011; Simmons 2018; Durmaz 2019), but in some other
cases, samples were not collected from all participants, were not
collected at long-term follow-up, or were not used to correct self-
reports. In one unpublished study, it was unclear whether results
were validated (STRATUS-WW 2006), and Ruger 2008 reported the
use of biochemical validation but not the cut-oH value or the
level of misreport. Pbert 2004 noted greater deception amongst
intervention group participants than amongst those in the control
condition. Brandon 2012 only performed biochemical validation of
abstinence in participants within 100 miles of the research team.
In studies of behavioural smoking cessation interventions, lack of
biochemical validation of self-reported smoking status risks the
introduction of significant bias. Participants who received more
intensive care can be expected to be trying harder to please their
advisors and report ‘good news’. When the intervention group
received more face-to-face contact than the control group and the
results were not biochemically validated, we judged studies to be
at high risk of detection bias.
Overall, we judged seven studies to be at high risk of detection
bias because of lack of verification of results. Eleven studies did
not provide suHicient information; we judged these to be at unclear
risk. The remaining studies were all at low risk of detection bias.
Incomplete outcome data
Another risk of bias specific to smoking cessation studies concerns
excluding participants lost to follow-up from the analysis or
imputing their outcomes as if their loss to follow-up was
independent of outcome. This is because in smoking cessation
treatments, participants who fail in stopping smoking may feel
embarrassed and may find further participation unhelpful, while
those who are successful may be more likely to stay in touch.
Treating those lost to follow-up as still smoking is likely to be a
reasonable assumption, but sometimes the actual figures were not
available, or loss to follow-up was such that most participants did
not provide data, or many more participants had been followed up
in one arm than in another. When these limitations were present,
studies were judged to be at unclear or high risk of attrition bias.
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Most studies reported low or moderate losses to follow-up in
suHicient detail to be judged at low risk of bias in this domain. Three
studies were at high risk from attrition bias. In Evins 2014 there was
a 55% follow-up rate in the control group compared with 88% in
the intervention group. In Hicks 2017 there was a 50% follow-up
rate in the control group compared with 80% in the intervention
group. In Van Osch 2008, loss to follow-up was high in both arms
(less than 40% of participants followed up at seven months); the
study authors cautioned that this limited the validity of the results.
A further 22 studies were judged to be at unclear risk of bias in this
domain, as the studies did not report results in suHicient detail to
permit counting of all participants lost to follow-up as continuing
smokers in our analyses.
Other potential sources of bias
We judged two studies to be at high risk of bias from other sources
(Mayer 2010; Segan 2011). Mayer 2010 reported a higher initial
abstinence in one study arm, and in Segan 2011 there was probable
contamination of study arms. We judged three studies to be at
unclear risk from other sources (Lowe 1997; Hays 2009; Cheung
2015). Lowe 1997 had potential contamination of study arms. In
Hays 2009 there was a discrepancy in reported results data. In
Cheung 2015 it was unclear whether results had been adjusted
for cluster randomisation. We did not detect any other sources of
potential bias in the remaining studies.
E=ects of interventions
See: Summary of findings for the main comparison Behavioural
interventions for assisted abstainers; Summary of findings 2
Pharmacotherapy for assisted abstainers
Section 1. Studies of abstainers
Behavioural interventions in special populations
Pregnant and postpartum ex-smokers
Pooled results from eight studies of interventions in pregnancy
did not demonstrate a benefit at the end of pregnancy (n = 1523,
risk ratio [RR] 1.05, 95% confidence interval [CI] 0.99 to 1.11,
I2 = 0%; Analysis 1.1). FiBeen studies included follow-up during
the postpartum period. We also detected no significant benefit
among this group of studies, overall or in subgroups, according
to timing of intervention, with the confidence interval narrowly
missing significance (n = 4606, RR 1.02, 95% CI 0.94 to 1.09, I2 =
3%; Analysis 1.2). There were two studies that we could not include
in the meta-analysis. We were unable to extract data from Pbert
2004 in a comparable format to pool with the other studies, but it
did not detect any significant eHect of intervention on spontaneous
quitters at delivery; the postpartum non-smoking rate was higher in
the usual care group. Unlike the other studies, Levine 2016 matched
contact between the two intervention groups, so the study was not
included in the meta-analysis. However, it did not detect an eHect
in favour of either group (n = 300, RR 0.80, 95% CI 0.53 to 1.20).
Hospital inpatients
There was no evidence of a benefit of behavioural intervention
in hospitalised patients who had not smoked in hospital, based
on pooled results from four studies (Schmitz 1999; Hajek 2002;
Hasuo 2004; Campos 2018), and the behavioural arm of Cummins
2016 (n = 1385, RR 1.10, 95% CI 0.82 to 1.47, I2 = 58%; Analysis
2.1). Pharmacological interventions were not found to be beneficial
either, based on pooled results of nicotine replacement therapy
(NRT) from Brandstein 2012, and two arms from Cummins 2016, one
of NRT, and one of NRT plus telephone counselling (n = 1078, RR
1.23, 95% CI 0.94 to 1.60, I2 = 0%; Analysis 2.2).
Military recruits
We did not display results graphically or pool results because
denominators were unclear and reported results were corrected for
clustering. In all three studies, the period of enforced abstinence
did give rise to a higher quit rate than the spontaneous rate
expected in these populations of young smokers, but only Klesges
2006 reported a statistically significant eHect. With adjustments
for clustering and predictors, the result for continuous abstinence
at one year was odds ratio (OR) 1.23 (95% CI 1.07 to 1.41, n =
33,215). Crude abstinence rates were 15.47% versus 13.74%, so the
absolute eHect was small. An earlier study of 25,996 participants
reported 18% abstinence in the intervention group compared with
17% in the control group, however the denominators for these
percentages were unclear (Klesges 1999). A study of 2781 female
naval recruits provided the intervention aBer the end of training
and did not detect an eHect of mail (RR 1.03, 95% CI 0.93 to 1.14) or
phone intervention (RR 0.93, 95% CI 0.84 to 1.04); fewer than 3% of
participants called the helpline for counselling (Conway 2004).
Behavioural interventions in unselected populations
Behavioural interventions for unaided abstainers
We found no evidence of a benefit of interventions to prevent
relapse in people who had initially quit unaided (Killen 1990;
Fortmann 1995; Brandon 2000; Borland 2004; Brandon 2004) (n =
3561, RR 1.06, 95% CI 0.96 to 1.16, I2 = 1%; Analysis 3.1). All five
studies used low-intensity self-help interventions.
Behavioural interventions for assisted abstainers
We detected no long-term benefit of skills-based interventions in
preventing relapse in 11 studies in which abstaining smokers were
randomly assigned aBer they had taken part in a formal treatment
programme (n = 5523, RR 0.98, 95% CI 0.87 to 1.11, I2 = 52%;
Analysis 4.1). There was also no diHerence between higher intensity
interventions (four studies, n = 1121, RR 1.06, 95% CI 0.82 to 1.36, I2
= 54%) and lower intensity interventions (seven studies, n = 4332,
RR 0.95, 95% CI 0.82 to 1.09, I2 = 49%). This meta-analysis compared
the most intensive intervention with the least intensive control in
the studies with more than two arms, except in Cheung 2015, where
two intervention arms were combined, and McDaniel 2015, where
two intervention arms of diHering intensities were listed separately
compared with a split control group. Using diHerent comparison
conditions did not change the conclusion.
One study compared workplace group counselling with proactive
phone counselling post-cessation and did not detect a significant
diHerence between the two at 12 months (workplace versus phone,
RR 1.07, 95% CI 0.88 to 1.31; analysis not shown, Mayer 2010).
Pharmacological interventions
Pharmacological interventions for short-term unaided abstainers
Pooled results of two large studies of nicotine gum detected a small
eHect (Killen 1990; Fortmann 1995) (n = 2261, RR 1.24, 95% Cl 1.04
to 1.47, I2 = 56%; Analysis 6.1). In both of these studies, the period
of unassisted abstinence was short, and these studies were distinct
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from the next group, in which a more extended period of abstinence
was required before the relapse prevention phase was initiated.
Pharmacological interventions for abstainers aKer cessation therapy
Pooling two studies of NRT (Covey 2007 using gum and Croghan
2007 using inhaler, both with factorial designs entered separately)
did not reveal a long-term eHect (n = 553, RR 1.04, 95% CI 0.77 to
1.40, I2 = 0%; Analysis 5.1). This contrasted with the two studies
discussed in the previous section. It is worth noting that adherence
with oral NRT was low, and that one study replaced the initial patch
treatment with 2 mg gum (Covey 2007). It is also worth noting
that this analysis included only a small number of participants and
hence confidence intervals were very wide.
The estimated eHect of extended therapy with bupropion, based
on six studies, slightly favoured the intervention and narrowly
missed statistical significance (n = 1697, RR 1.15, 95% CI 0.98
to 1.35, I2 = 0%; Analysis 5.2). Whilst there was no evidence of
statistical heterogeneity, some clinical heterogeneity was noted
in the intervention used for the cessation induction phase, the
duration of treatment, and the duration of follow-up aBer cessation
of medication.
Two studies (Covey 2007; Croghan 2007) allowed a comparison
between combination therapy of bupropion and NRT versus
neither. No significant benefit was detected (n = 243, RR 1.18, 95%
CI 0.75 to 1.87; Analysis 5.3), and some evidence of heterogeneity
was found (I2 = 66%).
Two studies (Tonstad 2006; Evins 2014) detected a significant
benefit of extended varenicline with some heterogeneity (n =
1297, RR 1.23, 95% CI 1.08 to 1.41, I2 = 82%; Analysis 5.4). Both
studies detected statistically significant eHects in favour of the
intervention.
One further study (STRATUS-WW 2006; n = 1017) detected a
significant benefit of extended treatment with rimonabant (RR 1.29,
95% CI 1.08 to 1.55; Analysis 5.5). Rimonabant is not licensed for use
in any country, and its manufacturers are no longer supporting its
development because of safety concerns (Cahill 2013).
Section 2. Studies randomly assigning smokers before their
quit date
Intervention and control groups matched for contact time
We found that no benefit was derived from the use of specific
relapse prevention components in group or individual format
interventions; this finding was based on the results of 10 studies
(n = 872, RR 0.92, 95% CI 0.72 to 1.16; Analysis 7.1). No evidence of
heterogeneity was noted (I2 = 11%). All but Niaura 1999 involved
treatment contact for longer than four weeks; therefore, we did not
conduct a subgroup analysis by treatment duration. Most studies
used a skills-training approach, so we did not conduct a subgroup
analysis by treatment type.
One study with two arms, comparing diHerent versions of a self-
help programme, did not detect a diHerence in quit rates (Curry
1988, n = 91, RR 1.52, 95% CI 0.67 to 3.46; Analysis 7.2).
Intervention and control arms not matched for contact time or
duration
Behavioural interventions
Varying intensity of face-to-face intervention
We detected no eHect in seven studies that tested extended face-
to-face contact (Killen 1984; Hall 1985; Brandon 1987; Hall 1987;
Buchkremer 1991 1; Lifrak 1997; Shoptaw 2002) (n = 699, RR 1.02,
95% CI 0.80 to 1.29, I2 = 4%; Analysis 8.1). There was no evidence
of diHerences between subgroups based on the number of control
group contacts.
Extended contact using proactive telephone calls
Three studies (Lando 1996; Segan 2011; Blebil 2014) did detect
a benefit of providing extended contact by telephone, though
the lower end of the confidence interval encompassed no
eHect (n = 2758, RR 1.18, 95% CI 0.93 to 1.49; Analysis 9.1.1).
Statistical heterogeneity was moderate (I2 = 67%), likely because
of diHerences in the initial cessation programme: In Lando 1996,
participants received additional calls aBer an intensive eight-week
group programme, whereas in Segan 2011, additional calls were
tested as an adjunct to standard quitline treatment and in Blebil
2014, participants received extra calls in adjunct to smoking clinic
visits.
Additional print-based support
Three studies (SheHer 2010; Unrod 2016; Simmons 2018) detected
a benefit from providing additional print-based support (n = 6224,
RR 1.16, 95% CI 1.01 to 1.33, I2 = 70%; Analysis 9.1.2), though
confidence intervals also encompassed no meaningful benefit.
In the main analysis, we split the control groups of two studies
with multiple intervention arms (Unrod 2016 and Simmons 2018)
to avoid double-counting. We conducted a sensitivity analysis
combining the intervention arms; eHects were consistent with
the main result though the confidence interval now crossed one
(RR 1.20, 95% CI 0.96 to 1.50, I2 = 83%). Further, SheHer 2010
reported significant baseline imbalances between study groups,
so we conducted another sensitivity analysis removing the study,
again not detecting a benefit (RR 1.13, 95% CI 0.97 to 1.31, I2 = 72%).
Additional intervention delivered by computer or mobile phone
Four studies (Japuntich 2006; Wetter 2011; Hicks 2017; Durmaz
2019) did not detect a benefit of providing additional support via
computer or mobile phone (n = 729, RR 1.19, 95% CI 0.85 to 1.66, I2
= 26%; Analysis 9.1.3).
Formulation of coping strategies
Van Osch 2008 evaluated the impact of asking participants of a Quit
and Win contest to formulate coping strategies in advance and also
did not detect an eHect (n = 1566, RR 1.27, 95% CI 0.97 to 1.67;
Analysis 9.1.4).
Combined behavioural and pharmacological interventions
Joseph 2011 tested extended therapy with both NRT and proactive
telephone counselling and did not detect a significant eHect at 18
months (n = 443, RR 1.28, 95% CI 0.94 to 1.75; Analysis 9.2).
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Section 3. Subgroup analysis by duration of prior abstinence
For analyses of studies randomising abstainers, we conducted
subgroup analyses grouping studies by the duration of prior
abstinence of participants (analyses 10 to 15). We grouped studies
based on whether participants had been abstinent for four or more
weeks, less than four weeks, or if prior abstinence varied or was
not adequately specified. We summarised the duration of prior
abstinence of participants in studies recruiting abstainers in Table
1. Only analysis 10.2 and analysis 13.1 included enough studies
in the diHerent subgroups for a meaningful subgroup comparison.
Neither analysis detected diHerences between subgroups. The P
value for subgroup diHerence between the ≥ 4 weeks and < 4 weeks
groups in Analysis 10.2 was 0.83, with I2 = 0%. The P value for
subgroup diHerence between the ≥ 4 weeks and < 4 weeks groups
in Analysis 13.1 was 0.97, with I2 = 0%.
D I S C U S S I O N
Summary of main results
As discussed further below, studies that randomised abstainers
provided the best evidence on the eHectiveness of relapse
prevention interventions, and we focus on these when
summarising main results and drawing conclusions. In this
review, we did not detect a clinically significant eHect of existing
behavioural 'relapse prevention' methods for people quitting
smoking. Our certainty in the evidence for behavioural methods
for relapse prevention in people randomised aBer assisted quitting
was moderate and was limited by heterogeneity (Summary of
findings for the main comparison), meaning further studies may
change our estimate of eHect.
Results for some pharmacotherapies in abstainers were more
encouraging, with the certainty of evidence ranging from low to
moderate (Summary of findings 2). The two studies of extended
varenicline found it to be beneficial in preventing relapse.
Certainty in the eHect estimate was moderate, limited by statistical
heterogeneity. The study of rimonabant also detected a significant
eHect in favour of the intervention, but this drug has been
withdrawn from the market because of concerns about its safety.
Whilst nicotine replacement therapy (NRT) was found to help in
unassisted abstainers, two studies of extended NRT in assisted
abstainers did not detect an eHect, but the certainty of evidence
was low. The two comparisons of bupropion plus NRT versus
double placebo did not detect an eHect either, and the six studies
of bupropion, when combined, narrowly missed significance; none
yielded a significant result on their own. We graded the certainty
of evidence for this comparison as moderate due to imprecision,
meaning that future studies may have an important impact on our
confidence in the estimate of eHect and may change the estimate.
In discussing the further implications of this review, we first
comment on the technical aspects and limitations and attempt to
make some methodological recommendations for future work in
this area. We then discuss some of the conclusions pertaining to
diHerent treatment formats.
Inclusion and exclusion of studies
Identifying criteria for including studies in this review was diHicult.
We included all studies that randomly assigned abstainers, as
these provide the best test of interventions aimed at maintaining
abstinence. Studies randomly assigning smokers before quitting
presented a challenge. Although such studies may be described as
studies of relapse prevention, they usually test primarily smoking
cessation interventions, with interventions aimed at preventing
relapse added to the treatment programme but not analysed
separately. One of the problems involved in considering the
inclusion of smoking cessation studies with a specified relapse
prevention component is that they were sometimes similar in
design to other studies that did not specifically mention relapse
prevention in their title or abstract but used virtually identical
methods. In our initial analyses, we included a wider group of
studies (e.g. Goldstein 1989; Zelman 1992; Hall 1994; Hall 1996;
Brown 2001), but in the end we decided to restrict the analysis
of studies randomly assigning smokers to those that mentioned
relapse prevention explicitly. The results of the review were not
aHected by this decision, as the excluded studies were also small
and did not show significant treatment eHects. We also excluded
a small number of studies that randomly assigned smokers
before quitting and that explicitly included relapse prevention or
maintenance but concerned smoking cessation interventions that
are already covered by three other Cochrane reviews: exercise
(Ussher 2012), aversive smoking (Hajek 2001a), and interventions
for hospitalised smokers (Rigotti 2012).
The negative results of the individual studies are fairly consistent,
and it is unlikely that using alternative inclusion criteria would lead
to diHerent conclusions; however, identifying appropriate studies
in this challenging area is diHicult. Possible limitations of the
review are that we may not have identified all relevant research
and that we may not have pooled studies appropriately. We think
it is unlikely that large eHects have been missed in the studies
conducted so far, but, in some cases, the studies were too small to
allow detection of moderate eHects.
The two study designs according to the timing of
randomisation
The key methodological feature of existing attempts to evaluate
relapse prevention interventions concerns the time when
participants were randomly assigned (i.e. before or aBer they
stopped smoking).
The main logical argument in favour of randomly assigning smokers
before they stop smoking is that much relapse prevention advice
could be relevant even in the very first stages of quitting smoking.
On the practical side, although it is relatively easy to attract smokers
to start an experimental treatment, the samples would be much
smaller if only those abstinent at the end of treatment were
enrolled. However, combining cessation and relapse prevention
reduces the power to detect specific relapse prevention eHects.
The primary outcome variable is normally the abstinence rate
at follow-up, and it is diHicult to diHerentiate any eHects that
the intervention may have had on the initial smoking cessation
from eHects on preventing relapse in smokers who were initially
successful. The initial success or failure is likely to be determined
by a number of intervention and participant variables other than
the relapse prevention component, which is usually only a small
part of the overall programme. One way to resolve this problem
could be to focus the analysis on the initial successes only. However,
none of the existing studies used this approach, and the published
data usually did not include suHicient details to allow survival
analysis. Even if relapse rates for initially successful abstainers
were available, the relapse prevention eHect would be diHicult
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to interpret when comparison groups have diHerent short-term
cessation rates.
Randomly assigning only those smokers who have made a
successful quit attempt represents a stronger study design. As
cessation interventions are segregated from relapse prevention
interventions, the results cannot be skewed by uneven initial
cessation rates, any relapse prevention eHects are more likely
to be detected, and the results are easy to interpret. On the
downside, this approach requires greater eHort to recruit suHicient
samples. Among existing studies of behavioural treatments using
this approach, many used spontaneous abstainers, such as
pregnant women. The diHerence between the initial smoking
cessation and later relapse prevention treatment is much clearer in
pharmacotherapy.
The studies that randomly assigned abstainers varied considerably
in the periods of time for which participants had already abstained
from smoking (i.e. from 24 hours to 16 months). There seemed to be
broad agreement on the conceptual distinction between 'stopping
smoking' and 'staying quit' and on the common understanding
of the concept of relapse, but accepted operational definitions
were lacking, although some suggestions have been made (Ossip-
Klein 1986). It seems clear that abstinence for a period of time
close to inter-cigarette intervals, or overnight abstinence, does not
constitute cessation of smoking, and that a return to smoking aBer
several weeks of total abstinence can be classified as a relapse.
However, common behaviours such as abstinence for 24 hours
or smoking only a few cigarettes every few days, become more
diHicult to classify. Little consensus has been reached on what
amount of smoking aBer what type of smoking restraint over what
period of time represents a relapse as opposed to the initial failure
to stop smoking. Ideally, future relapse prevention studies should
follow the example of existing drug trials and should use suHiciently
long periods of no smoking and suHiciently strict definitions of the
initial abstinence and outcome to avoid areas of contention.
Some methodological recommendations
The ideal study of a relapse prevention intervention aimed at
complementing existing treatments for smokers seeking help
would randomly assign smokers who were abstinent continuously
and completely for at least four weeks. An appropriate outcome
measure would be continuous lapse-free abstinence of at least six
months when the intervention was aimed at avoiding lapses, but
some lapses would have to be allowed when the intervention was
aimed at helping patients to cope with lapses should these occur.
General agreement has been reached that, for dependent smokers
seeking treatment, becoming an occasional smoker is usually not
an option, and for long-term success, any lapses would have to
cease eventually. It would seem sensible to allow lapses over a
limited 'period of grace' (e.g. three or even six months), followed
by at least six months of lapse-free abstinence. Many studies in this
review were seriously underpowered, using 15 or 20 participants
per condition. Future research needs to acknowledge that any
eHects are likely to be small, and that large samples will be needed
to avoid type 2 errors.
Interpreting the review results
The 48 studies that randomly assigned abstainers provide the main
interpretable body of data in this field. The results of both special
population studies and studies of smokers seeking treatment
suggest that behavioural brief interventions and interventions
relying on written materials, mailings, and telephone contact are
ineHective for relapse prevention. It may be important to note
that more intensive approaches were examined in only a handful
of studies, and some were too small to allow detection of any
realistic eHect. Although intensive interventions in this area need to
resolve the likely problems related to intervention costs and patient
attendance, further work on such treatments may be needed.
Rates of abstinence were highly variable across studies because
of such factors as the population studied, the intensity of any
cessation intervention provided, the period for which abstinence
had already been maintained, the length of follow-up, and
the definition of cessation. Because of obvious problems with
comparisons of success rates across studies (Hajek 1994), we
did not discuss results in terms of the absolute abstinence rates
achieved.
With regard to the contents of the behavioural interventions, the
negative results concerned primarily the traditional skills-based
approach, which holds a virtual monopoly in this field. It remains
possible that the original concept is valid (i.e. that recent ex-
smokers can benefit from being taught how to identify tempting
situations), and that eHective strategies for coping with such
situations can also be taught. If this is the case, the negative
results could have been due to the fact that such skills were not
being taught eHectively. If future studies examine this approach,
investigators should try to check whether participants acquired
and practised the skills taught. However, an alternative possibility
has to be considered - that, despite the strong intuitive validity
and popularity of the classic relapse prevention procedures, they
do not produce the desired eHect. Future studies may be better
advised to focus on alternative approaches not studied extensively
or at all so far, such as opportunistic use of nicotine replacement,
contingency management, social support, cue exposure (only
imaginary exposure has been studied so far), interventions aimed
at maintaining abstainers' morale and awareness of the danger of
slips, and so forth.
Regarding pharmacological interventions, some large and well-
conducted studies have investigated the extended use of
bupropion and varenicline; however, NRT has mostly been studied
only in relatively small samples, as an add-on to bupropion trials
and in paradigms likely to generate low treatment compliance,
which lower the chance of detection of eHects of the expected
size. Given the good acceptability, safety, and cost profile of NRT,
further studies of extended use of traditional NRT and e-cigarettes
to prevent relapse in abstainers are needed.
Agreements and disagreements with other studies or
reviews
One large review by Coleman and colleagues of relapse prevention
interventions for abstinent smokers detected more positive results
than ours for some outcomes (Agboola 2010; Coleman 2010). In
particular, although we did not detect any significant eHects in
pooled comparisons, Coleman and colleagues concluded that self-
help materials, bupropion, and nicotine replacement therapy were
eHective at six months and longer. We investigated the reasons for
these discrepancies.
Coleman and colleagues used similar search strategies and
inclusion criteria to ours, hence at the time our included studies
lists mapped closely onto each other. Their review did not
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include some new studies added in the most recent updates, nor
did it include one study from previous versions of this review
(Klesges 2006 was excluded because participants included some
never-smokers). However, the diHerences in conclusions were not
attributable to the exclusion of these studies. DiHerences between
results for the most part were due to decisions about subgroups
and outcomes presented.
Although our meta-analysis of bupropion included an additional
two studies (Killen 2006; Hays 2009) to the four presented
by Coleman and colleagues, the reason for the discrepancy in
our pooled results from bupropion studies lies in the outcome
data used. Coleman and colleagues used diHerent definitions of
abstinence and diHerent denominators; in particular, they did
not always count dropouts as continuing smokers. We followed
the standard methods used by the Cochrane Tobacco Addiction
Group, which resulted in a more conservative outcome. The
diHerence in NRT results was attributable to subgroup decisions.
Our pooled results suggested that NRT could be eHective in unaided
abstainers but did not detect an eHect in assisted abstainers;
Coleman and colleagues merged the two groups and detected a
significant eHect overall. Finally, Coleman and colleagues detected
a significant eHect of written self-help at long-term follow-up. The
three included studies from their analysis were included in our
analysis of behavioural interventions for unaided abstainers, and
our analysis contained an additional two studies. However, the
exclusion of these two studies did not change the overall eHect in a
sensitivity analysis; rather, the diHerence in results was largely due
to the data presented for Brandon 2000. This was a factorial study
that tested access to a quitline and repeated mailings; whereas
Coleman and colleagues compared the arms that received mailings
with the arms that did not (quitline only and control), we compared
all intervention arms (quitline, quitline plus mailings, mailings
only) with the control arm and used slightly diHerent data obtained
via correspondence with the author.
With the exception of these three analyses, the results from
Coleman and colleagues were consistent with our own.
The Cochrane Review of nicotine receptor partial agonists included
the same studies of extended varenicline treatment and agreed
with our findings (Cahill 2016). However they also noted that the
integrity of the blinding in the studies may have been compromised
because the participants had already used open-label varenicline
to achieve initial abstinence. Lindson 2019 compares diHerent
regimens of NRT, and the review contains in-depth analyses of
treatment duration for NRT in current smokers. No evidence was
found to support extended use of NRT in this population, but
evidence was judged to be of low certainty.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In people who have successfully stopped smoking using
pharmacotherapy, there are mixed results regarding extending
pharmacotherapy for longer than is standard. Extended treatment
with varenicline helps to prevent relapse. The evidence does
not show a benefit from extended treatment with bupropion in
preventing relapse, but this evidence is limited by imprecision,
and the confidence intervals mean we cannot rule out a clinically
important benefit at this stage. Evidence from two studies has not
shown a benefit from extended nicotine replacement therapy in
assisted smokers, but it may be eHective in unassisted smokers.
The available evidence does not support the use of behavioural
interventions to help smokers who have successfully quit to avoid
relapsing. This evidence focused on interventions that encouraged
identifying and resolving tempting situations, as well as minimal
interventions using one-oH sessions and written materials. There is
limited evidence available on alternative approaches.
Implications for research
The current research has limitations both in the methodology and
in the treatment approaches tested. Future researchers, especially
those exploring behavioural interventions, should take account of
this in designing studies of adequate methodology and sample
size, and in examining alternatives to attempts to teach skills to
cope with risk situations. In pharmacological research, further
studies of extended treatment with front-line smoking cessation
pharmacotherapies and/or e-cigarettes in abstainers are needed.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Setting: cessation clinic, Spain
Recruitment: community volunteers
Group size: 36 to 40
Participants 76 smokers, ≥ 10 cigs/day (excluded an untreated control group of 40, not randomly selected). 51% fe-
male, average age 34, average cigs/day 28
Interventions Both conditions received 8 weekly sessions in groups of 36 to 40, duration not specified, TQD week 4, 2
experienced therapists
1. Standard programme: motivational contract, nicotine fading, stimulus control
2. Relapse prevention. As 1 plus problem solving
Outcomes Abstinence at 12 months (definition not specified)
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: quit smoking clinics, Malaysia
Recruitment: eligible clinic attendees
Participants 231 smokers, 120 in phone support arm and 111 in control
96.1% male, average age: 48, average cigarettes/day: 14
Interventions 1. Relapse prevention: as control with an additional phone call after each visit in month 1 providing in-
formation, encouragement, etc.
2. Control: attend quit smoking clinic 4 times in month 1, 2 times in month 2 with a phone call after
each visit, and 1 visit with 2 phone calls in month 3, self-help materials throughout
Outcomes Point prevalence abstinence at 6 months
Validation: CO ≥ 7 ppm at 6 months
Notes Dropouts counted as continuing smokers
Funding not declared
Declaration of Interests: "The authors declare that they have no competing interests."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Assignments created by Urn design
Allocation concealment
(selection bias)
Unclear risk No information on concealment
Blebil 2014 
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Unclear risk No information on blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: participants' own homes, UK
Recruitment: short-term quitters recruited from NHS Stop Smoking Clinics
Participants 1404 ex-smokers (4-week abstinence), 702 in intervention group and 702 in control
47.3% male, average age 47, average cigarettes per day 20
Interventions 1. Relapse prevention: eight 'Forever Free' self-help booklets by post
2. Control: single leaflet 'Learning to Stay Stopped' routinely given to NHS patients
Outcomes Continuous abstinence from 2 to 12 months
Validation: CO < 10 ppm at 12 months
Notes Funding: "This project was funded by the National Institute for Health Research (NIHR) Health Technol-
ogy Assessment programme"
Declaration of Interest: "Paul Aveyard has done ad hoc consultancy and research for the pharmaceuti-
cal industry on smoking cessation."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Simple randomisation method used
Allocation concealment
(selection bias)
Unclear risk Quote: "The participant allocation was ‘concealed’ because the recruitment of
quitters occurred before the random allocation." However, it was unclear how





Low risk Blinding not performed, but face-to-face contact was the same between the
two groups, so performance bias unlikely.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemically validated abstinence
Blyth 2015 
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Methods Setting: Quitline, Australia
Recruitment: volunteers calling a quitline to request self help materials
Participants 215 smokers who had quit at time of recruitment (other participants not included in this review)
Demographics for all participants: 54% female, approximately 47% < 30 years, average cigs/day 21
63% had quit in previous week
Interventions All participants received a quit pack at the time of first contact with the quitline, 1 to 2 days before re-
cruitment
1. Series of tailored advice letters based on standardised telephone assessment. 2 to 3 pages, tailored
in part by stage of change, timing varied
2. No further intervention




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated numbers with even numbers allocated to intervention
Allocation concealment
(selection bias)





Low risk Blinding not possible because of nature of the intervention, but "participants
in each condition [did] not know about the other condition unless they specifi-
cally asked ... (none did)"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding or validation of smoking status, but because of low-contact nature








Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Brandon 1987 
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Participants 39 smokers
Sex not specified, average age 31, average cigs/day 27
Treatment: groups of 3 to 7 (probably)
Therapists: 3, counterbalanced across treatments
Interventions All-included cessation programme 6 × 2 hours over 2 weeks
1. Relapse prevention 4 × 1.5 hour sessions, 2, 4, 8, 12 weeks post-cessation: self-monitoring, advice, as-
signment of exposure and coping exercises
2. No maintenance, one assessment session at 12 weeks
Outcomes Abstinence at 12 months (assume point prevalence) (phone assessment, non-therapist).
Validation: CO only during treatment, phoning 2 collaterals - no results given
Notes A treatment arm that included rapid puffing not included
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk 8 randomly assigned participants did not achieve initial cessation and were




Methods Setting: community, USA
Recruitment: advertisements for ex-smokers wanting to avoid relapse
Participants 584 ex-smokers (abstinent > 7 days at baseline).
Average age 49, median abstinence 6.5 months, mean 16 months
Interventions 2 × 2 factorial design testing mail and phone intervention
Mailings condition: 8 Stay Quit booklets mailed at 1, 2, 3, 5, 7, 9, 12 months
Hotline condition: information about Stay Quit hotline. Asked to call to register. Participants were
called if they did not register within 2 weeks and at 3 months if they had not called
Minimal contact condition received; first Stay Quit booklet
Outcomes Abstinence at 12 months (no smoking in past 7 days)
All participants were abstinent at baseline, and relapse rates were low.
Brandon 2000 
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Validation: CO < 10 ppm for participants living within 75 miles of laboratory
Notes No true control
Of 804 randomly assigned, results were based on 584 who met inclusion criteria and were sent materi-
als (until 2009 update, denominator of 446 was used. Author provided additional data).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "The CO results from the subsample suggest that participants' self-reported








Methods Setting: community, USA
Recruitment: advertisements for ex-smokers wanting to avoid relapse
Participants 481 ex-smokers (abstinent > 7 days at baseline)
66% female, average age 52, average cigs/day 25. Median 75 days of abstinence
Interventions 2 × 2 factorial design testing effects of contact versus content
1. Repeated mailings. High contact-high content. 8 "Forever Free" booklet mailings at enrolment and 1,
2, 3, 5, 7, 8, 12 months
2. Massed mailings. Low contact - high content. Same 8 booklets at enrolment
3. Repeated letters. High contact - low content. Single "Forever Free" booklet, 7 supportive letters,
same schedule as 1. Provided extended contact and social support without skills training
4. Control. Low contact - low content. Single booklet, no further contact
Outcomes Abstinence at 24 months (no smoking in past 7 days)
Validation: CO for 21 local quitters, no misreporting identified
Notes New for 2009 update
No true control. Other 3 arms compared with single booklet condition in main analysis. Of 895 ran-
domly assigned, results based on 431 who met inclusion criteria and returned follow-up questionnaire.
Non-responders excluded rather than assumed to have relapsed
Brandon 2004 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Low risk Because of the nature of the intervention, blinding not possible, but no ad-
ditional phone or face contact between personnel and participants; lack of
blinding unlikely to affect performance
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Minimal contact, misreport unlikely to be differential and validation of sub-








Methods Setting: participants' own homes, USA
Recruitment: by phone via purchased telephone numbers from marketing companies
Participants 504 ex-smokers (abstinent > 7 days at baseline), 245 intervention, 259 control
Pregnant women, average age 25, average cigs/day 15
Interventions 1. Relapse prevention: 9 'Forever Free' self-help booklets by post up to 8 months postpartum
2. Control: 2 leaflets, content not customised for pregnant women
Outcomes 7-day point prevalence abstinence at 12 months postpartum
Validation: CO < 8 ppm and Cotinine < 10 ng/mL at 12 months only for participants within 100 miles of
lab, otherwise self-report
Notes Funding: "This research was supported by National Cancer Institute (grant R01 CA94256)."
Declaration of interests: not specified
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer algorithm for randomisation
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not described
Brandon 2012 
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Unclear risk Blinding not mentioned
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: hospital, USA
Recruitment: hospitalised patients
Participants 126 ex-smokers (quit during hospitalisation), 64 intervention and 62 control
65% male, average age: 47, average cigs/day: 10 to 20
Interventions Relapse prevention: as control plus 8-week supply of nicotine patches, telephone counselling up to 2
months post-discharge and mailed self-help materials
Control: brief 'Ask, Advise and Refer' beside intervention by a respiratory therapist
Outcomes 180 days prolonged abstinence at 6 months
Validation: Self-report plus saliva sample bogus pipeline test
Notes Funding: "This study was funded by a $50,000 grant from the Scripps Clinical Research Development
Award for new investigators at Scripps Health"
Declaration of interest: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The PI used computer generated randomization lists so that random-
ization was stratified by the RT and subjects were allocated to treatment con-
dition using blocks of four."
Allocation concealment
(selection bias)





Unclear risk Blinding not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Abstinence self-reported with saliva sampling for bogus pipeline testing in mi-
nority
Brandstein 2012 
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Low risk Quote: "The contact rate for the six-month evaluation was 57.9%. There was
no significant difference in contact between the groups; 62.5% and 56.4%





Methods Setting: cessation clinic, Germany
Recruitment: community volunteers
Participants 256 smokers, no demographic details
Interventions 5 conditions, partly factorial. All received nicotine patch, dose individualised for conditions 1 to 4, plus
9 weekly sessions, including reduction, self-monitoring, contract management, risk avoidance. TQD af-
ter 6 weeks
1. Additional training in relapse-coping strategies (during cessation phase)
2. Additional 3 booster sessions, 6 months after end of main therapy
3. Relapse-coping and boosters
4. Control
5. Control (fixed-dose nicotine patch)
Outcomes Abstinence 12 months post-EOT (point prevalence). Rates estimated from graphs
Validation: random urine nicotine, 'almost 100% conformity', no correction
Notes 3 versus 4 in contact matched comparison, 1 plus 2 versus 4 in extended contact comparison
Inclusion of control group 5 (fixed dose) would marginally increase intervention benefit
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomly assigned to experimental groups after previously being matched
for age, sex and cigarette consumption"
Allocation concealment
(selection bias)





Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
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Methods Setting: cessation clinic, Germany
Recruitment: community volunteers
Participants 185 smokers, no demographic details
Interventions 4 conditions, partly factorial. All received nicotine patch (dose individualised for conditions 1 to 3) plus
9 weekly sessions, including reduction, self-monitoring, contract management, risk avoidance. TQD af-
ter 6 weeks
1. Relapse coping training using role play, TQD at 6 weeks
2. Modified relapse coping. Rapid abstinence, TQD session 4, covert sensitisation, thought-stopping
3. Control, individualised patch dose
4. Control, fixed patch dose
Outcomes Abstinence 12 months post-EOT (point prevalence). Rates estimated from graphs
Validation: random urine, 'almost 100% conformity', no correction
Notes 1 plus 2 versus 3 in contact matched comparison. Inclusion of control group 4 (fixed dose) would mar-
ginally increase intervention benefit
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 'Randomly assigned to experimental groups after previously being matched
for age, sex and cigarette consumption'
Allocation concealment
(selection bias)





Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes










Methods Setting: Inpatient department of university hospital, Brazil
Recriutment: Enrolled within first 48 hours of hospital admission
Participants 90 inpatients
61% male, average age 51, average cigs/day 20.7
Campos 2018 
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Interventions Intervention: Counselled in a session that lasted approximately 40 min, comprising a 10-min oral inter-
vention and a 30-min educational video presentation
Control: Counselled on the dangers of smoking and the benefits of quitting in an ordinary session last-
ing 10 min
Outcomes 6 months after discharge
Validation: Exhaled carbon monoxide
Notes Funding: publisher website claimed no funding
Declaration of interests: none reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not specified
Allocation concealment
(selection bias)





Low risk Blinding not performed, but face-to-face contact was the same between the
two groups, so performance bias unlikely.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Smoking status was assessed and self-reported abstinence was biochemical-










Methods Setting: mobile apps, Hong Kong
Recruitment: patients of smoking cessation centre
Participants 136 ex-smokers (7-day abstinence), 42 Whatsapp, 40 Facebook and 54 Control
76.5% male, average age 40, average cigs/day 15
Interventions Whatsapp: Control + Whatsapp online group with 3 reminders per week from moderator and booklet
Facebook: Control + Facebook online group with 3 reminders per week from moderator and booklet
Control: 8-week counselling, telephone follow-ups, physician assessment and free NRT
Outcomes 7-day point prevalence at 6 months
Validation: CO > 4 ppm and cotinine < 10 ng/mL at 6 months
Cheung 2015 
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Notes Participants given HK $100 if validated as abstinent. Only participants who reported abstinence were
notified of incentive.
Funding: "the Tung Wah Group of Hospitals Integrated Centre on Smoking Cessation (ICSC) and Tobac-
co Control Office of Hong Kong Department of Health"
Declaration of interests: "The study was funded by Tung Wah Group of Hospitals Integrated Centre on
Smoking Cessation, which was funded by Tobacco Control Office of Department of Health. Prof Tai-
hing Lam is the principal investigator of the FAMILY project, which was funded by the Hong Kong Jock-
ey Club Charities Trust. All other authors do not have connection with the tobacco, alcohol, pharma-
ceutical, or gaming industries, and nobody was substantially funded by one of these organizations"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised cluster-randomisation
Allocation concealment
(selection bias)





Low risk Quote: "All participants received a specific relapse prevention intervention,
but they did not know what the other interventions were."
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "All assessors of outcomes were blinded to the RCT group of each par-




Low risk Low rates of attrition




Methods Setting: Academic obstetrics clinic, USA
Recruitment: While attending first prenatal visit
Participants 128 pregnant women, low-income
100% women, average age 26, average cigs/day 8.6
Interventions Intervenion: Standard care + Phone-based Postpartum Continuing Care - 10 phone calls with health
coach using motivated interviewing techniques, recovery management checkups and 5 A’s (questions)
Control: standard care only
Outcomes 7-day PP abstinence
Validation: Urine cotinine
Notes Funding: a grant from the National Institute on Drug Abuse (NIDA)
Coleman-Cowger 2018 
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Declaration of interests: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-based urn randomisation
Allocation concealment
(selection bias)
Unclear risk Project Coordinator informed Chestnut Global Partners (CGP) staH (via email)
and participants (via mailed letter with an enclosed “Healthy Mom, Healthy






High risk Participants were not blinded, and contact levels differed between study arms.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Sixteen participants (25%) withdrew from the Intervention only (n = 13) or




Methods Setting: Naval training, USA
Recruitment: smokers who had enforced abstinence during naval training, unselected, not volunteers
Participants 1682 female navy recruits with a history of smoking (661 reached at follow-up). All should have been
abstinent for 2 months during training,
average age 19, no details of cigs/day
Interventions 1. 6 mail contacts over 12 months, at 1, 2, 4, 5, 7, 10 months (2 after follow-up), 1-page flyers, cogni-
tive-behavioural relapse prevention; stress management, weight, fitness, tailored for naval women
2. Access to toll-free telephone helpline for support and counselling on relapse prevention and quitting
if relapse occurred, cognitive-behavioural approach. Once participant called, sessions scheduled in line
with risk of relapse
3. No intervention control
Outcomes Abstinence at 12 months (30-day) (Edwards 1999 reported 6-month outcomes)
Validation: none
Notes Results not displayed graphically because denominators not explicit. No evidence of intervention ef-
fect. Impact of clustering was negligible
Risk of bias
Bias Authors' judgement Support for judgement
Conway 2004 
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Random sequence genera-
tion (selection bias)
Unclear risk Cluster randomisation by division (80 people)
Allocation concealment
(selection bias)





Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Self-reported smoking status, interventions of varying intensities, but no face-




Unclear risk High loss to follow-up (52% at 12 months); participants lost to follow-up not




Methods Setting: cessation clinic, USA
Recruitment: community volunteers quit after 8 weeks bupropion & nicotine patch
Participants 289 abstainers (excludes 5 withdrawing consent before starting medication)
45% female, average age 43, average cigs/day 21
Therapists: counsellors, 1-month training
Interventions All participants received 8 weeks open-label bupropion and nicotine patch (21 mg with weaning) for
7 weeks from TQD. Transition procedures preserved blinding for the relapse prevention phase but al-
lowed weaning from bupropion. Individual counselling, including CBT techniques, 15 minutes × 6 dur-
ing open-label, × 4 during relapse prevention, × 2 during follow-up
1. Bupropion (300 mg) and nicotine gum (2 mg, use as needed to manage craving) for 16 weeks
2. Bupropion and placebo gum
3. Nicotine gum and placebo pill (150 mg bupropion for first week)
4. Double placebo (150 mg bupropion for first week)
Outcomes Abstinence (no relapse to 7 days of smoking) for 12 months (10 months after randomisation, 6 months
after EOT) (primary outcome for study was time to relapse)
Validation: CO ≤ 8 ppm at each visit
Notes New for 2009 update
Contributed to NRT, bupropion, and combination therapy analyses
Quit rate after open-label treatment was 52%, so the final quit rate of 30% for combination therapy is
equivalent to ˜16% of people starting treatment
Risk of bias
Bias Authors' judgement Support for judgement
Covey 2007 
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Random sequence genera-
tion (selection bias)
Low risk "A statistician who did not participate in the clinical phases of the study pro-
vided computer-generated randomization lists that were not accessible to the
clinical staH", stratified by gender and depression history
Allocation concealment
(selection bias)
Low risk A research nurse who did not have direct contact with participants prepared





Low risk "Participants and clinical researchers with direct participant contact were
blinded to the randomization". Identical placebos used
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 5 randomly assigned participants withdrew before double-blind phase.




Methods Setting: clinic, USA
Recruitment: community volunteers for pharmacotherapy cessation and relapse prevention trial
Participants 405 abstainers after 3 months pharmacotherapy, 74 from inhaler, 141 bupropion, 190 combination
Participant characteristics not presented at start of relapse prevention phase
Interventions In cessation phase, participants had been randomly assigned to bupropion (300 mg), nicotine inhaler
(up to 16 cartridges/day) or combination. Physician advice at entry, brief (< 10 min) counselling at
monthly study visits (total 12 to 18, including relapse prevention phase) and self-help. Abstainers (7-
day point prevalence after 3 months therapy) eligible for relapse prevention phase
relapse prevention intervention randomly assigned single-therapy abstainers to continue cessation
therapy or placebo for 9 months
Combined therapy abstainers randomly assigned to 4 groups: combination, placebo and single thera-
py, or double placebo
Outcomes Abstinence at 15 months (from TQD, 12 months from relapse prevention start, 3 months from EOT) (PP)
Validation: CO ≤ 8 ppm
Notes New for 2009 update
Arms contributed to NRT, bupropion, and combination therapy analyses, ignoring differences in cessa-
tion induction therapy
Cessation rates at end of induction phase were 14% for inhaler, 26% for bupropion, and 34% for com-
bination
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Randomisation procedure made prior knowledge of allocation unlikely
Croghan 2007 
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Unclear risk Placebo used, but insufficient information provided re: blinding to permit
judgement
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Losses to follow-up post-medication were high and were not enumerated by




Methods Setting: hospitals, USA
Recruitment: hospitalised smokers approached by Respiratory Therapists
Design: 2 x 2 (nicotine patches x counselling) factorial design
Participants 1270 smokers, 320 no patches, 317 patches, 317 no counselling, 316 counselling
56.7% male, average age 50, average cigs/day 15
Interventions 2 x 2 factorial design
Intervention 1: control plus NRT patches matched to cigs/day: 6 to 10 cigs/day = 6 weeks of 14 mg
patches and 2 weeks of 7 mg patches. 11/+ cigs/day = 4 weeks of 21 mg patches and 2 weeks of 14 mg
patches and 2 weeks of 7 mg patches
Intervention 2: control plus telephone counselling: initial call: 30 to 40 minutes, with up to 8 follow-up
calls of 10-15 minutes
Intervention 3: control plus telephone counselling and patches
Control: standard care: brief beside intervention < 10 minutes
Outcomes 30-day point prevalence at 6 months
Validation: Cotinine < 10 ng/mL at 6 months
Notes No attempt to constrain participants from using other quit-smoking services
Funding: "This research was supported by a grant from the National Cancer Institute (CA159533)"
Declaration of interests: "No financial disclosures were reported by the authors of this paper."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation stratified by recruitment site and cigarettes per day
Allocation concealment
(selection bias)
Unclear risk Concealment not described
Cummins 2016 
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Unclear risk Blinding not described
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Participants 139 smokers, 48 in group arms, 91 in self-help arms
Therapists for groups: 2 teams of 2 PhD psychologists. Each team led one group in each programme
Interventions Compared 2 approaches, in both group and self-help formats
Groups met 8 × 2 hours weekly, including relaxation training, enlisting social support and practising al-
ternative behaviours. self-help intervention provided same components in 8 workbooks
1. relapse prevention: focused on smoking as learned behaviour. Quit day (for group format) at 3rd ses-
sion. Additional elements included identifying high-risk situations, cognitive restructuring, and role
playing
2. 'Absolute Abstinence' (AA) group. Focused on addictive component of smoking. Quit day (for group
format) at 5th session. Additional elements included focused smoking, health education, and contin-
gency contract
Outcomes Abstinence from month 9 to month 12 of follow-up
Validation: saliva thiocyanate and two collateral verifiers
Notes Group and self-help arms used in different comparisons within the matched contact time section
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Part by coin toss and part random number table. Friends co-randomly as-
signed to same programme but not necessarily same format. More assigned to
self-help than group by design
Allocation concealment
(selection bias)






Unclear risk No information reported
Blinding of outcome as-
sessment (detection bias) 
Low risk Abstinence validated
Curry 1988 
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Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Group size: 3 to 8
Participants 45 smokers who completed treatment
Therapists: 9 advanced clinical psychology graduate students with no previous experience. Each con-
ducted one group
Interventions All conditions received 6 × 1½ to 2 hour weekly meetings based on Pomerleau and Pomerleau broad-
spectrum cessation package. TQD week 5
1. 'Experimental' condition added active cognitive behavioral skills training focusing on 11 problem sit-
uations
2. 'Enhanced control' added discussion of same problems
3. 'Control' using Pomerleau and Pomerleau alone
Outcomes Abstinence at 12 months (point prevalence)
Validation: CO
Notes 1 and 2 treated as relapse prevention
Condition 2 not displayed. 3/14 quit
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Low risk Blinding not possible because of nature of the intervention, but all partici-
pants received same amount of contact, and no therapists had previous expe-
rience with stop-smoking groups, hence performance bias unlikely
Blinding of outcome as-
sessment (detection bias) 
All outcomes
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Methods Setting: Smoking cessation outpatient clinic, Turkey
Recruitment: Whilst participants were applying to the clinic
Participants 132 smokers wanting help to quit
61% male, 39.4 average age
Interventions Common components: 45-min counselling, support booklet on quitting, relapse prevention compo-
nent
Intervention: + 60 WhatsApp messages about having a plan of action and preventing relapse were de-
veloped through expert panels for 3 months.
Control: common component only
Outcomes Self-report continuous prevalence at 6 months
Notes Funding: none
Declaration of interests: no competing interests
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Stratified randomization achieved using a computer spreadsheet
Allocation concealment
(selection bias)
Low risk The researcher enrolling participants did not know in advance which treat-





Low risk Participants and the researcher who sent the messages were not blinded but
face-to-face contact amounts did not vary between study groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Abstinence was not biochemically validated, but face-to-face contact amounts
did not vary between study groups and the physicians were blind throughout








Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Participants 49 smokers; 71% female, average age 41, average cigs/day 31 (significant difference between groups,
35 vs 27)
Interventions 1. Cessation programme with relapse prevention focus. 8 × 1½ hours weekly, TQD between 3 and 4.
pre-quit self-monitoring. Choice of 'cold turkey' or gradual reduction. Relaxation, role-play, cognitive
coping
Emmons 1988 
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2. Broad-spectrum (BS) programme. 12 × 1 hour over 8 weeks. TQD between 3 and 4. Included nicotine
fading
Outcomes Abstinence at 6 months (point prevalence) (EOT and 3 months also reported)
Validation: saliva thiocyanate ≤ 85 microg/mL
Notes Included in contact matched section, although different number of sessions
Inclusion of 4 non-completers would increase apparent benefit of BS
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation in blocks, method not described
Allocation concealment
(selection bias)
Unclear risk No details given. Friends and relatives assigned to same condition, and signifi-





Low risk "Although facilitators knew that different treatments were being conducted,
they were unaware of the components of the alternate treatments". Same du-
ration of contact in both groups. Performance bias unlikely
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Results excluded 4 pretreatment dropouts, 4 non-completers (3 relapse pre-




Methods Setting: HMO health centre, USA
Recruitment: pregnant women who had quit smoking since becoming pregnant
Participants 171 pregnant recent quitters, average length of prior abstinence 31 days, 58% had > 7 days of total ab-
stinence
Average age 25, average cigs/day 10
Interventions 1. Relapse prevention self-help booklets; 4 on cessation given at baseline visit, 4 relapse preven-
tion-oriented mailed at weekly intervals
2. Control. 1-page tip sheet on behavioural techniques for avoiding relapse
Both groups had a 2 minutes' discussion on smoking and pregnancy with health educator, were given
2-page pamphlet, congratulated on quitting
Outcomes Point prevalence (7-day), late in 3rd trimester (also week 26 and week 34 of pregnancy)
Validation: cotinine, at least 1 ≤ 10 ng/mL and none ≥ 80 ng/mL
Notes 11% of women misreported abstinence
Risk of bias
Ersho= 1995 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)






Low risk "The health educator was blind to group assignment until the end of data col-
lection... The program was presented as a standard part of prenatal care... Pa-
tients had no further contact with the prenatal intake health educator. Prena-
tal care providers were blind to group assignment, and no effort was made to
modify their usual counselling practices"
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: community mental health centres, USA
Recruitment: patients of mental health centres
Participants 87 ex-smokers (2 weeks abstinence), 40 varenicline plus CBT, 47 placebo plus CBT
62% male, average age 47, average cigs/day 23
Interventions Relapse prevention: varenicline pus CBT over a 40-week period
Control: placebo plus CBT over a 40-week period
Outcomes Continuous abstinence at week 52
Validation: CO < 9 ppm at week 52
Notes Funding: "This study was funded by grants R01 DA021245 by National Institute on Drug Abuse with sup-
plemental financial and material support from an investigator-initiated award from Pfizer for study
medications and funding, and by 05B1MACMHS to the Massachusetts Department of Mental Health
from the Department of Health and Human Services, Substance Abuse and Mental Health Services Ad-
ministration, Treatment Strategies for Smoking Cessation in Patients with Schizophrenia to the North
Suffolk Mental Health Association (Dr Evins). Pfizer provided study medication and supplemental sup-
port through an investigator-initiated award after the protocol was approved by the institutional re-
view board and the data and safety monitoring board."
Declaration of interest: see above – "The external funders had no role in design and conduct of the
study; collection, management, analysis, and interpretation of the data; preparation, or approval of the
manuscript; and decision to submit the manuscript for publication. At the time of submission and sole-




Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)




Low risk Not specified, but randomisation performed "by Massachusetts General Hospi-
tal research pharmacy staH members, who were not otherwise involved in the





Low risk Double-blind conditions
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: community, USA
Recruitment: smokers identified via a random telephone survey (volunteers)
Participants 1044 smokers able to quit for 24 hours; 42% female, average age 40, average cigs/day 20
Interventions Factorial trial of nicotine gum and self-help for relapse prevention. All participants also offered an in-
centive of $100 for quitting for 6 months
1. Nicotine gum 2 mg
2. Self-help materials
3. Nicotine gum and self-help materials
4. Monetary incentive only
Outcomes PP abstinence at 12 months
Validation: CO < 9 ppm, salivary cotinine < 20 ng/mL
Notes 1 and 3 compared with 2 and 4 to assess effect of nicotine gum
2 and 3 compared with 1 and 4 to assess effect of behavioural component
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)
Unclear risk No details given
Fortmann 1995 
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Unclear risk No details given
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: antenatal clinics, UK
Recruitment: pregnant smokers and recent quitters
Participants 249 pregnant recent (within 6 months) quitters, average abstinence 7 weeks (smokers also in trial, not
included for this review)
Average age 28, average cigs/day approximately 12
Interventions 1. Advice from midwife with explanation of CO reading, pamphlet, prompt placed in notes for reinforce-
ment
2. Usual midwife care
Outcomes Abstinence at 12 months (prolonged for last 12 weeks of pregnancy and 6 months since birth), also at
birth
Validation: CO ≤ 10 ppm
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Cluster randomised by midwife. "The allocation schedule was generated by
drawing of folded tags with Intervention or control designations and assigning
them to consecutive names on the list of midwives"
Allocation concealment
(selection bias)
High risk Randomised midwives were responsible for recruiting participants, fewer con-





Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Women who were untraceable or unsuitable for follow-up were excluded, oth-
er losses included as smokers
Hajek 2001 
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Methods Setting: 17 hospitals, UK
Recruitment: inpatients with MI or for CABG
Participants 540 smokers or recent quitters (26%) who had not smoked since admission to hospital and motivated
to quit
Interventions 1. As control + CO reading, booklet on smoking and cardiac recovery, written quiz, offer to find support
'buddy', commitment, reminder in notes. Implemented by cardiac nurses during routine work, estimat-
ed time 20 months
2. Verbal advice, 'Smoking and Your Heart' booklet
Outcomes Abstinence at 12 months, sustained (no more than 5 cigarettes since enrolment and 7-day PP)
Validation: saliva cotinine < 20 ng/mL (CO used at 6 weeks follow-up and for visits at 12 months)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)






Unclear risk Not reported, some contamination possible
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 26 deaths and 9 moved. address excluded from denominator in analysis; all




Methods Setting: clinic, USA
Recruitment: media adverts and referral
Participants 135 smokers; 59% female, average age approximately 36, average cigs/day 29
Therapists: 2 psychologists, randomly assigned to groups
Interventions 2 × 2 factorial trial, aversive smoking conditions collapsed
1. Skills training, 14 × 75 minute sessions. 8 sessions over 3 weeks involved 6 seconds or 30 seconds of
aversive smoking. 6 sessions over week 1 to 6 covered relaxation, commitment and cost benefits, and
relapse prevention skills with role-play of risk situations
2. Discussion control. Same aversive smoking. Other 6 sessions used self-scoring tests and group dis-
cussion. Discussion of specific skills discouraged
Hall 1984 
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Outcomes Abstinence at 12 months (point prevalence)
Validation: CO < 10 ppm, plasma thiocyanate < 85 ng/mg and confirmation from significant other
Notes Matched for contact time
Author tested for therapist and cohort main effects. None significant
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk No details given
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 8 dropouts from group 1 and 4 from group 2 before start of relapse prevention




Methods Setting: clinic, USA
Recruitment: referred by physicians, friends or self
Participants 84 smokers in relevant arms; 53% male, average age 38, average cigs/day 30.5
Therapists: 2 psychologists
Interventions 1. Intensive behavioural treatment (including relapse prevention skill training, relaxation, 30 seconds
aversive smoking of 3 cigarettes). 14 × 75 min sessions over 8 weeks
2. Same as 1. plus 2 mg nicotine gum available for 6 months
3. Low-contact plus nicotine gum. Met 4 times in 3 weeks, educational materials, written exercises,
group discussion
Outcomes Abstinence at 52 weeks (assume point prevalence)
Validation: CO < 10 ppm, thiocyanate < 85 mg/mL, reports of significant others (biochemical measures
failed to confirm self-report in 3 instances)
Notes 2 versus 3, not matched for contact time, controlled for gum. 1 not included in meta-analysis; 10/36
quit
Risk of bias
Bias Authors' judgement Support for judgement
Hall 1985 
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Random sequence genera-
tion (selection bias)
Unclear risk Randomly assigned within time constraints, method not described
Allocation concealment
(selection bias)





High risk No placebo NRT; no blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 3 dropouts in conditions 1 and 2 are assumed to be included in denominator




Methods Setting: clinic, USA
Recruitment: community volunteers or referrals
Participants 139 smokers; 53% male, average age 39, average cigs/day 30
Therapists: advanced graduates in clinical psychology or health psychology
Interventions 2 × 2 factorial trial. Nicotine gum/placebo arms collapsed
1. Intensive behavioural treatment including 6 seconds aversive smoking, relapse prevention skills
training, written exercises. 14 × 75 minute sessions (period not stated)
2. 'Low contact', including written exercises, educational materials, group discussions, quitting tech-
niques. 5 × 60 minutes
Outcomes Abstinence at 52 weeks (assume point prevalence)
Validation: thiocyanate < 95 mm/L (unless marijuana use reported), CO < 8 ppm, significant other
Notes Not matched for contact time
No reported interaction between behaviour therapy condition and gum condition so gum/no gum col-
lapsed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk Placebo gum used but gum/no-gum conditions collapsed in meta-analysis. No
information provided re behavioural sessions in this domain
Hall 1987 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 6 dropouts in 1 and 5 in 2 included in ITT analyses. "Differences between con-




Methods Setting: maternity services, Germany
Recruitment: postpartum women in maternity wards
Participants 304 women who had not smoked for 4 weeks at baseline assessment
Interventions 1. Counselling using motivational interviewing. Face-to-face session ˜40 days postpartum, telephone
boosters 4 weeks and 12 weeks later
2. Usual care from health system, self-help materials on postpartum smoking and partner smoking
Outcomes Sustained abstinence since birth of baby at 24 months (at 6 months, 12 months, PP also reported)
Validation: none
Notes Baseline assessment was conducted at median of 35 days after birth
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Alternation of screening forms
Allocation concealment
(selection bias)
High risk Alternate allocation done at study centre so not known to screener in advance,





Unclear risk "The nature of the intervention made blinding impossible", but assessors
"were blind to the women's group membership"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Self-reported cessation only, intervention face-to-face and intensive compared









Methods Setting: hospital, Japan
Recruitment: hospitalised volunteers, recently quit or expecting to quit in hospital
Participants 106 smokers, quit on day of hospital discharge 87% male, average age 60. 83% quit before admission
Hasuo 2004 
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Interventions 1. In-hospital counselling from public health nurse, 3 × 20 min sessions, + 3 × 5 min calls, 7, 21, 42 days
postdischarge
2. Control: in-hospital counselling only
Outcomes Abstinence at 12 months (assume PP)
Validation: Urine cotinine
Notes New for 2009 update
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Low risk Public health nurse and participant did not know allocation until the day be-
fore discharge, so common treatment component unlikely to be affected by
performance bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 106 excluded 6 deaths within 12 months and 8 who were smoking on day of




Methods Setting: mailed intervention, USA
Recruitment: via state telephone quitlines
Participants 577 smokers (> 24 hour abstinence), 286 intervention and 291 control
27% male, average age 37, average cigs/day: 10 to 20
Interventions Relapse prevention: 'Smoke-free Kids' mailed parenting program
Control: no treatment
Outcomes 30-day point prevalence at 3 years
Validation: self-report only
Notes Funding: "National Cancer Institute, National Institutes of Health, Grant No. R01CA148634."
Declaration of interests: "The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article."
Risk of bias
Hayes 2018 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Unclear how randomisation performed
Allocation concealment
(selection bias)





Unclear risk Blinding unclear
Blinding of outcome as-
sessment (detection bias) 
All outcomes










Methods Setting: clinics, USA, 5 sites
Recruitment: 784 community volunteers for cessation and relapse prevention trial
Participants 429 abstainers (previously ≥ 15 cigs/day) quit after 7 weeks open-label bupropion; 51% female, average
age 46, average cigs/day 26
Interventions All participants first received 7 weeks bupropion, physician advice, self-help materials, and brief indi-
vidual counselling at follow-up visits to assist cessation
1. Bupropion 300 mg/day, 45 weeks
2. Placebo
Outcomes Continuous abstinence at 2 years (1 year after EOT)
Validation: CO ≤ 10 ppm
Notes Quit rate after open-label phase was 59%, so the final quit rate of 29% in the bupropion group is equiv-
alent to 17% of people starting treatment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Randomization to the placebo or bupropion groups was computer generated
at a central location..."
Allocation concealment
(selection bias)





Low risk "...the investigators did not know the patient assignments. All bupropion and
placebo pills were identical in shape, size, and color"
Hays 2001 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: clinic, USA
Recruitment: 195 community volunteers for cessation and relapse prevention trial (110 included in re-
lapse prevention trial)
Participants 110 recovering alcoholic abstainers with at least 1 year continuous abstinence from alcohol and drugs,
18+ years old, smoking at least 20 cpd for previous year. Quit for at least last week of 8 weeks patch
therapy
78% male; average age 44; average cpd 29.9 (in initial population of 195 volunteers)
Interventions All participants first received brief weekly counselling sessions and nicotine patch for 8 weeks. Patch
tailored on the basis of baseline serum cotinine concentration
1. Bupropion: 150 mg/day first 3 d, then 300 mg/d until week 52
2. Placebo on same schedule
Brief individual counselling (≤ 10 min) at each clinic visit (weekly for week 9 to week 12, monthly for
week 13 to week 24, then at 52, 53, 64, and 76 weeks)
Outcomes Abstinence at 76 weeks (continuous and 7-d PP)
Validation: CO < 8 ppm
Notes New for 2013 update
Study did not report number of participants allocated to each group or number of successful abstain-
ers in each group; numbers obtained through extrapolation
Authors contacted to clarify re discrepancy in 76 weeks data, but no response
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk "Randomized", method not stated
Allocation concealment
(selection bias)





Unclear risk Described as "double-blind", placebo used, but no further information given
Hays 2009 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk At week 76, similar rate of dropout in both groups (34% intervention; 37% con-
trol). Participants lost to follow-up counted as relapsed smokers




Methods Setting: mobile app, USA
Recruitment: not specified, patients with chronic PTSD
Participants 11 smokers, 5 intervention and 6 control
Patients with chronic PTSD, 36.4% male, average age 53, average cigs/day 17
Interventions Relapse prevention: QUIT4EVER where Stay Quit Coach app tailored to patients with chronic PTSD pre-
installed on provided mobile phones in addition to control app
Control: Contingency management app pre-installed on provided mobile phones
Outcomes 7-day point prevalence at 6 months
Validation: Cotinine < 10 ng/mL
Notes Funding: "Duke University School of Medicine Bridge Funding Program, and the National Cancer In-
stitute (R01CA196304- 02S1), Veterans Affairs Office of Academic Affiliations Advanced Fellowship
Program in Mental Illness Research and Treatment, and U.S. Department of Veterans Affairs Clinical
Sciences Research and Development Senior Research Career Scientist Award (1lK6CX001494)."
Declaration of interests: "The authors have no competing financial interests to report"
6-month results for control group provided by correspondence with study authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer randomisation performed
Allocation concealment
(selection bias)





Unclear risk Blinding unclear
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Results biochemically verified
Hicks 2017 
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Methods Setting: clinics, USA, 14 sites
Recruitment: 578 community volunteers for cessation and relapse prevention trial
Participants 176 abstainers (previously ≥ 15 cigs/day) quit after 8 weeks of nicotine patch; baseline group: 57% fe-
male, average age 42, average cigs/day 26
Interventions All participants first received nicotine patch for 8 weeks at a dose of 22, 33 or 44 mg/day, matched to
baseline cigs/day. Brief advice to quit and self-help materials but no formal counselling
1. Bupropion 300 mg/day for 6 months
2. Placebo
No additional counselling during maintenance phase
Outcomes Abstinence at 12 months (PP) (6 months after EOT).
Validation: CO < 8 ppm
Notes Quit rate after open-label phase was 31%, so the final quit rate of 22% in the bupropion group is equiv-
alent to 7% of people starting treatment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Described as "double-blind", placebo used, but no further information given
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: clinic/internet, USA
Recruitment: community volunteers
Participants 284 smokers (≥ 10 cigs/day); 55% female, average age 41, average cigs/day 22
Japuntich 2006 
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Interventions All participants received bupropion (300 mg) for 9 weeks, 3 brief (20 mins) individual counselling ses-
sions, 5 clinic visits for assessment, monthly assessment calls
1. Access to Comprehensive Health Enhancement Support System for Smoking Cessation and Relapse
Prevention (CHESS SCRP) for 12 weeks, computer and access provided, daily use recommended, re-
minders to log on up to 3 times a week
2. No additional support
Outcomes Abstinence at 6 months (PP)
Validation: CO ≤ 10 ppm
Notes New for 2009 update
12-month follow-up results not published
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Low risk No details given, but as support provided to both groups pre-intervention, and
not during intervention period, performance bias unlikely
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 20% losses to follow-up and intervention participants who didn't get comput-




Methods Setting: Minnesota, USA
Recruitment: community volunteers (via local labour unions)
Participants 443 adult smokers of at least 5 cpd interested in quitting in next 14 d
60.2% female, average age 42, average cpd 17.7
Interventions All participants received 5 telephone calls and NRT (patch; gum; lozenge, provision modelled on com-
mon clinical practice) by mail for 4 weeks. Randomly assigned to:
1. Longitudinal care modelled on chronic disease mgmt approach. Telephone counselling and NRT by
mail for additional 48 weeks. Counsellors aimed to call every 2 weeks but adjustment based on par-
ticipants’ progress/receptivity; if participants chose not to make a quit attempt or reduce, calls made
monthly
2. Usual care. 1 additional call at 8 weeks
Outcomes 6 months prolonged abstinence at 18 months follow-up
Joseph 2011 
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Validation: none
Notes New for 2013 update
Number abstinent not provided, extrapolated from percentages given
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Participants were randomly assigned... by a computer-generated scheme,
blocked in masked groups of 20"
Allocation concealment
(selection bias)






Unclear risk Not specified, allocation occurred before end of common treatment compo-
nent
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk Low and similar rates of loss to follow-up in both groups (8.6% intervention,




Methods Setting: clinic, USA
Recruitment: community volunteers
Participants 64 smokers (44 in relevant arms); 72% female, average age 44, average cigs/day 32
Behaviour therapy provided by 2 psychologists, 1 medical social worker, assigned randomly to treat-
ment conditions, group size 10 to 12
Interventions All participated in cessation training (including cognitive-behavioural skills training and an aversive
smoke-holding procedure), 4 × 1½ hour sessions over 4 days, in groups of 10 to 12
1. Nicotine gum (2 mg) for 7 weeks
2. Skills training for relapse prevention. 2 sessions in 2 weeks, then 4 weekly drop-in sessions. Included
identification of high-risk situations and coping strategies, homework
3. Combined 1 and 2
Outcomes Abstinence for 4 weeks at 10½ months after quit date
Validation: CO < 8 ppm (2 people unable to attend assessment, based on self-report), Serum thio-
cyanate measured at 6 weeks only
Notes 3 versus 1 for effect of relapse prevention component over NRT alone 3 versus 2 tests for effect of NRT
for initial cessation, not included
Risk of bias
Bias Authors' judgement Support for judgement
Killen 1984 
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Random sequence genera-
tion (selection bias)









High risk No blinding reported. "Interpretation of this data is hampered by the lack of a
placebo control condition". Unclear whether therapists aware of gum alloca-
tion
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: community, USA (Stanford Stop Smoking Project)
Recruitment: media advertisements for volunteers for self-help relapse prevention research pro-
gramme. To be eligible for randomisation, had to have quit for 48 hours unaided. (Quit validated by CO
< 9 ppm)
Participants 1218 smokers who had quit for 48 hours; 52% female, average age 43, average cigs/day 25
Interventions 4 × 3 factorial design crossing gum and self-help conditions:
Nicotine gum (2 mg) conditions:
1. Ad lib schedule, whenever strong need to smoke
2. Fixed schedule (1 piece/hour for at least 12 hours/day)
3. Placebo gum
4. No gum
Self-help intervention was based on 16 specially written modules. All participants were given the first
'How to cope with the urge to smoke without smoking' booklet. Then randomly assigned to:
• Self-selected: chose 7 more to receive in weekly mailings
• Random: sent 7 modules at random
• No modules: no further contact
Outcomes Abstinence at 12 months (7-day point prevalence)
Validation: saliva cotinine < 20 ng/mL, except for participants who had moved away
Notes Quit rates for module/no module conditions provided by authors. Gum conditions collapsed
Risk of bias
Bias Authors' judgement Support for judgement
Killen 1990 
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Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not stated
Allocation concealment
(selection bias)





Unclear risk "Assignment to gum condition was double-blind" but further information not
provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: clinic, USA
Recruitment: community volunteers
Participants 362 smokers ≥ 10 cigs/day, no current major depression
46% female, average age 45, average cigs/day 20, 25% previous bupropion use
Interventions All participants received open-label combination pharmacotherapy of bupropion 300 mg for 11 weeks,
nicotine patch for 10 weeks. TQD day 7, 30-min individual relapse prevention skills training at 6 clinic
visits
1. Bupropion 150 mg for 14 weeks
2. 2 weeks tapering bupropion, then placebo
Both arms had 4 further clinic visits during extended therapy
Outcomes Abstinence at 12 months (6 months post-EOT) (continuous). PP and 7-day relapse-free outcomes also
reported
Validation: CO (10 people not required to provide samples)
Notes New for 2009 update
PP outcomes favoured placebo, but no outcomes showed significant effects
Approximately 52% were quit at the end of baseline therapy
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Preassigned random sequence stratified by gender, before open-label phase
Allocation concealment
(selection bias)




Low risk Blinded drugs provided to investigator; " ... [the pharmaceutical company]...
packaged the treatment and then shipped the blinded drug to the investiga-
tor"
Killen 2006 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: Air Force, USA
Recruitment: recruits undergoing basic military training (BMT)
Participants 18,010 recruits, 29% regular smokers before enforced abstinence during training. 28% female, average
age 20
Interventions 1. Single 50-min intervention during final week of training, 50/group, including non-smokers. Discussed
health effects, costs, social impact, role-play
2. Control: general health video
All participants exposed to 6 weeks smoking ban and shown 2 videos to preview primary intervention
Outcomes Abstinence at 12 months (not defined)
Validation: none
Relapse amongst baseline ex-smokers and initiation amongst non-smokers also reported
Notes Results not displayed graphically because denominators not explicit. No significant overall benefit. ICC
small (0.004 for smokers)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised by training flight. 75% assigned to intervention, method
of sequence generation not specified
Allocation concealment
(selection bias)
Low risk Not specified, but training flight allocation was independent of this trial, so po-





Unclear risk No blinding reported, control knowledge of intervention unclear, personnel
knowledge of participant assignment not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Although no biochemical validation used, intervention was of low intensity
with limited face-to-face contact, sample size was large, follow-up rate was
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Methods Setting: Air Force, USA
Recruitment: recruits undergoing basic military training (BMT)
Participants Subgroup of ˜7525 regular smokers in intervention and ˜2639 in control
Interventions 1. Two 1 hour sessions during week 6 of BMT, emphasis on discrepancy between Air Force ideals and
smoking. Barriers, role-playing. One sheet of NRT gum available for use at end of training
2. Same schedule, health-related and first aid videos




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised by training flight. 75% assigned to intervention, method
of sequence generation not specified
Allocation concealment
(selection bias)
Low risk Not specified, but training flight allocation was independent of this trial, so po-





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk StaH who conducted follow-ups were not blinded to treatment assignment at
follow-up; differential follow-up possible for participants who did not respond




Unclear risk Random subgroup targeted for follow-up, 86% reached. People lost to fol-




Methods Setting: community, USA
Recruitment: community volunteers
Participants 1083 smokers who attended a smoking cessation clinic; 60% female, average age 45, average cigs/day
27
Interventions All participated in 15-session 8-week group cessation programme
1. Telephone counselling at 3, 9, 21 months. At each point, up to 3 calls could be made if requested
2. Control. No additional contact
Outcomes Abstinence at 34 months (12 months after EOT (7-day point prevalence)). Also assessed at 6, 12, and 24
months
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk Unclear whether counsellors for group sessions were aware of participant allo-
cation. Unclear if control group was aware of additional support offered to in-
tervention group
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used in subsample with low level of discrepancies indi-
cated, "difference between the intervention and comparison conditions in dis-








Methods Setting: clinic and home-based, USA
Recruitment: prenatal smoking cessation programs, obstetric and paediatric offices and women's
health clinics
Participants 300 ex-smokers (abstinence > 2 weeks), 150 in each group
Pregnant women, average age 25, average cigs/day 11
Interventions Relapse prevention: 'STARTS' enhanced cognitive behavioural intervention
Control: 'SUPPORT' supportive, time and attention-controlled comparison
Outcomes Sustained abstinence at 52 weeks postpartum
Validation: CO < 8 ppm or cotinine 15 ng/mL at 52 weeks postpartum
Notes Funding: "Support for this trial was provided by grant R01DA021608 (principal investigator Dr Levine)
from the National Institute on Drug Abuse. Role of the Funder/Sponsor: The National Institute on Drug
Abuse had no role in the design and conduct of the study; collection, management, analysis, or inter-
pretation of the data; preparation of the manuscript for publication; or decision to submit the manu-
script for publication."
Declaration of interests: "Dr Marcus reported serving on the scientific advisory board of Weight Watch-
ers International, Inc. No other disclosures were reported."
Risk of bias
Bias Authors' judgement Support for judgement
Levine 2016 
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Random sequence genera-
tion (selection bias)
Low risk Statistician-generated randomisation stratified by self-reported ethnicity
Allocation concealment
(selection bias)





Low risk Blinding could not be performed because of nature of intervention, but control
was "time and attention–controlled", so no difference in face-to-face contact
between groups. Low risk of performance bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: substance abuse outpatient facility, USA
Recruitment: community volunteers
Participants 69 smokers (≥ 1 pack/day); 62% female, average age 39, average cigs/day 25
Interventions All received nicotine patch (24 hours, 10 weeks tapered dose)
1. Moderate intensity: 4 meetings with nurse practitioner who reviewed self-help materials and in-
structed in patch use
2. High intensity: as 1 plus 16 weekly 45-minute cognitive-behavioural relapse prevention therapy from
clinical social worker or psychiatrist
Outcomes Abstinence at 12 months (1-week point prevalence)
Validation: urine cotinine for some participants, but no corrections made for misreporting
Notes High-intensity participants attended median of 8¼ sessions
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk No information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Incomplete urinary cotinine samples collected, so not used to validate absti-
nence. Intervention group received significantly more intensive face-to-face
contact, differential misreport possible
Lifrak 1997 
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Methods Setting: prenatal clinic, USA
Recruitment: volunteer recent quitters
Participants 78 pregnant women who had quit within previous 3 months (9 exclusions and 19 lost to follow-up not
included)
Age/smoking history not described
Therapists: health educator. Reinforcement provided by doctors and nurse trained at workshops
Interventions 1. 10 minutes counselling with health educator. Relapse prevention materials at 5th grade reading lev-
el, enhanced social support with materials, chosen 'buddy'. Reinforcement at routine visits by clinic
staH
2. Usual care, including nurse advice




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Low risk Blinding not relevant because of nature of the intervention (all relevant per-
sonnel involved in delivering intervention); any potential causes of perfor-
mance bias could be considered deliberate elements of the intervention
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Greater loss to follow-up in control, so losses to follow-up not included in de-
nominators to give conservative relapse prevention
Other bias Unclear risk Potential contamination, "the issue of contamination, while monitored, is one




Methods Setting: workplaces, Belgium
Mayer 2010 
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Recruitment: participants achieving abstinence in workplace-based smoking cessation programme,
randomly assigned by workplace
Participants 275 adult attendees of workplace-based cessation programme who achieved 4 weeks continuous ab-
stinence at 3 months after quit date (42 companies)
74% male, average age 40.6, more than 50% smoked 12 to 25 cpd, average FTND 6.5
Interventions Smokers wishing to quit invited to join cessation program through companies (13 group sessions, nico-
tine patches provided). Then randomly assigned to relapse prevention interventions:
1. Workplace Group Counselling (WGC), conducted at work (company decided if during or after work
hours), 90 min each. Groups of 5 to 10 participants
2. Proactive Phone Counselling (PPC), each session minimum of 10 mins
Both programmes: 10 sessions (2 in month 1, monthly thereafter); participants had to pay 50 euros to
participate (some companies decided to cover fees); content focused on participants' difficulties and
provided psychological support, where relevant
Outcomes 4 weeks continuous abstinence at 12 months post-quit date (immediately after end of relapse preven-
tion intervention)
Validation: CO < 10 ppm, urinary cotinine ≤ 317 ng/mL
Notes New for 2013 update
Higher participation rate in PPC arm (81% to 95%) vs WGC arm (49% to 70%). Not included in any meta-
analyses: 87/141 quit WGC, 77/134 PPC
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Cluster-randomised by worksite. “Workplace randomization was based on us-










Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 5 participants lost to follow-up and counted as smokers
Other bias High risk Higher rates of abstinence detected in those with biochemically validated ab-
stinence at enrolment (≤ 317 ng/mL). WGC arm had significantly more of these
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Methods Setting: two managed care organisations, USA
Recruitment: pregnant smokers and recent quitters
Participants 897 pregnant women (excluded miscarriages), 44% already quit, no minimum consumption
Average age 28, average cigs/day: 15 before pregnancy, 5 if still smoking
Interventions 1. Prepartum intervention: letter tailored to baseline stage of change, health concerns and motivation,
self-help book. After 28 weeks follow-up, sent relapse prevention kit
2. Telephone counselling calls, approximately 2 weeks after self-help mailing, and 1 month and 2
months later. Motivational interviewing approach. Average 8½ min
3. Pre/postpartum intervention: as 1, plus 3 calls within first 4 months postpartum, av 7.7 min, 3
newsletters
4. Control: self-help booklet only
Outcomes Abstinence at week 28 of pregnancy (analysis 1.1) and 12 months postpartum (7-day PP) (analysis 2.1).
Also assessed at 8 weeks, 6 months postpartum
Validation: saliva cotinine requested by mail, < 20 ng/mL. Only self-reported rates, no difference in
confirmation rates
Notes Abstinence at week 28 reported separately for baseline quitters
Relapse rate in 28 weeks quitters also reported. 1 versus 2 in analysis 1.2.1 and 1 versus 3 in analysis
1.2.2, control group split to avoid double counting in pooled total. No significant benefit of postpartum
intervention
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Low risk "The intervention was delivered via mail and telephone without involvement
of prenatal health care providers". "Counsellors were not involved in any fol-
low-up survey activities"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used, not reported: "Since there were no be-
tween-group differences in the proportion of saliva samples returned or the









Methods Setting: Army Medical Center, USA
Recruitment: pregnant smokers and recent quitters with partners
Participants 316 pregnant recent quitters, 267 continuing smokers (excluded miscarriages); average age 24, average
cigs/day prepregnancy 13
McBride 2004 
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Interventions Both interventions included prepartum and postpartum components, in addition to usual care
1. Women only (WO); 3 counselling calls in pregnancy, 3 postpartum, monthly. Motivational interview-
ing. Late pregnancy relapse prevention kit
2. Partner-assisted (PA); as WO, plus advice on using partner as coach, and 6 calls to partner. Cessation
support for smoking partners
3. Usual care; provider advice and mailed pregnancy-specific self-help
Outcomes Abstinence at week 28 of pregnancy and 12 months postpartum (7-day PP). Also assessed at 8 weeks, 6
months postpartum
Validation: saliva cotinine requested by mail, no difference in return rates, disconfirmation rates not
given, only self-reported rates reported
Notes New for 2009 update
End of pregnancy abstinence amongst baseline quitters, combining interventions 1 and 2 versus con-
trol in analysis 1.1. No significant effect of either intervention on end of pregnancy abstinence amongst
baseline smokers. 12 months postpartum abstinence for those quit at end of pregnancy in analysis 1.2.
Abstinence rates not given separately for those quit at randomisation, but ⅔ of end-of-pregnancy quit-
ters came from this category, and the prepartum interventions did not increase cessation
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not stated
Allocation concealment
(selection bias)





Unclear risk No blinding reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Biochemical validation conducted but not used in outcome data. "Saliva re-
turn rates did not differ by condition at either follow-up", but rates of return








Methods Setting: Quit for Life employers/health plans, USA
Recruitment: users enrolled from employer and health Quit for Life programmes
Participants 1785 smokers who were abstinent for at least 24 hours, 591 TEQ-20, 602 TEQ-10 and 592 control
45.8% male, average age 43, average cigs/day 17
Interventions TEQ-20: Technology Enhanced Quitline-20: 20 Interactive Voice Response - delivered relapse risk as-
sessments which triggered a transfer to a Quit Coach for participants exceeding thresholds
TEQ-10: Technology Enhanced Quitline-10: 10 Interactive Voice Response - delivered relapse risk as-
sessments which triggered a transfer to a Quit Coach for participants exceeding thresholds
McDaniel 2015 
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Control: Standard treatment
Outcomes 30-day point prevalence at 12 months
Validation: self-report only
Notes Funding: “The study was funded by the National Institutes for Health (National Cancer Institute grant
number R01 CA138936-03) from the United States Department of Health and Human Services.”
Declaration of interests: “KAV, BHC, and SMZ declare employment at Alere Wellbeing, the provider of
quitline services in this study.”
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-randomisation performed
Allocation concealment
(selection bias)





Unclear risk Blinding unclear
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: outpatient clinic, Canada
Recruitment: newspaper advertisements
Participants 44 smokers who had quit following a course of varenicline, 23 intervention and 21 control
66.6% male, average age 54, average cigs/day 17
Interventions Pre-randomisation, both groups received 12 weeks varenicline + Interactive Voice Response calls
Relapse prevention: Interactive Voice Response calls every 2 weeks from weeks 13 to 52
Control: No further treatment
Outcomes Prolonged abstinence at 2 years
Validation: CO < 10 ppm
Notes Funding: "This study was funded by Pfizer Canada, producers of varenicline"
McNaughton 2013 
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Declaration of interests: "Jiri Frohlich was a member of Pfizer (Canada) Medical Advisory Board and re-
ceived speaking honoraria. He also participated in several clinical trials and received grants for investi-
gator initiated studies."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation stratified by motivation and addiction levels
Allocation concealment
(selection bias)





Unclear risk Blinding not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: cessation clinic, USA
Recruitment: community volunteers for cessation programme
Participants 341 quitters at the end of a 7-week group cessation programme (non-abstinent subgroup not relevant
to this review)
Demographics for all 771: 66% female, average age 43, average cigs/day 23
Interventions 1. Tailored proactive telephone counselling calls from counsellor who provided cessation course. 3
weekly then 3 to 6 alternate weeks, 15 min each
2. Supportive but nonspecific proactive counselling calls from counsellor, same schedule
Outcomes Abstinence at 15 months, 7-day point prevalence
Validation: none
Notes Analysis 4.1 but borderline to pool with other studies because both groups could constitute relapse
prevention; primarily a test of content. Exclusion did not change finding
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised by cessation group
Allocation concealment
(selection bias)
Unclear risk Not specified
Mermelstein 2003 
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Low risk "Counselors were kept blind to condition until the last group meeting"
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: prenatal clinic, USA
Recruitment: recent quitters
Participants 33 pregnant recent quitters (7 days) (subgroup of trial); average age 22, average cigs/day before quit 13
Interventions All participants received prompted provider advice and self-help
1. Individual counselling; 90-min psychotherapy session and bimonthly phone calls from mental
health counsellors
2. Usual care
Outcomes Abstinence at end of pregnancy and 6 months postpartum (7-d PP)
Validation: CO ≤ 8 ppm
Notes New for 2009 update. Baseline smoker results reported separately, not used in this review
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk No details given
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Participants lost to follow-up counted as smokers, but numbers lost to fol-
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Methods Setting: cessation clinic, USA
Recruitment: community volunteers
Participants 120 smokers; 50% female, average age 44, average cigs/day 28
Interventions All participants received single brief individual counselling session 1 week before TQD and instructed to
use ALA self-help manual 'Freedom from smoking for you and your family', CO measured. All interven-
tions used 5 sessions over 2 weeks post TQD, led by PhD level therapists
1. Cognitive-behavioural with cue exposure (75-min sessions) imagined high-risk settings
2. Cognitive-behavioural with cue exposure and nicotine gum (90 min)
3. Brief cognitive-behavioural. Reviewed progress and reinforced use of self-help manual. (15-min ses-
sions). Control for 1
4. Cognitive-behavioural and nicotine gum (60 min). Control for 2
Outcomes Sustained abstinence, 12 months and all previous follow-ups (1, 3, 6 months)
Validation: CO < 8 ppm
Notes Test of imaginary cue exposure for relapse prevention. 1 and 2 vs 3 and 4 in Analysis 7.1
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not stated
Allocation concealment
(selection bias)





Unclear risk "Counselors were kept blind to the relapse prevention condition to which sub-
jects were assigned". Participants not blinded, and no placebo
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: five community health clinics, USA
Recruitment: low-income women receiving prenatal care and participating in Special Supplemental
Nutrition Programme
Participants 168 pregnant recent quitters (subgroup of trial); average age 26, average cigs/day 15 to 18 for whole
sample
Interventions System-level intervention
1. Training to implement guideline-based 4 A's approach for obstetric, paediatric and nutrition pro-
gramme providers in the Community Health Centres, practice management system for screening and
prompts, interclinic communication
Pbert 2004 
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2. No training, usual care from clinic providers
Outcomes Abstinence at delivery (30-d PP) assessed retrospectively at 1-month postpartum assessment, 6
months postpartum
Validation: saliva cotinine ≤ 20 ppm
Notes New for 2009 update
Saliva collection was incomplete, and lesser agreement was noted between self-report and cotinine
values in intervention group, although difference significant only at final follow-up. Not pooled with
other studies. When non-responders were treated as smokers, the OR for not smoking at end of preg-
nancy was 0.95 (P = 0.95)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised by clinic, method not stated
Allocation concealment
(selection bias)
High risk Clinics recruited participants after randomisation, 1 control clinic dropped out





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: prenatal clinics, USA
Recruitment: contacted at prenatal clinics
Participants 382 ex-smokers (> 1 month abstinent), 188 intervention and 194 control
Pregnant women, average age 25, average cigs/day not reported
Interventions Relapse prevention: Stepped-care based on bio-behavioural risk profile + received one 'Forever Free for
Baby and Me' booklet in last trimester of pregnancy
• 'low-risk' offered one in-person session, one phone call in third trimester and 7 calls postpartum until
9 months postpartum
• 'high risk' offered one in-person session with nurse, two phone calls in third trimester and 11 calls
postpartum until 9 months postpartum
Control: Received one 'Forever Free for Baby and Me' booklet in last trimester of pregnancy, then
mailed 11 monthly newsletters
Outcomes Continuous abstinence at 12 months postpartum
Pollak 2016 
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Validation: CO < 10 ppm and cotinine < 0.5 mg/dL
Notes Funding: "This work was supported by the National Institutes of Health (R01NR009429). The opinions
and assentation’s [sic] contained herein are the private views of the authors and are not to be con-
strued as official or reflecting the views of the Department of the Army or the Department of Defense."
Declaration of interests: None declared
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised randomisation performed
Allocation concealment
(selection bias)





Unclear risk Blinding not described
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: clinic, USA
Recruitment: community volunteers
Therapist: senior author
Participants 51 quitters (2 treatment dropouts excluded); 57% female, average age 36, average cigs/day 29
Interventions All participants received the same cessation programme in a single group. Introductory meeting and 4
consecutive treatment meetings a week later, 1½ hours. Systematic focus on skill development. Also
used a novel aversive smoking exercise conducted at each session
Maintenance/relapse prevention conditions:
1. 4-week support group (number of meetings not specified)
2. Telephone contact system allowing participants to phone each other
3. No contact control
Outcomes Abstinence at 1 year, not defined
Validation: none
Notes Arm 2 not shown in graphs, all arms had similar quit rates
Risk of bias
Bias Authors' judgement Support for judgement
Powell 1981 
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Random sequence genera-
tion (selection bias)









Low risk Subjects randomly assigned to maintenance condition "at the end of the treat-
ment phase", performance bias during treatment phase not likely
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No biochemical validation used, intensity of contact different between condi-








Methods Setting: obstetric wards in 5 hospitals, Canada
Recruitment: postpartum women
Participants 251 women who had given up smoking for at least 6 weeks before delivery; average age 28, average
cigs/day 10, 74% first child
Interventions 1. Counselling session in hospital + 8 telephone (weekly for 1 month, biweekly for 2 months). Skills
training. Self-help pamphlets, no-smoking materials. Therapists: trained nurse counsellors
2. Usual care
Outcomes Continuous abstinence 12 months postdelivery
Validation: CO < 10 ppm for participants interviewed in person. Data collectors blind
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Research assistants responsible for outcome assessment were blinded, further
details not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used at in-person follow-ups (89% of participants)
Ratner 2000 
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Methods Setting: workplaces, Belgium
Recruitment: employee volunteers
Participants 993 began cessation programme, 349 abstinent at 3 months, 344 entered relapse prevention phase.
38% female, average age 39
Interventions Initial cessation programme of 7 fortnightly visits. Nicotine patch provided if FTQ score ≥ 5. Only quit-
ters abstinent for 1 month enrolled in relapse prevention
1. 10 monthly sessions, including group discussion and role-play led by professional counsellor
2. 10 sessions of group discussion led by former smokers
3. No relapse prevention
Outcomes Abstinence for 9 months from start of relapse prevention programme
Validation: CO < 10 ppm and urine cotinine ≥ 317 ng/mL required
(Rates for CO and self-report alone also reported; higher than for doubly validated rates)
Notes Interventions 1 and 2 combined in Analysis 4.1. Separate quit rates: Intervention 1. 59/135 (44%); Inter-
vention 2. 33/88 (37.5%), difference not statistically significant
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Cluster-randomised by company, using random number and blinded list
Allocation concealment
(selection bias)





Low risk No blinding reported but randomisation once achieved cessation and cluster
randomisation by worksite, performance bias unlikely
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: Texas, USA
Recruitment: pregnant women recruited through local health system or community advertisements
Reitzel 2010 
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Participants 251 low-income women who quit smoking during pregnancy
Average age 24.6, average cpd 10.2 pre-quit, 92.4% quit smoking approximately 8 weeks after pregnan-
cy
Interventions All participants received self-help materials and 5 to 10 min of US guideline-based brief relapse preven-
tion advice
1. MAPS: 6 telephone-based counselling sessions at weeks 34 and 36 prepartum and at week 2, 4, 7, and
16 postpartum, using combined motivational enhancement and social cognitive approach
2. MAPS+: As per 1, plus 2 additional in-person counselling sessions at baseline and at week 8 postpar-
tum
3. Control: usual care
Outcomes Continuous abstinence at 8 and 26 weeks postpartum (defined as no smoking since delivery date)
Validation: CO < 10 ppm and/or cotinine < 20 ng/mL
Notes New for 2013 update
80% of intervention participants received at least 4 calls
MAPS and MAPS+ combined for analysis in trial report; groups did not differ on baseline characteristics,
completed calls, session length, or percentage of participants abstinent.
Number abstinent not provided, extrapolated from percentages given in trial report
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk No blinding: "Neither participants nor research personnel was blind to treat-
ment condition assignment following randomization"
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Participants lost to follow-up counted as smokers in ITT analysis. Similar rates




Methods Setting: obstetric clinics, USA
Recruitment: pregnant women who smoked or had quit within 3 months of baseline
Ruger 2008 
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Participants 57 pregnant recent quitters (subgroup of trial), average age of whole sample 26
Interventions 1. Motivational interviewing at home visits (average 3). Tailored to stage of change, self-help materials
2. Usual care
Outcomes Quit at 6 months postpartum
Validation: salivary cotinine, but cut-oH and percentage validated not specified
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not described
Allocation concealment
(selection bias)
High risk No details given, but higher proportion of recent quitters in control (23%) than





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk "Smoking status was verified biochemically by collecting saliva samples for










Methods Setting: hospital, USA
Recruitment: women with or at risk of coronary artery disease (CAD)
Participants Two separate samples recruited:
1. 53 inpatients with CAD who stopped smoking during hospitalisation and wanted to stay quit
2. 107 women volunteering for cessation treatment who had > 1 CAD risk factor
Therapists: 2 smoking counsellors and 2 clinical psychology interns
Interventions 1. Coping skills relapse prevention, 6 × 1 hour, including stress management, homework
2. Health Belief model, 6 × 1 hour smoking-related health information related to disease state or CAD
profile. Focus on benefits of stopping
Outcomes PP abstinence at 6 months
Validation: CO < 9 ppm, urine cotinine < 10 ng/mL
Not all quitters tested, confirmation rates not reported
Notes Inpatient subgroup in quitters section, Analysis 2.1; CAD risk group in trials in smokers, matched con-
trol section, Analysis 7.1
Quit rates were lower in the CAD sample than in the at-risk group
Schmitz 1999 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not described
Allocation concealment
(selection bias)





Unclear risk Not specified
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Low risk Post-randomisation dropouts who did not complete baseline and begin treat-





Methods Setting: four workplaces, Germany
Recruitment: volunteer employees
Participants 79 smokers (≥ 10 cigs/day); 42% female, average age 40, average cigs/day 24
Interventions Both conditions provided 6 × 90 min sessions over 8 weeks in groups of 8 to 12 led by qualified
providers
1. relapse prevention; skills training, planning and practising coping strategies
2. Standard behavioural cessation course with focus on positive changes obtained through abstinence.
Included self-monitoring, environmental cue control, problem-solving skills
Outcomes Continuous abstinence at 12 months, not defined further
Validation: none
Notes New for 2009 update
Compared relapse prevention with matched standard programme
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised, 2 groups in each workplace, researchers randomly as-
signed 1 to each condition, no further details
Allocation concealment
(selection bias)




Unclear risk Not specified
Schroter 2006 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No validation used, but similar amount of interaction in both groups suggest-








Methods Setting: private and public prenatal clinics, USA
Recruitment: women at 1st prenatal visit
Participants 165 women previously smoking 1+ cigs/day who had quit since start of pregnancy (excluded 10 adverse
pregnancy outcomes)
Average age 25
Interventions 1. Individual counselling focusing on pros and cons, problem solving, skills rehearsal. 10 to 15 minutes
at 1st, 2nd, and 3rd prenatal visit, 36 weeks and 6 weeks postpartum. (93% received postpartum ses-
sion)
2. Usual care control
Outcomes Abstinence at 36 weeks pregnancy (Analysis 1.1) and at 8 to 54 months postpartum (Analysis 1.2). Fol-
low-up point varied
Validation: at 36 weeks, cotinine/creatinine ratio > 80 ng/mg, but some missing data, no validation
postpartum
Notes Sensitivity analysis excluding losses to follow-up did not alter results
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation method not stated
Allocation concealment
(selection bias)





Unclear risk No details given, possible care providers were aware of participants' assign-
ment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Self-report used postpartum and for some women at 36 weeks ("We includ-
ed the 40 women who reported not smoking, but were missing 36-week coti-
nine/creatinine ratios, in the non-smoking group, rather than count them as
having relapsed".) Reason for missing validation data at 36 weeks not report-





Unclear risk No significant differences in loss to follow-up at 1 year (35%). Numbers ran-
domly assigned used in analyses, but restricting to numbers available for fol-
low-up did not alter findings
Secker-Walker 1995 
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Methods Setting: prenatal clinic, USA
Recruitment: women at 1st prenatal visit
Participants 116 women previously smoking 1+ cigs/day who self-reported quitting since start of pregnancy (exclud-
ed 9 adverse pregnancy outcomes). 19 of the women showed evidence of smoking at 1st prenatal visit
Interventions 1. Structured intervention from physician, individual counselling by nurse counsellor, 1st, 2nd, 3rd, 5th,
36 weeks prenatal visits
2. Usual care from physician, prompted at 1st visit
Outcomes Sustained abstinence at 36 weeks pregnancy (Analysis 1.1), 1-year postpartum (Analysis 1.2)
Validation: CO ≤ 6 ppm at 36 weeks, also urine cotinine ≤ 500 ng/mL but some missing data
Notes Process analysis showed counselling to have been received fairly consistently but fell to 66% at 5th visit
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not described
Allocation concealment
(selection bias)





Unclear risk No details given
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used at 36 weeks and differential misreport not iden-
tified. Similar rates abstinent at 1 year postpartum, differential misreport not




Low risk No significant differences in loss to follow-up at 1 year (33%). Numbers ran-





Methods Setting: Victoria, Australia Quitline
Recruitment: callers to Quitline
Participants 698 smokers or recent ex-smokers calling Victoria, Australia, Quitline and abstinent for at least 1 week
(1444 randomly assigned, but study conducted only in those achieving abstinence)
54% female, average age 37, average cpd 21
Interventions Participants received same callback service before quitting and same service in first month after quit-
ting (revised version of standard Quitline service: 4 calls in first month after quitting to help deal with
daily cravings and withdrawal). Service based on 3 Tasks of Quitting Framework. Both groups receive
counselling for first 2 tasks
Segan 2011 
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1. 4 to 6 additional calls 1 to 3 months post-quitting to actively assist with learning to enjoy and value a
smoke-free lifestyle (task 3), initiated when participant reported fewer than daily cravings or complet-
ed 4 standard calls (whichever came first)
2. No additional calls
Outcomes 12 months continuous abstinence
Validation: none
Notes New for 2013 update
n not provided, data extrapolated from percentages given. Only those participants abstinent for 1 week
or longer included in final analyses
74% of intervention group received extra calls, on average 1.7 more calls after quitting than control
group
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









High risk "Follow-up interviewers were blinded to participant treatment condition,
although for the four-month follow-up blinding was lost…" Participant and
provider unblinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No biochemical validation, but no face-to-face contact, so differential misre-




Low risk Similar rate lost to follow-up in both groups (28% control; 30% intervention),
participants lost to follow-up counted as smokers. Analysis excluding partici-
pants lost to follow-up did not affect final comparisons
Other bias High risk Probable lack of differentiation between the two conditions and risk of con-
tamination: “In practice, the first couple of integration callbacks typically re-
placed the last call or two of the standard service (rather than adding on to
it)…. Usual care participants received on average 2.2. calls after reaching the





Methods Setting: 49 private paediatric practices, USA
Recruitment: mothers attending for well baby visits
Participants 1026 ex-smoking mothers (intervention also given to smoking mothers, not relevant to this review)
Therapists: paediatricians.
25 intervention practices, 23 control
Severson 1997 
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Interventions 1. Information pack, including a letter from paediatrician on risks of passive smoking, provided by birth
hospital, and extended support (counselling plus follow-up at 2, 4, and 5 months visits) and materials
(including video tape, written materials, signs, magnets, bib)
2. Information pack only
Outcomes Sustained abstinence at 12 months (7-day point prevalence at 6 months and 12 months)
Validation: none
Notes Study design allowed for clustering in calculating sample size. ICC proved to be low. Use of a corrected
odds ratio, which did not show a significant benefit, did not change conclusions (sensitivity analysis us-
ing inverse variance)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Cluster-randomised by practice, method not described
Allocation concealment
(selection bias)
Unclear risk Method of allocating practices not described. All eligible patients enrolled in
study, "because the survey information was anonymous, and because smok-
ing counselling was considered to be standard medical practice, the study was





Unclear risk Participants not aware enrolled in study, so blinding not applicable Unclear
whether study personnel (administering surveys) were blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No biochemical validation but cluster-randomised by practice, followed up









Methods Setting: Quitline for Arkansas, USA
Recruitment: all participants calling the Quitline within a set amount of time were included
Participants All Arkansas Quitline callers whose primary form of tobacco use was smoking who ended treatment
(completing treatment or ending prematurely) within the set period and did not re-enter counselling
within 2 years of index episode (n = 892)
35% male, average age 43, average cpd not specified, mean FTND 7
Interventions 1. Intervention: 8 "Forever Free" booklets (aimed at relapse prevention) mailed to all Quitline callers
who ended treatment (within given 6 weeks period)
2. Nothing mailed to callers (all participants who consecutively ended treatment 1 month before or 1
month after intervention group)
She=er 2010 
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All participants received standard Quitline service (average 6 weekly structured CBT sessions 20 to 30
mins each); nicotine patches provided free of charge
Outcomes 7-day point prevalence at 6 months after discontinuation of treatment
Validation: none
Notes New for 2013 update
Quasi-randomised; baseline imbalances between groups, adjusted OR available
Intervention did not improve quit rates for participants receiving at least 1 session of counselling and
nicotine patches but doubled abstinence rate for those unwilling/unable to receive nicotine patches at
6 months
n not provided, extrapolated from percentages reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quasi-randomised. "The 'Forever Free' booklets were mailed to all quitline
callers who ended treatment during a six-week period. For comparison, we in-
cluded quitline callers whose treatment ended during the months immediate-
ly prior and succeeding the 6-week intervention period"
Allocation concealment
(selection bias)





Low risk "Quitline staH including tobacco treatment specialists and follow-up inter-
viewers were unaware that some participants had received additional materi-
als"
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No biochemical validation but no additional personalised contact received by




Low risk Similar rates of dropout in both groups (34.7% intervention, 40.0% control);




Methods Setting: three narcotics treatment centres, USA
Recruitment: volunteers on methadone maintenance
Participants 175 smokers (≥ 10/day); 33% female, average age 43 to 45, average cigs/day approximately 22
Interventions All participants received 21 mg nicotine patch for 12 weeks. Factorial design crossing contingency man-
agement, arms collapsed
1. Group counselling: 12 × 1 hour weekly sessions, including mood management
2. Control: NRT alone
Outcomes PP abstinence at 12 months
Validation: CO ≤ 8 ppm, urine cotinine < 30 ng/mL
Shoptaw 2002 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation using urn technique
Allocation concealment
(selection bias)






Unclear risk Not reported
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Number lost to follow-up not reported, but all missing included as smokers,
and study reported, "no statistically significant differences across the four




Methods Setting: Mailed interventions, USA
Recruitment: Nationally via multiple recruitment strategies (newspapers, radio, public transit, cable TV,
public service announcements) publicising cessation materials for current smokers interested in quit-
ting
Participants 1874 smokers: Traditional Self Help (TSH, n = 638), Standard Repeated Mailings (SRM, n = 614), Inten-
sive Repeated Mailings (IRM, n = 622)
34% male, average age 47.5, average cigs/day 20.5
Interventions 1. Intensive repeated mailings – 10 smoking cessation booklets and additional social support material
over 18 months
2. Standard repeated mailings – 8 smoking cessation booklets over 12 months
Control: Traditional self-help – one self-help smoking cessation booklet
Outcomes Self-report 7-d PP abstinence at 30 months
Notes Funding: a grant from the National Cancer Institute
Declaration of interests: H. Brandon has received research support from Pfizer, Inc.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No method stated
Simmons 2018 
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Allocation concealment
(selection bias)





Low risk Not stated but due to remote nature of intervention (mailing), performance
bias was unlikely.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Follow-up assessments completed by participants – self-report and self-doc-





Unclear risk Quote: "The percent of surveys not returned increased from 27% at 6 months




Methods Setting: Clinic, USA
Recruitment: community volunteers
Participants 677 smokers (> 10/day) attempted quit for 1 week; 57% female, average age 42; average cigs/day ap-
proximately 25
Interventions All participants had attended 3 brief (5 to 10 min) individual counselling sessions pre-quit, quit day and
8 days post TQD, + nicotine patches (8 weeks) + NCI booklet, 'Clearing The Air'
1. Cognitive-behavioural skills training, × 6 from 1 week post TQD, including managing negative affect,
homework, manual
2. Motivational interviewing, supportive group counselling, × 6 from 1 week post TQD. No homework or
manual
3. No further intervention
Outcomes Abstinence at 12 months (7-d PP)
Validation: CO < 10 ppm
Notes 1 versus 3 in Analysis 4.1, including 2, did not alter findings; 17.6% quit in 1, 18.8% in 2. No evidence
found for hypothesised differences in relative efficacy for smokers at high or low risk of relapse. High-
risk smokers expected to do better with motivational intervention
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)









Unclear risk Participants randomly assigned after receiving pre-quit interventions. No fur-
ther details provided
Blinding of outcome as-
sessment (detection bias) 
Unclear risk Biochemical validation used
Smith 2001 
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Methods Setting: HMO, USA
Recruitment: HMO member volunteers
Participants 587 smokers who successfully abstained from smoking for 4 days after a 4-day intensive cessation pro-
gramme
Interventions Both group conditions met for 3 × 2 hours weekly meetings
1. Skills condition. Development and active rehearsal of coping strategies
2. Discussion condition. Social support meetings without rehearsal of strategies
3. No further treatment control
Outcomes Abstinence at 1 year, no tobacco use in previous 6 months
Validation: saliva thiocyanate < 0.8 mg/mL or cotinine < 5 ng/mL
Notes Study hypothesis that discussion control would not increase rates, so in main analysis 1 versus 2 + 3
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Predetermined random number list
Allocation concealment
(selection bias)






Unclear risk Subjects randomly assigned after initial treatment phase, no further informa-
tion provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Biochemical validation used. StaH following up non-attenders at 1 year meet-









Methods Setting: Australia, Canada, USA, setting type not reported but presumably clinic
Recruitment: not stated
Participants 5055 adult smokers (> 18) motivated to quit. Randomly assigned to rimonabant 5 mg (n = 2026) or ri-
monabant 20 mg (n = 3029)
STRATUS-WW 2006 
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50% male, 88.8% female, mean age 44.1, average CPD 23.6, mean year smoking 24.1, mean quit at-
tempts 4.1, mean FTND score 5.4, 31.7% with FTND score > 7. Mean BMI 27.8
Interventions Phase 1: cessation trial: participants randomly assigned to rimonabant 5 mg [R5] (n = 2026) or rimon-
abant 20 mg [R20] (n = 3029) for 10 weeks, with TQD at day 15. Cessation rates at EOT: R5: 644/2026
(31.8%); R20 1017/3029 (33.6%), difference non-significant; Quitters eligible for phase 2 if: (a) self-re-
ported abstinence for 7+ days, (b) CO ≤ 10 ppm, and (c) compliance level of 80%+ in last 4 weeks of
phase 1
Phase 2: Relapse prevention: re-randomly assigned 644 quitters in R5 group to (i) R5 (n = 322) or (ii)
placebo (n = 322), and 1017 quitters in R20 group to (i) R5 (n = 335) or (ii) R20 (n = 340) or (iii) placebo (n
= 342). All groups received treatment for a further 42 weeks
Behavioural support: not reported
Outcomes Primary outcome: time to relapse for quitters from weeks 10 to 32. Relapse defined as ≥ 7 consecutive
days of smoking (even a puH), or ≥ 2 consecutive days with ≥ 5 cigs (even a puH) smoked per day
Long-term follow-up: 52 weeks, 104 weeks
Secondary outcome: time to relapse for quitters from week 10 to week 52
Other outcomes: weight change; fasting HDL-cholesterol, triglycerides; safety, adverse events
Validation: phase 1: expired CO < 10 ppm; phase 2: not reported
Notes New for 2013
Two-year follow-up data were not reported. Results not published and hence are limited, data not
available on phase 1 R5 group
Trial was funded by the manufacturer, Sanofi Aventis
Percentage abstinent at 12 months very similar in R5 and R20 phase II groups (41.8 vs 41.5), combined
in meta-analysis
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Unclear risk "Double-blind", no further information provided
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: cessation clinics in 7 countries. 6 sites in United States
Recruitment: smokers of ≥ 10/day for cessation phase
Tonstad 2006 
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Participants 1210 adults previously smoking ≥ 10/day, quit for at least 1 week after 12 weeks open-label varenicline
Interventions 1. Varenicline 1 mg × 2 daily for 12 weeks with 5 clinic visits
2. Placebo
Outcomes Sustained abstinence for 9 months at 1 year
Validation: CO ≥ 10 ppm
Notes The quit rate after the open-label phase was 64%
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Centralised computer-generated randomisation
Allocation concealment
(selection bias)





Low risk "Double-blind treatment phase"; "participant blinding was maintained during
this [non-treatment follow-up] phase"
Blinding of outcome as-
sessment (detection bias) 
All outcomes









Methods Setting: home-based, USA
Recruitment: clients of New York Smokers' Quitline
Participants 3458 smokers, 1142 repeated mailing, 1127 mass mailing, 1189 control
49.3% male, average age 46, average cigs/day 17
Interventions Repeated mailings: Eight 'Forever Free' booklets mailed over 12 months
Mass mailings: Eight 'Forever Free' booklets mailed upon enrolment
Control: Standard mail intervention
Outcomes 7-day point prevalence abstinence at 24 months
Validation: Not described
Notes Funding: "National Cancer Institute of the National Institutes of Health under award number
R01CA137357. This work has also been supported in part by the Biostatistics and Survey Methods Core
Facilities at the H. Lee Moffitt Cancer Center and Research Institute, an NCI designated Comprehensive
Cancer Center (P30CA76292)."
Unrod 2016 
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Declaration of interests: "THB has received research support from Pfizer, Inc. KMC has received grant
funding from the Pfizer Corporation to study the impact of a hospital based tobacco cessation interven-
tion. He also receives funding as an expert witness in litigation filed against the tobacco industry. No
other financial disclosures or conflicts of interest were reported by the authors of this paper."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computerised randomisation performed
Allocation concealment
(selection bias)





Low risk Blinding could not be performed because of the nature of the intervention, but
there was no difference in face-to-face contact between intervention and con-
trol groups.
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Methods Setting: participants in national Quit and Win contest, Netherlands
Recruitment: email to Quit and Win participants
Participants 1566 participants in national Quit & Win contest (daily smokers, smoking for at least 1 year, 18 years or
older)
60.8% female, average age 36.2, average cpd 18.5, average length of smoking 19.1 years
Interventions Quit and Win contest included 1-month cessation period, including computer-tailored cessation advice
and telephone counselling
Intervention: participants asked to formulate three coping plans when completing baseline survey
Control: baseline survey only (not prompted to formulate coping strategies)
Outcomes Continuous abstinence and 7-d PP at 7 months
Validation: none, although participants had buddies and were informed that biochemical abstinence
would be performed for contest winners
Notes New for 2013 update
Unclear how abstinence data were obtained
Including only respondents increased evidence of effect
Risk of bias
Van Osch 2008 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk "Based on odd or even registration numbers"
Allocation concealment
(selection bias)






Low risk No blinding reported, but because of the nature of the intervention, perfor-
mance bias unlikely
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk 'Buddy' validation and knowledge of biochemical validation would be used





High risk Very high rates of dropout at 7 months (64% control, 63% intervention). "The
relatively high attrition suffered across the two follow-up measurements may





Methods Setting: six hospitals, USA
Recruitment: women at time of delivery
Participants 277 women who had quit during pregnancy, cotinine verified as not smoking at recruitment (excluded
10 not followed up for a variety of reasons). Average age 25, previous cigs/day not reported. 65% were
very confident of remaining quit
Interventions 1. 15 min to 30 min of relapse prevention counselling from Visiting Nurse after baseline interview. Rein-
forcement by paediatric care provider at 2 weeks, 2 months, 4 months well baby clinics, written materi-
als. Chart sticker used to prompt intervention
2. Usual care, baseline assessment from Visiting Nurse
Outcomes Abstinence at 6 months (assume PP)
Validation: none (assessment by phone, no details of blinding of assessor)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomised, method not described
Allocation concealment
(selection bias)





Unclear risk No details given
Van't Hof 2000 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk No biochemical validation, intervention participants received more face-to-










Methods Setting: University affiliated outpatient medical practices, USA
Recruitment: Via posters and clinician referrals to attend smoking cessation group treatment
Participants 115 previous smokers who had quit in the first part of the study; 40% male, average age 50, average
cigs/day 15.5
Interventions Intervention: 8 self-directed relapse prevention materials
Control: 1 information booklet on cigarettes (with no advice on quitting/relapse prevention)
Outcomes 7-day PP abstinence
Validation: Exhaled carbon monoxide
Notes Funding: internal grant from Penn State Cancer Institute to JF. JF, SV, JY, and SH are primarily funded
by the National Institute on Drug Abuse of the National Institutes of Health and the Center for Tobacco
Products of the U.S. Food and Drug Administration.
Declaration of interests: JF has done paid consulting for pharmaceutical companies involved in pro-
ducing smoking cessation medications, including GSK, Pfizer, Novartis, J & J, and Cypress Bioscience.
The other authors have no conflicts of interest to disclose.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method not described
Allocation concealment
(selection bias)





Low risk Participants were unaware of other conditions and received similar levels of
contact, so performance bias was unlikely.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk 27 dropouts, similar across conditions
Veldheer 2018 
 
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
 
Methods Setting: Seattle, WA, USA
Recruitment: community volunteers
Participants 302 female smokers, 18 to 70 years old, smoking at least 10 cpd
Average age 43, average cpd 20.6, average FTND 5.2
Interventions All participants received 6 weeks nicotine patch (21 mg/d); 2 group counselling sessions pre-quit and
three post-quit (through day 7); ecological momentary assessment (EMA) procedures for week immedi-
ately following quit date
1. 1-month computer-delivered treatment (CDT) on palmtop computers (3 modules: managing urge,
treatment info and motivational messages) and EMA
2. EMA only for 1-month post-quit date
Outcomes Repeated 7-day PP (day 35, month 6, month 12)
Validation: CO < 10 ppm
Notes New for 2013 update
Trial report provided only OR and adjusted OR (no raw data), n provided by authors
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "the study biostatistician generated the randomization sequence"
Allocation concealment
(selection bias)





Unclear risk Blinding not specified, unclear whether participants aware of additional ele-
ment offered to intervention group
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Dropouts counted as smokers in ITT analysis, similar number lost to follow-up
in each group at 12 months (21 dropouts control, 19 dropouts treatment)
Wetter 2011 
ALA = American Lung Association
BMI = body mass index
BMT = basic military training
BS = Broad-spectrum
CABG = coronary artery bypass graB
CAD = coronary artery disease
CBT = cognitive-behavioural therapy
CDT = computer-delivered treat
CHESS SCRP = Comprehensive Health Enhancement Support System for Smoking Cessation and Relapse Prevention
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CO = carbon monoxide
cpd = cigarettes per day
EMA = ecological momentary assessment
EOT = end of treatment
FTND = Fagerström Test for Nicotine Dependence
FTQ = Fagerström Tolerance Questionnaire
HMO = health maintenance organisation
ICC = Intraclass correlation
ITT = intention to treat
MAPS; MAPS+ = Motivation and Problem-Solving; Motivation and Problem-Solving+
MDD = major depressive disorder
MI = myocardial infarction
min = minutes
NCI = National Cancer Institute
NHS = National Health Service
NRT = nicotine replacement therapy
NS = not stated
PA = partner-assisted
PP = point prevalence abstinence (abstinent at that time but not necessarily continuously since treatment)
PPC = proactive phone counselling
ppm = parts per million
PTSD = post traumatic stress disorder
RCT = randomised controlled trial
TEQ-20; TEQ-10 = Technology Enhanced Quitline-20; Technology Enhanced Quitline-10
TQD = target quit day
UC = usual care
WGC = workplace group counselling
WO = women only
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ACTRN12618000408280 No appropriate comparator
Adams 2011 Only 2 months follow-up
Allen 2007 Only 12 weeks follow-up
Alterman 2001 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Berndt 2012 Content of intervention did not involve relapse prevention
Bottausci 1995 Small trial, < 10 participants per condition
Brown 2001 Considered for inclusion because comparison of different intensity interventions. Intervention fo-
cus was on use of CBT for treatment of depression. Relapse mentioned only in text
Carmody 1988 Only 3 months follow-up reported. No significant differences at this point
Carmody 2017 Wrong comparator as both groups had the same amount of contact
Cather 2013 All participants received the same intervention
Cinciripini 2000 Not possible to distinguish relapse prevention from cessation components
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Study Reason for exclusion
Copeland 2006 Evaluated a weight management programme for preventing relapse; see separate Cochrane review
Davis 1995 Short follow-up
DiSantis 2010 Pilot study with only 1-month follow-up
Dooley 1992 Only 3 months follow-up reported. No significant differences at this point
Dubren 1977 Only 1-month follow-up reported
Dunphy 2000 Only 4 to 8 weeks follow-up after delivery and intervention
Elfeddali 2012 Participants randomly assigned before quitting, no cessation intervention provided to controls, so
test of an Internet cessation programme. Not relapse prevention
Evins 2011 Only 60-day follow-up
Feeney 2001 Not explicitly described as a relapse prevention intervention, and the control condition had low im-
plementation of the basic cessation programme
French 2007 Not randomised
French 2018 Study of incentives
Froelicher 2000 Described a trial in progress, no intervention results
Garvey 2012 Considered for inclusion because of front-loading of counselling sessions in one group. No mention
of relapse prevention
George 2000 Tested a specialised group therapy intervention for people with schizophrenia compared with a
standard programme. Included other components in addition to relapse prevention
Goldstein 1989 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Gruder 1993 Not possible to distinguish between relapse prevention and cessation components
Hall 1994 Considered for inclusion because comparison of different intensity interventions. Primary focus
was on CBT for depression as adjunct to cessation intervention. No mention of relapse prevention
Hall 1996 Considered for inclusion because comparison of different intensity interventions. Primary focus
was on mood management as adjunct to cessation intervention. No mention of relapse prevention
Hall 1998 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Hall 2011 Considered for inclusion because study evaluated extended therapy. Not relapse prevention
Hassandra 2017 Wrong intervention. Relapse prevention but exercise-based
Juliano 2006 Previously included study. Excluded from 2018 update because included relapsed smokers rather
than abstainers
Klesges 1987 Randomisation and analysis by worksite, number of individuals in each treatment condition not
given. A non-significant difference favoured relapse prevention
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Study Reason for exclusion
Lando 1997 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Laude 2017 Not relapse prevention
Macleod 2003 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Miller 1997 Hospital intervention included relapse prevention components but excluded because no informa-
tion on smoking status of participants, and intervention similar in other respects to other inpatient
trials. Also compared 2 intensities of telephone follow-up but these were not described as relapse
prevention
NCT00218465 Only 5-week follow-up
NCT00621777 Only 3 months' follow-up
NCT01131156 Only 8-week follow-up
NCT02888444 Only 24-week follow-up
NCT02968095 Only 6-week follow-up
NCT03113370 Only 12-week follow-up
NCT03262662 Not relapse prevention
NCT03690596 Only 12-week follow-up
NCT03930329 Only 8-week follow-up
Phillips 2012 Only 8-week follow-up
Reid 1999 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Schlam 2016 Study of extended NRT in smokers: covered in Lindson 2019
Schnoll 2015 Previously included study. Excluded in 2019 update as extended NRT is covered in Lindson 2019
Snuggs 2012 Wrong design, all participants received text messages
Solomon 2000 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Storro 2008 Controlled cohort study of postpartum intervention, not randomised
Tonstad 2013 Test of vaccine versus placebo. Effect of pharmacotherapy post-quit confounded with pharma-
cotherapy before quitting
Yoon 2009 Only 2-week follow-up
Zelman 1992 Considered for inclusion because comparison of different intensity interventions. No mention of re-
lapse prevention
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
CBT = cognitive-behavioural therapy
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Real-time video counselling for smoking cessation in regional and remote areas
Methods RCT
Participants Not yet recruiting
Interventions Real-time video counselling via Skype, Face Time or other video communication
Outcomes Self-reported 7-day PPA at 12 months
Starting date 28/4/17
Contact information Flora Tzelepis
Notes Funding: Cancer Institute New South Wales








Interventions Yoga, comparison health and wellness program
Outcomes Prolongued abstinence at 12 months
Starting date September 2012





Trial name or title Preventing smoking initiation or relapse following basic military training
Methods RCT
Participants 7495 airmen recently completed 8.5 weeks basic miliary training with involuntary tobacco absti-
nence
Interventions Standard smoking cessation booklet (standard condition), targeted guide (targeted guide condi-
tion), targeted guide plus a brief tailored intervention delivered face-to-face (face-to-face condi-
tion)
Brandon 2014 
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Outcomes Self-reported continuous and 7-day PPA at 24 months
Starting date Jan 2013





Trial name or title Surviving smokefree randomised controlled trial
Methods RCT
Participants 414 smoking cancer patients
Interventions Smoking Relapse Prevention intervention (SRP): brief clinical intervention and Forever Free book-
lets and Surviving SmokeFree DVD, Usual Care (UC): one-time routine assessment of smoking be-
haviour and brief clinical intervention
Outcomes Self-reported 7-day PPA at 12 months
Starting date June 2012





Trial name or title Non-invasive brain stimulation for nicotine addiction
Methods RCT
Participants 74 smokers
Interventions 4 sessions of intermittent Theta Burst Stimulation (iTBS) as add-on to cognitive behavioural
therapy, Sham iTBS plus CBT
Outcomes Abstinence at 12 months (unclear how assessed)
Starting date Unclear





Trial name or title Duration of behavioral counseling treatment needed to optimize smoking abstinence
Garvey 2012a 
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Methods RCT
Participants Unknown recruitment status
Interventions Brief duration counselling: 3-month duration
Moderate duration counselling: 6-month duration
Extended duration counselling: 12-month duration
Outcomes Abstinence at 1 and 2 years
Starting date February 2008
Contact information Arthur J. Garvey




Trial name or title Virtual reality exposure therapy for relapse prevention
Methods RCT
Participants 120 smokers
Interventions CBT group, CBT with virtual reality exposure therapy
Outcomes CO-verified abstinence at 6 months
Starting date August 2014





Trial name or title Helping people cope with temptations to smoke to reduce relapse: a factorial randomised con-
trolled trial
Methods RCT
Participants 1400 users of Stop Smoking Service, UK
Interventions Smoking replacement produce plus online support, personalised plan and access to Structured
Planning and Prompting programme, smoking replacement product and text message support,
usual care
Outcomes Validated abstinence at 12 months
Starting date April 2016
ISRCTN11111428 
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Contact information Anna Phillips




Trial name or title Prevent Relapse In SMoking (PRISM)
Methods RCT
Participants 250 postpartum women who quit smoking in the six months before pregnancy or no later than the
end of the first pregnancy trimester and remained abstinent (which was biochemically verified) un-
til delivery
Interventions Intervention: up to 4 postnatal counselling calls for mothers and their partners using motivational
interviewing, usual care
Outcomes Maternal abstinence at 6 months postpartum
Starting date December 2013
Contact information Cristian Ioan Meghea




Trial name or title Maintaining nonsmoking
Methods Randomised parallel assignment
Participants Unknown recruitment status and intended sample size
Interventions Extended brief contact, extended health education, extended relapse prevention, extended relapse
prevention plus varenicline
Outcomes Smoking status (undefined) at up to 104 weeks following treatment initiation
Starting date May 2010
Contact information University of California, San Francisco; National Institute on Drug Abuse (NIDA)




Trial name or title Exercise and smoking
Methods RCT
NCT01305447 
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Participants 413 females
Interventions Exercise maintenance + relapse prevention, exercise maintenance, relapse preven-
tion
Outcomes Continuous abstinence at 56 weeks
Starting date October 2009





Trial name or title Extended varenicline treatment for smoking among cancer patients
Methods Randomised parallel assignment
Participants 374 cancer patient smokers
Interventions Standard varenicline treatment: 12 weeks of active varenicline + 12 weeks of placebo + smoking
cessation counselling
Extended varenicline treatment: 24 weeks of active varenicline + smoking cessation counselling
Outcomes 7-day PPA at week 52
Starting date Jan 2013
Contact information Robert A Schnoll




Trial name or title Varenicline and combined Nicotine Replacement Therapy (NRT) for smoking cessation
Methods Randomised cross-over assignment
Participants Ongoing recruitment: 500 smokers
Interventions Varenicline: varenicline tablets, placebo patches, and placebo lozenges, nicotine patch + nicotine
lozenge group: placebo tablets, nicotine patches, and nicotine lozenges, tablets, patches, lozenges
previously assigned, switch to different active therapy, extra tablet + patch
Outcomes 7-day PPA at 12 weeks
Starting date May 2015
Contact information Paul Cinciripini
NCT02271919 
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Trial name or title Effectiveness of mindfulness based relapse prevention for tobacco dependents
Methods RCT
Participants Unknown recruitment status, 60 smokers
Interventions Mindfulness-based relapse prevention, control
Outcomes Abstinence (undefined measure and time point)
Starting date October 2012
Contact information Ana Regina Noto




Trial name or title Twitter-enabled mobile messaging for smoking relapse prevention (Tweet2Quit)
Methods RCT
Participants 960 smokers intended
Interventions NRT + web guide + Tweet2Quit-coed or Tweet2Quit-women only
Outcomes 7-day PPA at 6 months
Starting date October 2016





Trial name or title A trial of directly observed and long-term varenicline
Methods RCT
Participants Recruiting: 450 opioid treatment patients intended
Interventions 1) Behavioural: Directly observed therapy, 2) Varenicline tablet x 24 weeks, 3) Self-administered
therapy, 4) Short-term varenicline tablet for 12 weeks
Outcomes 7-day PPA at 1 year
NCT03365362 
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Starting date Oct 25 2018





Trial name or title Preventing smoking relapse after total joint replacement surgery
Methods RCT
Participants Not yet recruiting, 300 patients after total joint replacement surgery intended
Interventions Comprehensive relapse prevention intervention, inc visit prior to discharge, 6 follow-up calls up to
60 days after hospital visit, text message support, caregiver support, NRT
Outcomes Self-report PPA at 1 year
Starting date March 2019





Trial name or title Effectiveness of WhatsApp online group discussion for smoking relapse prevention
Methods RCT
Participants Recruiting: 1008 intended
Interventions WhatsApp group will allow real-time group discussion for 8 weeks vs text messages
Outcomes 7-day PPA at 1 year
Starting date Oct 4 2018
Contact information Derek Cheung
Notes  
NCT03760224 
CBT = cognitive behavioural therapy
CO = carbon monoxide
DVD = digital video disc
iTBS = intermittent Theta Burst Stimulation
NIDA = National Institute on Drug Abuse
NRT: nicotine replacement therapy
PPA = point prevalence abstinence
RCT = randomised controlled trial
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UC = usual care
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Behavioural interventions for abstinent pregnant/postpartum women





Statistical method Effect size
1 Not smoking at delivery/last fol-
low-up prior to delivery
8 1523 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.99, 1.11]
1.1 Self-help intervention 1 171 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.91, 1.21]
1.2 Individual counselling 5 641 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.89, 1.13]
1.3 Telephone counselling 2 711 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.99, 1.15]
2 Not smoking at longest follow-up
after delivery
14 4606 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.94, 1.09]
2.1 Intervention during pregnancy 5 690 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.80, 1.26]
2.2 Intervention initiated during
pregnancy and continued postpar-
tum
6 2071 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.90, 1.09]
2.3 Intervention initiated after birth 4 1845 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.87, 1.28]
 
 
Analysis 1.1.   Comparison 1 Behavioural interventions for abstinent pregnant/
postpartum women, Outcome 1 Not smoking at delivery/last follow-up prior to delivery.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 Self-help intervention  
Ershoff 1995 73/87 67/84 16.28% 1.05[0.91,1.21]
Subtotal (95% CI) 87 84 16.28% 1.05[0.91,1.21]
Total events: 73 (Treatment), 67 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
   
1.1.2 Individual counselling  
Hajek 2001 66/114 68/135 6.22% 1.15[0.91,1.45]
Lowe 1997 32/40 29/38 5.9% 1.05[0.83,1.33]
Morasco 2006 10/14 16/19 2.21% 0.85[0.58,1.25]
Secker-Walker 1995 55/85 54/80 6.84% 0.96[0.77,1.19]
Secker-Walker 1998 22/55 29/61 1.88% 0.84[0.55,1.28]
Subtotal (95% CI) 308 333 23.05% 1.01[0.89,1.13]
Total events: 185 (Treatment), 196 (Control)  
Heterogeneity: Tau2=0; Chi2=3.07, df=4(P=0.55); I2=0%  
Favours control 1 Favours treatment
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.12(P=0.91)  
   
1.1.3 Telephone counselling  
McBride 1999 224/258 110/137 35.75% 1.08[0.98,1.19]
McBride 2004 173/209 85/107 24.92% 1.04[0.93,1.17]
Subtotal (95% CI) 467 244 60.66% 1.06[0.99,1.15]
Total events: 397 (Treatment), 195 (Control)  
Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.63); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
   
Total (95% CI) 862 661 100% 1.05[0.99,1.11]
Total events: 655 (Treatment), 458 (Control)  
Heterogeneity: Tau2=0; Chi2=3.96, df=7(P=0.78); I2=0%  
Test for overall effect: Z=1.65(P=0.1)  
Test for subgroup differences: Chi2=0.61, df=1 (P=0.74), I2=0%  
Favours control 1 Favours treatment
 
 
Analysis 1.2.   Comparison 1 Behavioural interventions for abstinent pregnant/
postpartum women, Outcome 2 Not smoking at longest follow-up aKer delivery.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 Intervention during pregnancy  
Hajek 2001 26/114 34/135 2.74% 0.91[0.58,1.41]
McBride 1999 66/157 33/78 5.32% 0.99[0.72,1.37]
Morasco 2006 6/14 6/19 0.68% 1.36[0.55,3.33]
Ruger 2008 9/24 5/33 0.6% 2.48[0.95,6.45]
Secker-Walker 1998 25/55 32/61 3.84% 0.87[0.6,1.26]
Subtotal (95% CI) 364 326 13.17% 1[0.8,1.26]
Total events: 132 (Treatment), 110 (Control)  
Heterogeneity: Tau2=0.01; Chi2=4.65, df=4(P=0.33); I2=13.92%  
Test for overall effect: Z=0.02(P=0.98)  
   
1.2.2 Intervention initiated during pregnancy and continued postpar-
tum
 
Brandon 2012 190/343 210/357 28.66% 0.94[0.83,1.07]
McBride 1999 63/146 33/78 5.27% 1.02[0.74,1.4]
McBride 2004 105/231 47/118 7.67% 1.14[0.88,1.48]
Pollak 2016 66/188 71/194 7.37% 0.96[0.73,1.25]
Reitzel 2010 31/136 19/115 2.06% 1.38[0.82,2.31]
Secker-Walker 1995 28/85 26/80 2.83% 1.01[0.65,1.57]
Subtotal (95% CI) 1129 942 53.87% 0.99[0.9,1.09]
Total events: 483 (Treatment), 406 (Control)  
Heterogeneity: Tau2=0; Chi2=3.49, df=5(P=0.63); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
   
1.2.3 Intervention initiated after birth  
Hannöver 2009 34/148 39/156 3.37% 0.92[0.62,1.37]
Ratner 2000 25/119 22/119 2.07% 1.14[0.68,1.9]
Favours control 50.2 20.5 1 Favours treatment
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Severson 1997 200/609 109/417 13.24% 1.26[1.03,1.53]
Van't Hof 2000 78/133 91/144 14.28% 0.93[0.77,1.12]
Subtotal (95% CI) 1009 836 32.96% 1.06[0.87,1.28]
Total events: 337 (Treatment), 261 (Control)  
Heterogeneity: Tau2=0.02; Chi2=5.57, df=3(P=0.13); I2=46.18%  
Test for overall effect: Z=0.56(P=0.58)  
   
Total (95% CI) 2502 2104 100% 1.02[0.94,1.09]
Total events: 952 (Treatment), 777 (Control)  
Heterogeneity: Tau2=0; Chi2=14.44, df=14(P=0.42); I2=3.06%  
Test for overall effect: Z=0.43(P=0.67)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.85), I2=0%  
Favours control 50.2 20.5 1 Favours treatment
 
 
Comparison 2.   Interventions for abstinent hospitalised smokers





Statistical method Effect size
1 Behavioural interventions, cessation at longest
follow-up
5 1385 Risk Ratio (M-H, Random, 95%
CI)
1.10 [0.82, 1.47]
2 Pharmacotherapy interventions, cessation at
longest follow-up
2 1078 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.94, 1.60]
 
 
Analysis 2.1.   Comparison 2 Interventions for abstinent hospitalised smokers,
Outcome 1 Behavioural interventions, cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Campos 2018 24/43 9/42 13.59% 2.6[1.38,4.93]
Cummins 2016 57/317 59/316 26.24% 0.96[0.69,1.34]
Hajek 2002 94/254 102/251 32.31% 0.91[0.73,1.13]
Hasuo 2004 32/60 25/49 24.48% 1.05[0.73,1.5]
Schmitz 1999 3/29 3/24 3.39% 0.83[0.18,3.73]
   
Total (95% CI) 703 682 100% 1.1[0.82,1.47]
Total events: 210 (Treatment), 198 (Control)  
Heterogeneity: Tau2=0.06; Chi2=9.55, df=4(P=0.05); I2=58.1%  
Test for overall effect: Z=0.64(P=0.52)  
Favours control 100.1 50.2 20.5 1 Favours treatment
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Analysis 2.2.   Comparison 2 Interventions for abstinent hospitalised smokers,
Outcome 2 Pharmacotherapy interventions, cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Brandstein 2012 6/64 4/62 4.89% 1.45[0.43,4.9]
Cummins 2016 70/317 29/157 46.72% 1.2[0.81,1.76]
Cummins 2016 75/320 30/158 48.38% 1.23[0.85,1.8]
   
Total (95% CI) 701 377 100% 1.23[0.94,1.6]
Total events: 151 (Treatment), 63 (Control)  
Heterogeneity: Tau2=0; Chi2=0.09, df=2(P=0.95); I2=0%  
Test for overall effect: Z=1.52(P=0.13)  
Favours control 100.1 50.2 20.5 1 Favours pharmacotherapy
 
 
Comparison 3.   Behavioural interventions for unaided abstainers




Statistical method Effect size
1 Cessation at longest follow-up 5 3561 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
1.1 Low-intensity interventions 5 3561 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
 
 
Analysis 3.1.   Comparison 3 Behavioural interventions for
unaided abstainers, Outcome 1 Cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
3.1.1 Low-intensity interventions  
Borland 2004 45/139 33/147 5.7% 1.44[0.98,2.12]
Brandon 2000 302/449 91/135 45.47% 1[0.87,1.14]
Brandon 2004 187/320 60/111 21.91% 1.08[0.89,1.31]
Fortmann 1995 97/521 97/521 13% 1[0.78,1.29]
Killen 1990 171/814 74/404 13.92% 1.15[0.9,1.47]
Subtotal (95% CI) 2243 1318 100% 1.06[0.96,1.16]
Total events: 802 (Treatment), 355 (Control)  
Heterogeneity: Tau2=0; Chi2=4.06, df=4(P=0.4); I2=1.47%  
Test for overall effect: Z=1.19(P=0.23)  
   
Total (95% CI) 2243 1318 100% 1.06[0.96,1.16]
Total events: 802 (Treatment), 355 (Control)  
Heterogeneity: Tau2=0; Chi2=4.06, df=4(P=0.4); I2=1.47%  
Test for overall effect: Z=1.19(P=0.23)  
Favours control 20.5 1.50.7 1 Favours treatment
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Comparison 4.   Behavioural interventions for assisted abstainers





Statistical method Effect size
1 Cessation at longest follow-up 11 5523 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.87, 1.11]
1.1 Low-intensity interventions 7 4402 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.82, 1.09]
1.2 High-intensity interventions 4 1121 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.82, 1.36]
 
 
Analysis 4.1.   Comparison 4 Behavioural interventions for
assisted abstainers, Outcome 1 Cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
4.1.1 Low-intensity interventions  
Blyth 2015 217/702 238/702 14.69% 0.91[0.78,1.06]
Cheung 2015 21/82 8/54 2.46% 1.73[0.83,3.62]
Hayes 2018 58/286 42/291 7.24% 1.41[0.98,2.02]
McDaniel 2015 234/602 112/296 13.6% 1.03[0.86,1.23]
McDaniel 2015 176/591 111/296 12.96% 0.79[0.66,0.96]
McNaughton 2013 5/23 9/21 1.67% 0.51[0.2,1.27]
Mermelstein 2003 68/176 75/165 10.67% 0.85[0.66,1.09]
Veldheer 2018 24/59 25/56 5.89% 0.91[0.6,1.39]
Subtotal (95% CI) 2521 1881 69.18% 0.95[0.82,1.09]
Total events: 803 (Treatment), 620 (Control)  
Heterogeneity: Tau2=0.02; Chi2=13.8, df=7(P=0.05); I2=49.28%  
Test for overall effect: Z=0.77(P=0.44)  
   
4.1.2 High-intensity interventions  
Powell 1981 11/17 11/17 4.7% 1[0.61,1.64]
Razavi 1999 59/135 43/121 8.75% 1.23[0.9,1.67]
Smith 2001 40/226 54/223 7.18% 0.73[0.51,1.05]
Stevens 1989 76/184 65/198 10.19% 1.26[0.97,1.64]
Subtotal (95% CI) 562 559 30.82% 1.06[0.82,1.36]
Total events: 186 (Treatment), 173 (Control)  
Heterogeneity: Tau2=0.04; Chi2=6.52, df=3(P=0.09); I2=53.96%  
Test for overall effect: Z=0.42(P=0.67)  
   
Total (95% CI) 3083 2440 100% 0.98[0.87,1.11]
Total events: 989 (Treatment), 793 (Control)  
Heterogeneity: Tau2=0.02; Chi2=22.99, df=11(P=0.02); I2=52.14%  
Test for overall effect: Z=0.26(P=0.79)  
Test for subgroup differences: Chi2=0.55, df=1 (P=0.46), I2=0%  
Favours control 20.5 1.50.7 1 Favours treatment
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Comparison 5.   Pharmacotherapy for assisted abstainers





Statistical method Effect size
1 Nicotine replacement therapy versus
placebo. Cessation 12 months + after quit
date
2 553 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.77, 1.40]
1.1 16-week nicotine gum vs placebo 1 143 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.77, 2.69]
1.2 16-week nicotine gum + bupropion vs
placebo gum + bupropion
1 146 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.59, 1.56]
1.3 9-month nicotine inhaler vs placebo 1 168 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.54, 1.72]
1.4 9-month nicotine inhaler + bupropion vs
placebo inhaler + bupropion
1 96 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.39, 1.93]
2 Bupropion vs placebo. Cessation 12
months + after quit date
6 1697 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.98, 1.35]
2.1 52 weeks bupropion vs placebo 1 110 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.60, 1.55]
2.2 45 weeks bupropion vs placebo 1 429 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.82, 1.51]
2.3 24 weeks bupropion vs placebo 1 176 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.77, 2.77]
2.4 16 weeks bupropion vs placebo 1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.95, 3.12]
2.5 16 weeks bupropion + nicotine gum vs
placebo + nicotine gum
1 145 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.68, 1.92]
2.6 9 months bupropion vs placebo 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.64, 1.84]
2.7 9 months bupropion + placebo inhaler vs
double placebo
1 97 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.40, 1.68]
2.8 9 months bupropion + nicotine inhaler vs
placebo + nicotine inhaler
1 93 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.43, 2.39]
2.9 14 weeks bupropion vs placebo 1 362 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.84, 1.68]
3 Combination NRT & bupropion vs placebo.
Cessation at longest follow-up
2 243 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.75, 1.87]
4 Varenicline vs placebo. Cessation 12
months + after quit date
2 1297 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [1.08, 1.41]
5 Rimonabant vs placebo. Cessation 12
months + after quit date
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Analysis 5.1.   Comparison 5 Pharmacotherapy for assisted abstainers, Outcome 1
Nicotine replacement therapy versus placebo. Cessation 12 months + aKer quit date.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.1.1 16-week nicotine gum vs placebo  
Covey 2007 19/72 13/71 20.26% 1.44[0.77,2.69]
Subtotal (95% CI) 72 71 20.26% 1.44[0.77,2.69]
Total events: 19 (Treatment), 13 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.15(P=0.25)  
   
5.1.2 16-week nicotine gum + bupropion vs placebo gum + bupropion  
Covey 2007 22/73 23/73 35.59% 0.96[0.59,1.56]
Subtotal (95% CI) 73 73 35.59% 0.96[0.59,1.56]
Total events: 22 (Treatment), 23 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.18(P=0.86)  
   
5.1.3 9-month nicotine inhaler vs placebo  
Croghan 2007 17/81 19/87 28.35% 0.96[0.54,1.72]
Subtotal (95% CI) 81 87 28.35% 0.96[0.54,1.72]
Total events: 17 (Treatment), 19 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.89)  
   
5.1.4 9-month nicotine inhaler + bupropion vs placebo inhaler +
bupropion
 
Croghan 2007 9/49 10/47 15.8% 0.86[0.39,1.93]
Subtotal (95% CI) 49 47 15.8% 0.86[0.39,1.93]
Total events: 9 (Treatment), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.36(P=0.72)  
   
Total (95% CI) 275 278 100% 1.04[0.77,1.4]
Total events: 67 (Treatment), 65 (Control)  
Heterogeneity: Tau2=0; Chi2=1.44, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.27(P=0.79)  
Test for subgroup differences: Chi2=1.44, df=1 (P=0.7), I2=0%  
Favours control 50.2 20.5 1 Favours treatment
 
 
Analysis 5.2.   Comparison 5 Pharmacotherapy for assisted abstainers,
Outcome 2 Bupropion vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
5.2.1 52 weeks bupropion vs placebo  
Hays 2009 21/56 21/54 10.39% 0.96[0.6,1.55]
Subtotal (95% CI) 56 54 10.39% 0.96[0.6,1.55]
Total events: 21 (Treatment), 21 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.15(P=0.88)  
Favours control 50.2 20.5 1 Favours treatment
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
5.2.2 45 weeks bupropion vs placebo  
Hays 2001 62/214 56/215 27.16% 1.11[0.82,1.51]
Subtotal (95% CI) 214 215 27.16% 1.11[0.82,1.51]
Total events: 62 (Treatment), 56 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
5.2.3 24 weeks bupropion vs placebo  
Hurt 2003 19/88 13/88 6.32% 1.46[0.77,2.77]
Subtotal (95% CI) 88 88 6.32% 1.46[0.77,2.77]
Total events: 19 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.16(P=0.25)  
   
5.2.4 16 weeks bupropion vs placebo  
Covey 2007 23/73 13/71 6.41% 1.72[0.95,3.12]
Subtotal (95% CI) 73 71 6.41% 1.72[0.95,3.12]
Total events: 23 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.78(P=0.07)  
   
5.2.5 16 weeks bupropion + nicotine gum vs placebo + nicotine gum  
Covey 2007 22/73 19/72 9.3% 1.14[0.68,1.92]
Subtotal (95% CI) 73 72 9.3% 1.14[0.68,1.92]
Total events: 22 (Treatment), 19 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
   
5.2.6 9 months bupropion vs placebo  
Croghan 2007 21/71 19/70 9.3% 1.09[0.64,1.84]
Subtotal (95% CI) 71 70 9.3% 1.09[0.64,1.84]
Total events: 21 (Treatment), 19 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
   
5.2.7 9 months bupropion + placebo inhaler vs double placebo  
Croghan 2007 10/47 13/50 6.12% 0.82[0.4,1.68]
Subtotal (95% CI) 47 50 6.12% 0.82[0.4,1.68]
Total events: 10 (Treatment), 13 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.54(P=0.59)  
   
5.2.8 9 months bupropion + nicotine inhaler vs placebo + nicotine in-
haler
 
Croghan 2007 9/49 8/44 4.1% 1.01[0.43,2.39]
Subtotal (95% CI) 49 44 4.1% 1.01[0.43,2.39]
Total events: 9 (Treatment), 8 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
   
5.2.9 14 weeks bupropion vs placebo  
Favours control 50.2 20.5 1 Favours treatment
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Killen 2006 51/181 43/181 20.9% 1.19[0.84,1.68]
Subtotal (95% CI) 181 181 20.9% 1.19[0.84,1.68]
Total events: 51 (Treatment), 43 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.96(P=0.34)  
   
Total (95% CI) 852 845 100% 1.15[0.98,1.35]
Total events: 238 (Treatment), 205 (Control)  
Heterogeneity: Tau2=0; Chi2=3.88, df=8(P=0.87); I2=0%  
Test for overall effect: Z=1.73(P=0.08)  
Test for subgroup differences: Chi2=3.87, df=1 (P=0.87), I2=0%  
Favours control 50.2 20.5 1 Favours treatment
 
 
Analysis 5.3.   Comparison 5 Pharmacotherapy for assisted abstainers, Outcome
3 Combination NRT & bupropion vs placebo. Cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Covey 2007 22/73 13/71 50.6% 1.65[0.9,3.01]
Croghan 2007 9/49 13/50 49.4% 0.71[0.33,1.5]
   
Total (95% CI) 122 121 100% 1.18[0.75,1.87]
Total events: 31 (Treatment), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=2.95, df=1(P=0.09); I2=66.14%  
Test for overall effect: Z=0.71(P=0.48)  
Favours treatment 50.2 20.5 1 Favours control
 
 
Analysis 5.4.   Comparison 5 Pharmacotherapy for assisted abstainers,
Outcome 4 Varenicline vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Evins 2014 18/40 7/47 2.8% 3.02[1.41,6.49]
Tonstad 2006 263/603 224/607 97.2% 1.18[1.03,1.36]
   
Total (95% CI) 643 654 100% 1.23[1.08,1.41]
Total events: 281 (Treatment), 231 (Control)  
Heterogeneity: Tau2=0; Chi2=5.64, df=1(P=0.02); I2=82.28%  
Test for overall effect: Z=3.03(P=0)  
Favours control 20.5 1.50.7 1 Favours treatment
 
 
Relapse prevention interventions for smoking cessation (Review)









Cochrane Database of Systematic Reviews
Analysis 5.5.   Comparison 5 Pharmacotherapy for assisted abstainers,
Outcome 5 Rimonabant vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
STRATUS-WW 2006 281/675 110/342 1.29[1.08,1.55]
Favours control 20.5 1.50.7 1 Favours treatment
 
 
Comparison 6.   Pharmacotherapy for unaided abstainers





Statistical method Effect size
1 Cessation 12 months after quit date 2 2261 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.04, 1.47]
1.1 Nicotine gum vs placebo after brief unas-
sisted abstinence
2 2261 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.04, 1.47]
 
 
Analysis 6.1.   Comparison 6 Pharmacotherapy for unaided
abstainers, Outcome 1 Cessation 12 months aKer quit date.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
6.1.1 Nicotine gum vs placebo after brief unassisted abstinence  
Fortmann 1995 110/522 84/522 43.2% 1.31[1.01,1.69]
Killen 1990 129/600 112/617 56.8% 1.18[0.94,1.49]
Subtotal (95% CI) 1122 1139 100% 1.24[1.04,1.47]
Total events: 239 (Treatment), 196 (Control)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=2.47(P=0.01)  
   
Total (95% CI) 1122 1139 100% 1.24[1.04,1.47]
Total events: 239 (Treatment), 196 (Control)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=2.47(P=0.01)  
Favours control 20.5 1.50.7 1 Favours treatment
 
 
Comparison 7.   Behavioural interventions for smokers. RP vs cessation, matched for programme length





Statistical method Effect size
1 Group or individual format therapy (+/- adjunct phar-
macotherapy), cessation at longest follow-up
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Analysis 7.1.   Comparison 7 Behavioural interventions for smokers. RP vs
cessation, matched for programme length, Outcome 1 Group or individual
format therapy (+/- adjunct pharmacotherapy), cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Becona 1997 13/36 12/40 11.97% 1.2[0.63,2.29]
Buchkremer 1991 1 19/43 19/51 18.89% 1.19[0.73,1.94]
Buchkremer 1991 2 29/92 15/32 19.75% 0.67[0.42,1.08]
Curry 1988 6/24 9/24 7.01% 0.67[0.28,1.58]
Davis 1986 2/15 2/16 1.66% 1.07[0.17,6.64]
Emmons 1988 5/23 9/26 6.02% 0.63[0.25,1.6]
Hall 1984 26/65 20/70 19.81% 1.4[0.87,2.25]
Niaura 1999 3/62 8/67 3.33% 0.41[0.11,1.46]
Schmitz 1999 8/60 8/47 6.47% 0.78[0.32,1.93]
Schroter 2006 5/41 8/38 5.08% 0.58[0.21,1.62]
   
Total (95% CI) 461 411 100% 0.92[0.72,1.16]
Total events: 116 (Treatment), 110 (Control)  
Heterogeneity: Tau2=0.02; Chi2=10.06, df=9(P=0.35); I2=10.53%  
Test for overall effect: Z=0.71(P=0.48)  
Favours control 100.1 50.2 20.5 1 Favours treatment
 
 
Analysis 7.2.   Comparison 7 Behavioural interventions for smokers. RP vs cessation,
matched for programme length, Outcome 2 Self-help format, cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Curry 1988 13/50 7/41 100% 1.52[0.67,3.46]
   
Total (95% CI) 50 41 100% 1.52[0.67,3.46]
Total events: 13 (Treatment), 7 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1(P=0.32)  
Favours control 100.1 50.2 20.5 1 Favours treatment
 
 
Comparison 8.   Behavioural interventions for smokers. RP vs cessation, di=erent intensity programmes





Statistical method Effect size
1 Cessation at longest follow-up 7 699 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.80, 1.29]
1.1 More than four sessions for control
group
5 546 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.68, 1.33]
1.2 Four sessions or less for control
group
2 153 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.81, 1.86]
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Analysis 8.1.   Comparison 8 Behavioural interventions for smokers. RP vs cessation,
di=erent intensity programmes, Outcome 1 Cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
8.1.1 More than four sessions for control group  
Brandon 1987 8/20 7/19 9.02% 1.09[0.49,2.41]
Buchkremer 1991 1 31/98 19/51 25.78% 0.85[0.54,1.34]
Hall 1987 19/69 25/70 22.46% 0.77[0.47,1.27]
Killen 1984 11/22 5/22 7.48% 2.2[0.92,5.29]
Shoptaw 2002 3/89 5/86 2.97% 0.58[0.14,2.35]
Subtotal (95% CI) 298 248 67.71% 0.95[0.68,1.33]
Total events: 72 (Treatment), 61 (Control)  
Heterogeneity: Tau2=0.03; Chi2=4.99, df=4(P=0.29); I2=19.82%  
Test for overall effect: Z=0.32(P=0.75)  
   
8.1.2 Four sessions or less for control group  
Hall 1985 18/41 16/43 20.48% 1.18[0.7,1.98]
Lifrak 1997 12/33 10/36 11.81% 1.31[0.65,2.62]
Subtotal (95% CI) 74 79 32.29% 1.22[0.81,1.86]
Total events: 30 (Treatment), 26 (Control)  
Heterogeneity: Tau2=0; Chi2=0.06, df=1(P=0.81); I2=0%  
Test for overall effect: Z=0.96(P=0.34)  
   
Total (95% CI) 372 327 100% 1.02[0.8,1.29]
Total events: 102 (Treatment), 87 (Control)  
Heterogeneity: Tau2=0; Chi2=6.23, df=6(P=0.4); I2=3.77%  
Test for overall effect: Z=0.12(P=0.9)  
Test for subgroup differences: Chi2=0.89, df=1 (P=0.35), I2=0%  
Favours control 100.1 50.2 20.5 1 Favours treatment
 
 
Comparison 9.   Interventions for smokers, tests of adjuncts to cessation programmes





Statistical method Effect size
1 Behavioural interventions, cessation at
longest follow-up
11   Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Additional proactive telephone contact 3 2758 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.93, 1.49]
1.2 Additional print-based support 3 6224 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.01, 1.33]
1.3 Additional intervention delivered by
computer or mobile phone
4 729 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.85, 1.66]
1.4 Formulation of coping strategies 1 1566 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.97, 1.67]
2 Combined behavioural and pharma inter-
ventions, cessation at longest follow-up
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not select-
ed
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Statistical method Effect size
2.1 Additional proactive telephone coun-
selling + NRT
1   Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 9.1.   Comparison 9 Interventions for smokers, tests of adjuncts to cessation
programmes, Outcome 1 Behavioural interventions, cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
9.1.1 Additional proactive telephone contact  
Segan 2011 67/710 68/734 25.97% 1.02[0.74,1.4]
Blebil 2014 86/120 54/111 34.75% 1.47[1.18,1.84]
Lando 1996 177/542 165/541 39.28% 1.07[0.9,1.28]
Subtotal (95% CI) 1372 1386 100% 1.18[0.93,1.49]
Total events: 330 (Treatment), 287 (Control)  
Heterogeneity: Tau2=0.03; Chi2=6.14, df=2(P=0.05); I2=67.42%  
Test for overall effect: Z=1.38(P=0.17)  
   
9.1.2 Additional print-based support  
Sheffer 2010 77/380 77/512 13.54% 1.35[1.01,1.79]
Simmons 2018 176/614 74/319 16.61% 1.24[0.98,1.56]
Simmons 2018 207/622 74/319 17.07% 1.43[1.14,1.8]
Unrod 2016 499/1127 270/594 26.28% 0.97[0.87,1.09]
Unrod 2016 548/1142 270/595 26.51% 1.06[0.95,1.18]
Subtotal (95% CI) 3885 2339 100% 1.16[1.01,1.33]
Total events: 1507 (Treatment), 765 (Control)  
Heterogeneity: Tau2=0.02; Chi2=13.36, df=4(P=0.01); I2=70.05%  
Test for overall effect: Z=2.03(P=0.04)  
   
9.1.3 Additional intervention delivered by computer or mobile phone  
Hicks 2017 1/5 2/6 2.55% 0.6[0.07,4.83]
Japuntich 2006 21/140 17/144 24% 1.27[0.7,2.31]
Durmaz 2019 18/44 21/88 29.55% 1.71[1.02,2.87]
Wetter 2011 39/151 42/151 43.9% 0.93[0.64,1.35]
Subtotal (95% CI) 340 389 100% 1.19[0.85,1.66]
Total events: 79 (Treatment), 82 (Control)  
Heterogeneity: Tau2=0.03; Chi2=4.06, df=3(P=0.26); I2=26.04%  
Test for overall effect: Z=0.99(P=0.32)  
   
9.1.4 Formulation of coping strategies  
Van Osch 2008 103/764 85/802 100% 1.27[0.97,1.67]
Subtotal (95% CI) 764 802 100% 1.27[0.97,1.67]
Total events: 103 (Treatment), 85 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.75(P=0.08)  
Favours control 20.5 1.50.7 1 Favours treatment
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Analysis 9.2.   Comparison 9 Interventions for smokers, tests of adjuncts to cessation programmes,
Outcome 2 Combined behavioural and pharma interventions, cessation at longest follow-up.
Study or subgroup Treatment Control Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
9.2.1 Additional proactive telephone counselling + NRT  
Joseph 2011 67/222 52/221 1.28[0.94,1.75]
Favours control 1000.01 100.1 1 Favours treatment
 
 
Comparison 10.   Abstinent pregnant/postpartum women subgrouped by duration of prior abstinence





Statistical method Effect size
1 Not smoking at delivery/last fol-
low-up prior to delivery
8 1523 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.79, 1.07]
1.1 Prior abstinence ≥ 4 weeks 2 420 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.65, 1.08]
1.2 Prior abstinence < 4 weeks 1 33 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.48, 6.83]
1.3 Prior abstinence unclear/not re-
ported
5 1070 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.77, 1.17]
2 Not smoking at longest follow-up
after delivery
14 4606 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.94, 1.09]
2.1 Prior abstinence ≥ 4 weeks 3 924 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.79, 1.20]
2.2 Prior abstinence < 4 weeks 2 733 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.84, 1.08]
2.3 Prior abstinence unclear/not re-
ported
9 2949 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.95, 1.19]
 
 
Analysis 10.1.   Comparison 10 Abstinent pregnant/postpartum women subgrouped by duration
of prior abstinence, Outcome 1 Not smoking at delivery/last follow-up prior to delivery.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.1.1 Prior abstinence ≥ 4 weeks  
Ershoff 1995 73/87 67/84 5.81% 0.8[0.42,1.51]
Hajek 2001 66/114 68/135 31.7% 0.85[0.64,1.12]
Subtotal (95% CI) 201 219 37.5% 0.84[0.65,1.08]
Total events: 139 (Relapse prevention), 135 (Control)  
Heterogeneity: Tau2=0; Chi2=0.03, df=1(P=0.85); I2=0%  
Test for overall effect: Z=1.36(P=0.18)  
   
10.1.2 Prior abstinence < 4 weeks  
Morasco 2006 10/14 16/19 1.35% 1.81[0.48,6.83]
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 14 19 1.35% 1.81[0.48,6.83]
Total events: 10 (Relapse prevention), 16 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.88(P=0.38)  
   
10.1.3 Prior abstinence unclear/not reported  
Lowe 1997 32/40 29/38 3.36% 0.84[0.36,1.96]
McBride 1999 224/258 110/137 11.23% 0.67[0.42,1.06]
McBride 2004 173/209 85/107 10.5% 0.84[0.52,1.35]
Secker-Walker 1995 55/85 54/80 13.06% 1.09[0.71,1.66]
Secker-Walker 1998 22/55 29/61 23% 1.14[0.83,1.58]
Subtotal (95% CI) 647 423 61.15% 0.95[0.77,1.17]
Total events: 506 (Relapse prevention), 307 (Control)  
Heterogeneity: Tau2=0.01; Chi2=4.41, df=4(P=0.35); I2=9.38%  
Test for overall effect: Z=0.49(P=0.62)  
   
Total (95% CI) 862 661 100% 0.92[0.79,1.07]
Total events: 655 (Relapse prevention), 458 (Control)  
Heterogeneity: Tau2=0; Chi2=5.99, df=7(P=0.54); I2=0%  
Test for overall effect: Z=1.08(P=0.28)  
Test for subgroup differences: Chi2=1.57, df=1 (P=0.46), I2=0%  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Analysis 10.2.   Comparison 10 Abstinent pregnant/postpartum women subgrouped by
duration of prior abstinence, Outcome 2 Not smoking at longest follow-up aKer delivery.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
10.2.1 Prior abstinence ≥ 4 weeks  
Hannöver 2009 34/148 39/156 3.37% 0.92[0.62,1.37]
Pollak 2016 66/188 71/194 7.37% 0.96[0.73,1.25]
Ratner 2000 25/119 22/119 2.07% 1.14[0.68,1.9]
Subtotal (95% CI) 455 469 12.81% 0.97[0.79,1.2]
Total events: 125 (Relapse prevention), 132 (Control)  
Heterogeneity: Tau2=0; Chi2=0.44, df=2(P=0.8); I2=0%  
Test for overall effect: Z=0.25(P=0.8)  
   
10.2.2 Prior abstinence < 4 weeks  
Brandon 2012 190/343 210/357 28.66% 0.94[0.83,1.07]
Morasco 2006 6/14 6/19 0.68% 1.36[0.55,3.33]
Subtotal (95% CI) 357 376 29.34% 0.95[0.84,1.08]
Total events: 196 (Relapse prevention), 216 (Control)  
Heterogeneity: Tau2=0; Chi2=0.63, df=1(P=0.43); I2=0%  
Test for overall effect: Z=0.81(P=0.42)  
   
10.2.3 Prior abstinence unclear/not reported  
Hajek 2001 26/114 34/135 2.74% 0.91[0.58,1.41]
McBride 1999 66/157 33/78 5.32% 0.99[0.72,1.37]
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
McBride 1999 63/146 33/78 5.27% 1.02[0.74,1.4]
McBride 2004 105/231 47/118 7.67% 1.14[0.88,1.48]
Reitzel 2010 31/136 19/115 2.06% 1.38[0.82,2.31]
Ruger 2008 9/24 5/33 0.6% 2.48[0.95,6.45]
Secker-Walker 1995 28/85 26/80 2.83% 1.01[0.65,1.57]
Secker-Walker 1998 25/55 32/61 3.84% 0.87[0.6,1.26]
Severson 1997 200/609 109/417 13.24% 1.26[1.03,1.53]
Van't Hof 2000 78/133 91/144 14.28% 0.93[0.77,1.12]
Subtotal (95% CI) 1690 1259 57.85% 1.06[0.95,1.19]
Total events: 631 (Relapse prevention), 429 (Control)  
Heterogeneity: Tau2=0.01; Chi2=11.22, df=9(P=0.26); I2=19.77%  
Test for overall effect: Z=1.04(P=0.3)  
   
Total (95% CI) 2502 2104 100% 1.02[0.94,1.09]
Total events: 952 (Relapse prevention), 777 (Control)  
Heterogeneity: Tau2=0; Chi2=14.44, df=14(P=0.42); I2=3.06%  
Test for overall effect: Z=0.43(P=0.67)  
Test for subgroup differences: Chi2=1.79, df=1 (P=0.41), I2=0%  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Comparison 11.   Abstinent hospitalised smokers subgrouped by duration of prior abstinence





Statistical method Effect size
1 Behavioural interventions, cessa-
tion at longest follow-up
5 1385 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.82, 1.47]
1.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Prior abstinence < 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Prior abstinence unclear/not re-
ported
5 1385 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.82, 1.47]
2 Pharmacotherapy interventions,
cessation at longest follow-up
2 1078 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.94, 1.60]
2.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Prior abstinence < 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Prior abstinence unclear/not re-
ported
2 1078 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.94, 1.60]
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Analysis 11.1.   Comparison 11 Abstinent hospitalised smokers subgrouped by duration of
prior abstinence, Outcome 1 Behavioural interventions, cessation at longest follow-up.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.1.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
11.1.2 Prior abstinence < 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
11.1.3 Prior abstinence unclear/not reported  
Campos 2018 24/43 9/42 13.59% 2.6[1.38,4.93]
Cummins 2016 57/317 59/316 26.24% 0.96[0.69,1.34]
Hajek 2002 94/254 102/251 32.31% 0.91[0.73,1.13]
Hasuo 2004 32/60 25/49 24.48% 1.05[0.73,1.5]
Schmitz 1999 3/29 3/24 3.39% 0.83[0.18,3.73]
Subtotal (95% CI) 703 682 100% 1.1[0.82,1.47]
Total events: 210 (Relapse prevention), 198 (Control)  
Heterogeneity: Tau2=0.06; Chi2=9.55, df=4(P=0.05); I2=58.1%  
Test for overall effect: Z=0.64(P=0.52)  
   
Total (95% CI) 703 682 100% 1.1[0.82,1.47]
Total events: 210 (Relapse prevention), 198 (Control)  
Heterogeneity: Tau2=0.06; Chi2=9.55, df=4(P=0.05); I2=58.1%  
Test for overall effect: Z=0.64(P=0.52)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Analysis 11.2.   Comparison 11 Abstinent hospitalised smokers subgrouped by duration of
prior abstinence, Outcome 2 Pharmacotherapy interventions, cessation at longest follow-up.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
11.2.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
11.2.2 Prior abstinence < 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Not applicable  
   
11.2.3 Prior abstinence unclear/not reported  
Brandstein 2012 6/64 4/62 4.73% 1.45[0.43,4.9]
Cummins 2016 70/317 29/157 46.37% 1.2[0.81,1.76]
Cummins 2016 75/320 30/158 48.9% 1.23[0.85,1.8]
Subtotal (95% CI) 701 377 100% 1.23[0.94,1.6]
Total events: 151 (Relapse prevention), 63 (Control)  
Heterogeneity: Tau2=0; Chi2=0.09, df=2(P=0.95); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
   
Total (95% CI) 701 377 100% 1.23[0.94,1.6]
Total events: 151 (Relapse prevention), 63 (Control)  
Heterogeneity: Tau2=0; Chi2=0.09, df=2(P=0.95); I2=0%  
Test for overall effect: Z=1.51(P=0.13)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Comparison 12.   Unaided abstainers subgrouped by duration of prior abstinence - Behavioural interventions





Statistical method Effect size
1 Behavioural interventions for un-
aided abstainers
5 3561 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.96, 1.16]
1.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Prior abstinence < 4 weeks 4 3275 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.94, 1.14]
1.3 Prior abstinence unclear/not re-
ported
1 286 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.98, 2.12]
 
 
Analysis 12.1.   Comparison 12 Unaided abstainers subgrouped by duration of prior abstinence
- Behavioural interventions, Outcome 1 Behavioural interventions for unaided abstainers.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
12.1.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
12.1.2 Prior abstinence < 4 weeks  
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Brandon 2000 302/449 91/135 45.47% 1[0.87,1.14]
Brandon 2004 187/320 60/111 21.91% 1.08[0.89,1.31]
Fortmann 1995 97/521 97/521 13% 1[0.78,1.29]
Killen 1990 171/814 74/404 13.92% 1.15[0.9,1.47]
Subtotal (95% CI) 2104 1171 94.3% 1.04[0.94,1.14]
Total events: 757 (Relapse prevention), 322 (Control)  
Heterogeneity: Tau2=0; Chi2=1.29, df=3(P=0.73); I2=0%  
Test for overall effect: Z=0.77(P=0.44)  
   
12.1.3 Prior abstinence unclear/not reported  
Borland 2004 45/139 33/147 5.7% 1.44[0.98,2.12]
Subtotal (95% CI) 139 147 5.7% 1.44[0.98,2.12]
Total events: 45 (Relapse prevention), 33 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
   
Total (95% CI) 2243 1318 100% 1.06[0.96,1.16]
Total events: 802 (Relapse prevention), 355 (Control)  
Heterogeneity: Tau2=0; Chi2=4.06, df=4(P=0.4); I2=1.47%  
Test for overall effect: Z=1.19(P=0.23)  
Test for subgroup differences: Chi2=2.66, df=1 (P=0.1), I2=62.36%  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Comparison 13.   Assisted abstainers subgrouped by duration of prior abstinence - Behavioural interventions





Statistical method Effect size
1 Behavioural interventions for assist-
ed abstainers
11 5523 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.87, 1.11]
1.1 Prior abstinence ≥ 4 weeks 2 1660 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.77, 1.37]
1.2 Prior abstinence < 4 weeks 6 3363 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.85, 1.25]
1.3 Prior abstinence unclear/not re-
ported
3 500 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.68, 1.04]
 
 
Analysis 13.1.   Comparison 13 Assisted abstainers subgrouped by duration of prior abstinence
- Behavioural interventions, Outcome 1 Behavioural interventions for assisted abstainers.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
13.1.1 Prior abstinence ≥ 4 weeks  
Blyth 2015 217/702 238/702 14.69% 0.91[0.78,1.06]
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Razavi 1999 59/135 43/121 8.75% 1.23[0.9,1.67]
Subtotal (95% CI) 837 823 23.45% 1.03[0.77,1.37]
Total events: 276 (Relapse prevention), 281 (Control)  
Heterogeneity: Tau2=0.03; Chi2=2.94, df=1(P=0.09); I2=65.98%  
Test for overall effect: Z=0.18(P=0.86)  
   
13.1.2 Prior abstinence < 4 weeks  
Cheung 2015 21/82 8/54 2.46% 1.73[0.83,3.62]
Hayes 2018 58/286 42/291 7.24% 1.41[0.98,2.02]
McDaniel 2015 234/602 112/296 13.6% 1.03[0.86,1.23]
McDaniel 2015 176/591 111/296 12.96% 0.79[0.66,0.96]
Powell 1981 11/17 11/17 4.7% 1[0.61,1.64]
Smith 2001 40/226 54/223 7.18% 0.73[0.51,1.05]
Stevens 1989 76/184 65/198 10.19% 1.26[0.97,1.64]
Subtotal (95% CI) 1988 1375 58.33% 1.03[0.85,1.25]
Total events: 616 (Relapse prevention), 403 (Control)  
Heterogeneity: Tau2=0.04; Chi2=16.86, df=6(P=0.01); I2=64.42%  
Test for overall effect: Z=0.32(P=0.75)  
   
13.1.3 Prior abstinence unclear/not reported  
McNaughton 2013 5/23 9/21 1.67% 0.51[0.2,1.27]
Mermelstein 2003 68/176 75/165 10.67% 0.85[0.66,1.09]
Veldheer 2018 24/59 25/56 5.89% 0.91[0.6,1.39]
Subtotal (95% CI) 258 242 18.22% 0.84[0.68,1.04]
Total events: 97 (Relapse prevention), 109 (Control)  
Heterogeneity: Tau2=0; Chi2=1.31, df=2(P=0.52); I2=0%  
Test for overall effect: Z=1.61(P=0.11)  
   
Total (95% CI) 3083 2440 100% 0.98[0.87,1.11]
Total events: 989 (Relapse prevention), 793 (Control)  
Heterogeneity: Tau2=0.02; Chi2=22.99, df=11(P=0.02); I2=52.14%  
Test for overall effect: Z=0.26(P=0.79)  
Test for subgroup differences: Chi2=2.26, df=1 (P=0.32), I2=11.45%  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Comparison 14.   Unaided abstainers subgrouped by duration of prior abstinence - Pharmacotherapy





Statistical method Effect size
1 Nicotine gum vs placebo for unaid-
ed abstainers
2 2261 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.04, 1.47]
1.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Prior abstinence < 4 weeks 2 2261 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.04, 1.47]
1.3 Prior abstinence unclear/not re-
ported
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 14.1.   Comparison 14 Unaided abstainers subgrouped by duration of prior
abstinence - Pharmacotherapy, Outcome 1 Nicotine gum vs placebo for unaided abstainers.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
14.1.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
14.1.2 Prior abstinence < 4 weeks  
Fortmann 1995 110/522 84/522 43.83% 1.31[1.01,1.69]
Killen 1990 129/600 112/617 56.17% 1.18[0.94,1.49]
Subtotal (95% CI) 1122 1139 100% 1.24[1.04,1.47]
Total events: 239 (Relapse prevention), 196 (Control)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=2.46(P=0.01)  
   
14.1.3 Prior abstinence unclear/not reported  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 1122 1139 100% 1.24[1.04,1.47]
Total events: 239 (Relapse prevention), 196 (Control)  
Heterogeneity: Tau2=0; Chi2=0.33, df=1(P=0.57); I2=0%  
Test for overall effect: Z=2.46(P=0.01)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Comparison 15.   Assited abstainers subgrouped by duration of prior abstinence - Pharmacotherapy





Statistical method Effect size
1 Nicotine replacement therapy ver-
sus placebo. Cessation 12 months +
after quit date
2 553 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.77, 1.40]
1.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Prior abstinence < 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Prior abstinence unclear/not re-
ported
2 553 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.77, 1.40]
2 Bupropion vs placebo. Cessation
12 months + after quit date
6 1697 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.97, 1.34]
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Statistical method Effect size
2.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Prior abstinence < 4 weeks 2 472 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.83, 1.46]
2.3 Prior abstinence unclear/not re-
ported
4 1225 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.96, 1.41]
3 Combination NRT & bupropion vs
placebo. Cessation at longest fol-
low-up
2 243 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.49, 2.54]
3.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Prior abstinence < 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Prior abstinence unclear/not re-
ported
2 243 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.49, 2.54]
4 Varenicline vs placebo. Cessation
12 months + after quit date
2 1297 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.70, 4.34]
4.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Prior abstinence < 4 weeks 2 1297 Risk Ratio (M-H, Random, 95% CI) 1.75 [0.70, 4.34]
4.3 Prior abstinence unclear/not re-
ported
0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 Rimonabant vs placebo. Cessation
12 months + after quit date
1 1017 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.08, 1.55]
5.1 Prior abstinence ≥ 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Prior abstinence < 4 weeks 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Prior abstinence unclear/not re-
ported
1 1017 Risk Ratio (M-H, Random, 95% CI) 1.29 [1.08, 1.55]
 
 
Analysis 15.1.   Comparison 15 Assited abstainers subgrouped by duration of prior abstinence - Pharmacotherapy,
Outcome 1 Nicotine replacement therapy versus placebo. Cessation 12 months + aKer quit date.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.1.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.1.2 Prior abstinence < 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.1.3 Prior abstinence unclear/not reported  
Covey 2007 19/72 13/71 22.68% 1.44[0.77,2.69]
Covey 2007 22/73 23/73 37.43% 0.96[0.59,1.56]
Croghan 2007 17/81 19/87 26.29% 0.96[0.54,1.72]
Croghan 2007 9/49 10/47 13.6% 0.86[0.39,1.93]
Subtotal (95% CI) 275 278 100% 1.04[0.77,1.4]
Total events: 67 (Relapse prevention), 65 (Control)  
Heterogeneity: Tau2=0; Chi2=1.44, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
   
Total (95% CI) 275 278 100% 1.04[0.77,1.4]
Total events: 67 (Relapse prevention), 65 (Control)  
Heterogeneity: Tau2=0; Chi2=1.44, df=3(P=0.7); I2=0%  
Test for overall effect: Z=0.24(P=0.81)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Analysis 15.2.   Comparison 15 Assited abstainers subgrouped by duration of prior abstinence
- Pharmacotherapy, Outcome 2 Bupropion vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.2.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.2.2 Prior abstinence < 4 weeks  
Hays 2009 21/56 21/54 11.34% 0.96[0.6,1.55]
Killen 2006 51/181 43/181 20.99% 1.19[0.84,1.68]
Subtotal (95% CI) 237 235 32.33% 1.1[0.83,1.46]
Total events: 72 (Relapse prevention), 64 (Control)  
Heterogeneity: Tau2=0; Chi2=0.48, df=1(P=0.49); I2=0%  
Test for overall effect: Z=0.68(P=0.5)  
   
15.2.3 Prior abstinence unclear/not reported  
Covey 2007 23/73 13/71 7.21% 1.72[0.95,3.12]
Covey 2007 22/73 19/72 9.47% 1.14[0.68,1.92]
Croghan 2007 9/49 8/44 3.46% 1.01[0.43,2.39]
Croghan 2007 21/71 19/70 9.29% 1.09[0.64,1.84]
Croghan 2007 10/47 13/50 4.92% 0.82[0.4,1.68]
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Hays 2001 62/214 56/215 27.07% 1.11[0.82,1.51]
Hurt 2003 19/88 13/88 6.25% 1.46[0.77,2.77]
Subtotal (95% CI) 615 610 67.67% 1.16[0.96,1.41]
Total events: 166 (Relapse prevention), 141 (Control)  
Heterogeneity: Tau2=0; Chi2=3.31, df=6(P=0.77); I2=0%  
Test for overall effect: Z=1.53(P=0.13)  
   
Total (95% CI) 852 845 100% 1.14[0.97,1.34]
Total events: 238 (Relapse prevention), 205 (Control)  
Heterogeneity: Tau2=0; Chi2=3.88, df=8(P=0.87); I2=0%  
Test for overall effect: Z=1.64(P=0.1)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Analysis 15.3.   Comparison 15 Assited abstainers subgrouped by duration of prior abstinence -
Pharmacotherapy, Outcome 3 Combination NRT & bupropion vs placebo. Cessation at longest follow-up.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.3.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.3.2 Prior abstinence < 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.3.3 Prior abstinence unclear/not reported  
Covey 2007 22/73 13/71 53.71% 1.65[0.9,3.01]
Croghan 2007 9/49 13/50 46.29% 0.71[0.33,1.5]
Subtotal (95% CI) 122 121 100% 1.11[0.49,2.54]
Total events: 31 (Relapse prevention), 26 (Control)  
Heterogeneity: Tau2=0.24; Chi2=2.95, df=1(P=0.09); I2=66.14%  
Test for overall effect: Z=0.25(P=0.8)  
   
Total (95% CI) 122 121 100% 1.11[0.49,2.54]
Total events: 31 (Relapse prevention), 26 (Control)  
Heterogeneity: Tau2=0.24; Chi2=2.95, df=1(P=0.09); I2=66.14%  
Test for overall effect: Z=0.25(P=0.8)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
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Analysis 15.4.   Comparison 15 Assited abstainers subgrouped by duration of prior abstinence
- Pharmacotherapy, Outcome 4 Varenicline vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.4.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.4.2 Prior abstinence < 4 weeks  
Evins 2014 18/40 7/47 41.7% 3.02[1.41,6.49]
Tonstad 2006 263/603 224/607 58.3% 1.18[1.03,1.36]
Subtotal (95% CI) 643 654 100% 1.75[0.7,4.34]
Total events: 281 (Relapse prevention), 231 (Control)  
Heterogeneity: Tau2=0.36; Chi2=5.64, df=1(P=0.02); I2=82.28%  
Test for overall effect: Z=1.2(P=0.23)  
   
15.4.3 Prior abstinence unclear/not reported  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 643 654 100% 1.75[0.7,4.34]
Total events: 281 (Relapse prevention), 231 (Control)  
Heterogeneity: Tau2=0.36; Chi2=5.64, df=1(P=0.02); I2=82.28%  
Test for overall effect: Z=1.2(P=0.23)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
Analysis 15.5.   Comparison 15 Assited abstainers subgrouped by duration of prior abstinence
- Pharmacotherapy, Outcome 5 Rimonabant vs placebo. Cessation 12 months + aKer quit date.
Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
15.5.1 Prior abstinence ≥ 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.5.2 Prior abstinence < 4 weeks  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Relapse prevention), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
15.5.3 Prior abstinence unclear/not reported  
Favour relapse prevention 1000.01 100.1 1 Favours control
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Study or subgroup Relapse
prevention
Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
STRATUS-WW 2006 281/675 110/342 100% 1.29[1.08,1.55]
Subtotal (95% CI) 675 342 100% 1.29[1.08,1.55]
Total events: 281 (Relapse prevention), 110 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.84(P=0)  
   
Total (95% CI) 675 342 100% 1.29[1.08,1.55]
Total events: 281 (Relapse prevention), 110 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.84(P=0)  
Test for subgroup differences: Not applicable  
Favour relapse prevention 1000.01 100.1 1 Favours control
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Duration of prior abstinence
Blyth 2015 4 weeks
Borland 2004 Unclear/varied
Brandon 2000 7 days
Brandon 2004 7 days
Brandon 2012 7 days
Brandstein 2012 Unclear/varied
Campos 2018 Unclear/varied
Cheung 2015 7 days
Conway 2004 2 months
Covey 2007 Unclear/varied
Croghan 2007 Unclear/varied
Ershoff 1995 Mean 31 days
Evins 2014 2 weeks
Fortmann 1995 24 hours
Hajek 2001 Mean 7 weeks
Hajek 2002 Unclear/varied
Table 1.   Duration of prior abstinence in studies recruiting abstainers 
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Hannöver 2009 4 weeks
Hasuo 2004 Unclear/varied
Hayes 2018 24 hours
Hays 2001 Unclear/varied
Hays 2009 1 week
Hurt 2003 Unclear/varied
Killen 1990 48 hours
Klesges 1999 6 weeks
Klesges 2006 6 weeks
Levine 2016 2 weeks
Lowe 1997 Unclear/varied
Mayer 2010 4 weeks
McBride 1999 Unclear/varied
McBride 2004 Unclear/varied
McDaniel 2015 24 hours
McNaughton 2013 Unclear/varied
Mermelstein 2003 Unclear/varied
Morasco 2006 7 days
Pbert 2004 Unclear/varied
Pollak 2016 1 month
Powell 1981 5 days
Ratner 2000 6 weeks






Table 1.   Duration of prior abstinence in studies recruiting abstainers  (Continued)
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Severson 1997 Unclear/varied
Smith 2001 1 week
Stevens 1989 4 days
STRATUS-WW 2006 Unclear/varied
Tonstad 2006 1 week
Van't Hof 2000 Unclear/varied
Veldheer 2018 Unclear/varied
Table 1.   Duration of prior abstinence in studies recruiting abstainers  (Continued)
 
 
A P P E N D I C E S
Appendix 1. CRS search strategy
#1 relapse prevention:TI,AB,MH,EMT,XKY
#2 maintenance:TI,AB,MH,EMT,XKY
#3 (relapse NEAR prevent*):TI,AB,MH,EMT,XKY
#4 (relapse* NEAR smok*):TI,AB,MH,EMT,XKY
#5 recurrence:MH,XKY
#6 #1 OR #2 OR #3 OR #4 OR #5
W H A T ' S   N E W
 
Date Event Description
8 August 2019 New citation required but conclusions
have not changed
Conclusions unchanged
8 August 2019 New search has been performed Searches updated. Five new included studies
 
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 1, 2005
 
Date Event Description
4 October 2018 New citation required and conclusions
have changed
Conclusions changed
4 October 2018 New search has been performed Searches updated. Fifteen new included studies
3 June 2013 New citation required but conclusions
have not changed
Nine new included studies have not changed pooled results or
conclusions.
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Date Event Description
3 June 2013 New search has been performed New search run 2013; nine included studies added and risk of
bias tables updated to current Cochrane tool.
22 October 2008 New citation required and conclusions
have changed
Includes evidence from one trial that extended treatment with
varenicline reduces relapse
21 October 2008 New search has been performed Updated for issue 1, 2009 with 15 new included trials.
20 October 2008 Amended Converted to new review format.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
As of the last update of the review, meta-analyses of behavioural interventions were changed from a fixed-eHect to a random-eHects model
in line with new Cochrane Tobacco Addiction Group policy, to account for the expected variability in the interventions delivered.
We excluded one previously included study from the last update on the grounds that it included relapsed smokers rather than abstainers
(Juliano 2006).
As of this update, we removed the analysis of extended pharmacotherapy in smokers, as this is more extensively covered in individual
reviews of pharmacotherapies (Hughes 2014; Cahill 2016; Lindson 2019). As a result of this, we also excluded the previously included
study Schnoll 2015. We also ruled that incentives interventions in smokers were ineligible for inclusion in the review, as any incentives
intervention could be construed as rewarding participants for not relapsing. Incentives interventions are covered in Notley 2019.
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For the present update, at the request of NICE (the National Institute for Health and Care Excellence; the guideline development
organisation for England and Wales), for analyses of studies randomising abstainers, we conducted subgroup analyses grouping studies
by the duration of prior abstinence of participants. We grouped studies based on whether participants had been abstinent for four or more
weeks, less than four weeks, or if prior abstinence varied or was not adequately specified.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Secondary Prevention;  *Smoking Prevention;  Behavior Therapy;  Bupropion  [therapeutic use];  Chewing Gum;  Nicotine  [therapeutic
use];  Nicotinic Agonists  [therapeutic use];  Randomized Controlled Trials as Topic;  Smoking Cessation  [*methods];  Smoking Cessation
Agents  [*therapeutic use];  Varenicline  [therapeutic use]
MeSH check words
Female; Humans; Male; Pregnancy
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